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 V 
Abstract 
GABAA receptor encephalitis is a recently described form of inflammatory encephalitis, caused 
by antibodies against the GABAA receptors. The antibodies induce internalization of the 
receptor, resulting in a synaptic reduction of GABAA receptors. Thereby, the inhibitory receptor 
function is lost, and patients suffer from refractory seizures and status epilepticus. Even though 
auto-antibodies and their epitopes were described, nothing is known about the role of T cells 
in this disease, although CD4+ Th response is necessary for a humoral immune response. 
Further, it is known that CD8+ T cells often play key roles in encephalitis.  
For a better understanding of the role of T cells in GABAA receptor encephalitis, the T cell 
repertoire in the cerebrospinal fluid (CSF) as well as in inflamed brain regions of an encephalitis 
patient (termed Index patient 2 (IP2)) were analysed.  
Whereas the CD4+ T cell repertoire in CSF was polyclonal, one CD8+ T cell receptor, named 
IP2-8S1, was expanded in the CSF. The same clone was also detected in 11 % of isolated 
single CD8+ T cells from the hippocampus. Immunohistochemical stainings of brain biopsy 
indicated an obvious infiltration of activated, perforin expressing CD8+ T cells into the brain, 
whereas CD4+ T cells were found very rarely. These findings indicate a key role of IP2-8S1 in 
the disease etiology. Furthermore, it denotes the expression of an autoantigen in the CNS, 
recognised by IP2-8S1. 
To identify the antigen of IP2-8S1 and to analyse its HLA-restriction, the TCR was transferred 
into mouse hybridoma cells which express sGFP under the NFAT enhancer as a reporter. 
Possible peptide candidates from the GABAA receptors α1 subunit were analysed for their 
ability to activate the hybridoma cells. Additionally, antigen screening experiments using 
plasmid-encoded combinatorial peptide libraries (PECPL) were performed. 
Based on the presence of autoreactive antibodies in IP2, we initially expected to detect 
expanded CD4+ T cell clones, mediating humoral immune response in GABAA receptor 
encephalitis. To detect possible antigens of CD4+ T cell, the established method for identifying 
CD8+ T cell antigens with PECPL was modified to allow the screening of CD4+ T cell antigens. 
To this end, new libraries were designed and generated, where randomised nucleotide 
sequences were inserted into the invariant chain. Thus, randomized peptides are presented 
on MHC class-II molecules. As proof of concept, an auto-reactive TCR that recognises a known 
peptide presented by HLA-DR1 and HLA-DR2a was used. The positive control construct was 
characterized regarding the length of the sequence encoding the antigen as well as the 
influence of the signal sequence of the invariant chain. It was shown that by expression of 
antigenic peptides integrated into the invariant chain it is possible to load peptides with very 
low affinity onto MHC-II molecules and to activate TCRs.  
VI 
Zusammenfassung 
GABAA Rezeptor Enzephalitis ist eine erst kürzlich beschriebene Form der inflammatorischen 
Enzephalitiden, welche hervorgerufen wird durch Antikörper gegen den GABAA Rezeptor. Die 
Antikörper induzieren die Internalisierung des Rezeptors, was eine Reduktion der 
synaptischen Rezeptoren zur Folge hat. Die inhibitorische Funktion des Rezeptors geht 
dadurch verloren, und die Patienten leiden an für Medikamente unempfängliche 
Krampfanfällen als auch an Status epilepticus. Wenngleich Autoantikörpern als auch deren 
Antigene bereits beschrieben sind, weiß man bisher nichts über die Rolle von T Zellen in der 
Krankheit. Dies ist bemerkenswert, da CD4+ T-Helferzellen unabdingbar sind für eine 
humorale Immunantwort und CD8+ T-Zellen oft eine Schlüsselrolle in Enzephalitiden spielen. 
Für ein besseres Verständnis der Rolle von T Zellen in GABAA Rezeptor Enzephalitis, wurde 
deshalb das T Zell Repertoire der Zerebrospinalflüssigkeit (ZSF) als auch entzündeten Hirn-
Regionen eines Patienten mit GABAA-Rezeptor Enzephalitis ("Index Patient 2" (IP2)) 
untersucht.  
Während das CD4+ T-Zell-Repertoire im ZSF sich als polyklonal herausstellte, wurde ein 
expandierter, CD8+ T Zell Rezeptor, genannt IP2-8S1, im ZSF identifiziert. Derselbe Klon 
wurde in 11 % aller Einzelzellen, die aus dem Hippocampus isoliert wurden, wiedergefunden. 
Immunhistochemische Färbungen der Gehirnbiopsie zeigten eine starke Infiltration von 
aktivierten, Perforin exprimierenden CD8+ T-Zellen, während CD4+ T-Zellen im Gehirn nur 
selten anzutreffen waren. Diese Ergebnisse zeigen, dass CD8+ T-Zellen im Krankheitsverlauf 
eine Schlüsselrolle einnehmen. Des Weiteren deuten die Ergebnisse eine Expression des 
Autoantigens, welches von IP2-8S1 erkannt wird, im zentralen Nervensystem an. 
Um das Antigen von IP2-8S1 und seine HLA-Restriktion zu identifizieren, wurde der T-Zell-
Rezeptor in Maus Hybridomzellen, welche sGFP unter der Kontrolle des NFAT-enhancers 
exprimieren, eingebracht. Mögliche Kandidaten-Peptide aus der GABAA Rezeptor α1 
Untereinheit wurden hinsichtlich ihrer Fähigkeit, diese Hybridomzellen zu aktivieren, 
untersucht. Des Weiteren wurde versucht, Antigene mit Hilfe von Plasmid-kodierten 
kombinatorischen Peptid-Bibliotheken (PECPL) zu identifizieren.  
Basierend auf dem Vorhandensein autoreaktiver Antikörper in IP2, haben wir erwartet, 
expandierte CD4+ T-Zell-Klone zu finden, welche die humorale Immunantwort vermitteln. Für 
die Detektion von CD4+ T-Zell-Antigenen wurde die Methode zur Identifikation von CD8+ T-
Zell-Antigenen mit PECPL so modifiziert, dass sie die Charakterisierung von CD4+ T-Zell-
Antigenen erlaubt. Hierfür wurden neue Bibliotheken entworfen und hergestellt. Dazu wurde 
eine randomisierte Nucleotidsequenz in die invariante Kette integriert, so dass eine zufällige 
Aminosäuresequenz von Klasse-II MHC Molekülen präsentiert wird. Als Nachweis der 
Machbarkeit wurde ein auto-reaktiver T-Zell-Rezeptor, der ein bekanntes Peptid auf HLA-DR1 
 VII 
und HLA-DR2a erkennt, verwendet. Die Positivkontrolle wurde hinsichtlich der Länge der 
Peptidsequenz als auch hinsichtlich des Einflusses der Signalsequenz der Invarianten Kette, 
analysiert. Es konnte gezeigt werden, dass es durch die Expression von Antigen Peptiden 
integriert in der Invarianten Kette, möglich ist, Peptide mit sehr geringer Affinität auf MHC-II 
Moleküle zu laden und T-Zell-Rezeptoren zu aktivieren.  
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Abbreviation
AA  amino acid 
amp  Ampicillin 
APC  allophycocyanin 
APCs  antigen presenting cells 
bls  blasticidin 
bp  base pairs 
CD  cluster of differentiation 
CD40L  CD40 ligand 
cDNA  complementary 
desoxyribonucleoic acid 
CLIP  Class-II associated invariant 
chain peptides 
CNS  central nervous system 
CSF  cerebrospinal fluid 
CTL  cytotoxic T lymphocyte 
DAPI  4′,6-Diamidin-2-phenylindol 
DC  dendtritic cells 
ddH2O  double-distilled water 
DEPC  Diethyl pyrocarbonate 
DNA  desoxyribonucleoic acid 
DTT  Dithiothreitol 
EB  Elution buffe 
EDTA  Ethylenediaminetetraacetic 
  acid 
ER  endoplasmatic reticulum 
ERAP1  ER-aminopeptidase 1 
F  phenylalanine 
FACS  fluorescence-activated cell 
sorting 
FBS  fetal bovine serum 
FITC  fluorescein isothiocyanate 
GABA  γ-aminobutyric acid 
GAD  glutamic acid decarboxylase 
h  hour 
HC  hippocampus 
HIER  heat-induced epitope retrieval 
HLA  human leucocyte antigen 
HLA-DR1 HLA-DRB1*01:01 
HLA-DR2a HLA-DR5*01:01 
HLA-DR2b HLA-DRB1*15:01 
hMBP  human myelin basic protein 
His  histidine 
hygro  hygromycin 
Ii  invariant chain 
Ii-ECPL  invariant chain encoded 
combinatorial peptide library 
IP2  Index patient 2 
IP2-8S1 expanded CD8+ T cell clone of 
IP2 
IP2-AV8S1 α-chain of IP2-8S1 
IP2-BV8S1 α-chain of IP2-8S1 
ITAM  immunoreceptor tyrosine-
based activation motifs 
L  leucine 
LB  lysogeny broth 
LCL  B-Lymphoblastoid cell line 
LPS  lipopolysaccharides 
LS  lateral sulcus 
LMD  Laser microdissection 
m  mouse 
M  methionine 
MAIT  Mucosal-associated T  
MFI  Mean fluorescence intensity 
MHC  Major histocompatibility 
complex 
MHC-I  MHC class I 
MHC-II  MHC class II 
MIIC  MHC-II compartment 
Min  minutes 
MR1  MHC-related protein 1  
mRNA  messenger ribonucleic acid 
MS   multiple sclerosis 
n  number of cells 
neo  neomycin 
NFAT  Nuclear factor of activated t 
cells 
NGS  next generation sequencing 
NMDA  N-methyl-D-aspartate  
XII 
PAGE  polyacrylamide gel 
electrophiresis 
PCR  Polymerase chain reaction 
PE   phycoerythrin 
PECPL  plasmid encoded peptide 
library 
PI  propidium iodide 
PLC  peptide loading complex 
PND  paraneoplastic neurological 
disorders 
PVDF  polyfinylidenfluorid 
qPCR  quantitative polymerase chain 
reaction 
RPMI  Roswell Park Memorial  
  Institute 
RT  reverse transcriptase 
s  seconds 
sc  single cell  
SCLC  small cell lung cancer 
SDS  sodium dodecylsulfate 
sGFP  super green fluorescent protein 
Th cell  T helper cell 
TBE  Tris-Borate EDTA-Buffer 
TCR  T cell receptor 
TM  transmembrane 
TM  melting temperature 
U  units 
UMI  unique molecular identifier 
UV  ultra violett 
wt  wild type 
w/v  weight per volume 
v/v  volume per volume 
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1 Introduction 
1.1 The immune system 
The immune system protects the body from pathogens like viruses, bacteria, fungi and 
parasites as well as from altered cells. This complex system enables a differentiation of self 
and non-self, to eliminate infected or altered cells.  
To perform this task, the immune system is composed of two parts, the innate and the adaptive 
immune response. The innate immune system is quite unspecific and thereby fast and 
versatile. It consists of barriers, the complement system and immune cells (granulocytes, 
monocytes and natural killer cells).  
The selective and specific immune response, including the development of an immunological 
memory, is mediated by the adaptive immune system. This highly specialised system is an 
interaction of humoral and cellular immunity. The humoral immunity is mediated by antibodies 
(AB). B cells secrete ABs after activation by antigen recognition. AB can mark pathogens for 
elimination by the complement system or neutralize soluble antigens, like toxins, by binding. T 
cells represent the cellular immunity. They can induce apoptosis of infected cells or produce 
cytokines to enhance the immune response. In contrast to AB, T cell receptors (TCRs) do not 
recognize native antigens. For recognition by the TCRs, antigens are intracellularly degraded 
and the originated peptides are presented by major histocompatibility complexes (MHC) to 
TCR.  
Both, the humoral and the cellular immunity of the adaptive immune system are antigen 
specific. After an infection memory cells are formed. Thus a reinfection can be eliminated faster 
and more efficient.  
1.2 T lymphocytes 
T cells mature in the thymus from lymphoid progenitor cells. During the maturation, TCR 
rearrangement is performed and autoreactive T cells are eliminated. This ensures diversity of 
functional TCRs and prevents autoimmunity. 
One T cell carries around 30,000 TCR on the cell surface. Most TCRs are composed of one α 
and one β-chain. However, a minority of T cells also expresses TCR composed of one γ and 
one δ chain (Brenner et al., 1986).  
T lymphocytes can be subclassified into two main groups, depending on the expression of 
different co-receptors.  
CD8+ T cells, express the co-receptor CD8. They recognize peptides presented on major 
histocompatibility complex class I (MHC-I), which is expressed on all nucleated cells in the 
body. CD8+ T cells eliminate viral infected cells as well as tumor cells by the release of 
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effectorproteins like granzyme B and perforin or by inducing apoptosis in target cells via the 
expression of Fas ligand (Berke 1995).  
CD4 + T cells express the co-receptor CD4. They recognize peptides presented on major 
histocompatibility complex class II (MHC-II) of antigen presenting cells (APC). They play a 
crucial role in the regulation of the immune system by the production of cytokines and 
transcription factors (Nakayamada et al., 2012). Furthermore, CD4+ T cells induce humoral 
immunity by the recognition of the peptide-MHC-II-complex on B cells and additional binding 
of the CD40 Ligand (CD40L) to CD40 on B cells (Parker 1993). 
1.2.1 Structure of αβ T cell receptors 
The α- and β-chain of a classical T cell receptor are connected via a disulfide bridge. The 
extracellular part of both chains consists of a variable region (v), a joining segment (j) and a 
constant region (c). The chains are anchored in the membrane via a hydrophobic 
transmembrane domain, which ends in a short cytoplasmic tail (Kronenberg et al., 1986). This 
cytoplasmic tail of the TCR is too short for signal transduction into the cell. Therefore, the TCR 
assembles with accessory polypeptide chains, which form a CD3 complex. The complex is 
constructed by two heterodimeric chains (CD3 γ-ξ and CD3 δ-ξ) and a homodimeric ζ-chain 
(Figure 1-1 (A), Clevers et al., 1988). CD3 is important for correct assembly and surface 
expression of the TCR complex, as well as for the signal transmission into the cell. The 
intracellular parts of the CD3 complex contain immunoreceptor tyrosine-based activation 
motifs (ITAMs). After the binding of the TCR to a peptide-MHC-complex, the ITAMs get 
phosphorylated by receptor associated phosphotyrosine kinases of the Src-family kinases 
(Smith-Garvin et al., 2009). This phosphorylation activates a signal cascade whose actions 
include triggering Ca2+ influx into the cell. The increased Ca2+ concentration activates the 
phosphatase Calcineurin. The transcription factor nuclear factor of activated T cells (NFAT) 
gets activated by dephosphorylation via calcineurin. The activated NFAT gets translocated into 
the nucleus, where it activates the expression of specific genes, like interleukin-2 (IL-2).  
IL-2 regulates the proliferation and differentiation of T cells. It can be used as an activation 
marker of T cells. The expression of reporter genes, like lacZ or super green fluorescence 
protein (sGFP), under the control of the NFAT promoter can also be used as tool for the 
detection of T cell activation (Karttunen and Shastri 1991).  
For increased signal transduction, the co-receptors CD4 and CD8 bind to non-polymorphic 
regions of the MHC molecules. CD4 is a single polypeptide, composed of four domains (D1-
D4), whereas CD8 is a heterodimer with one α-chain and one β-chain (Figure 1-1 (B)). 
However, CD8 can also be formed as CD8αα homodimer (Zamoyska 1998). By binding to 
MHC, the co-receptor associated Src family kinase Lck gets activated and also phosphorylates 
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the ITAMs of the CD3 complex (Barber et al., 1989). Thereby, the signal transduction is 
increased. 
 
 
Figure 1-1 Structure of TCR complex and co-receptors. (A) Graphic of the TCR complex. The TCR 
is composed of one α and one β-chain connected via a disulfide bridge. This heterodimer is associated 
with CD3, which is formed by δξ and γξ and ζ, which is involved in the signal transduction. (B) The co-
receptors CD4 and CD8 of T lymphocytes. CD4 is formed by 4 domains (D1-D4), whereas CD8 is formed 
by two chains (red) connected by a disulfide bridge. CD8 can be a heterodimer formed by one α and 
one β-chain, as well as homodimer formed by two α-chains (modified from Janeway 2002).  
1.2.2 Diversity of T cell receptors 
T cell receptors cover a broad spectrum of antigens recognition. This receptor diversity is 
developed by gene recombination in the thymus. During T cell maturation, first the β-chain is 
reassembled. After successfully rearrangement, the α-chain also undergoes recombination. 
The recombination is illustrated in Figure 1-2. 
The alpha gene locus contains 54 TRAV genes, 61 TRAJ genes and one constant region. The 
beta gene locus contains 64-67 TRBV genes, followed by two gene groups, each composed 
of one TRBD (diversity, D1 or D2) followed by 13 TRBJ (TRBJ1.1-1.6 and TRBJ2.1-2.7) and 
one constant region (TRBC1 and TRBC2) (Arden et al., 1995, Rowen et al., 1996). During the 
rearrangement, a random V-gene is combined with a J-gene (α-chain) or with a D- and J-gene 
(β-chain). Additionally, palindromic (p) and non-germline (n) nucleotides are added between 
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the V- and J-region (α-chain) or between V-D and D-J (β-chain). The chains are transcribed to 
messenger RNA (mRNA), and the intron separating J- and C region is eliminated by post-
transcriptional splicing. By this recombination, every cell contains an individual TCR. The 
highly variable regions in the chains form three complementary determining regions (CDR) 
CDR1, CDR2 and CDR3. The variable region of both chains mainly code for the CDR1 and 
CDR2 regions. The CDR3 regions, which has the highest diversity, is formed by the N (α-
chain) and the NDN (β-chain).  
 
 
Figure 1-2 Rearrangement of TCR α- and β-chain. T cell diversity is generated by V-J (alpha chain, 
A) and V-D-J (β-chain, B) rearrangement. Some nucleotides are added randomly (N) to increase TCR 
diversity. The intron between J and the constant region C is removed after transcription by splicing 
(modified from Kronenberg 1986). 
1.2.3 T cell maturation 
T cell maturation in the thymus ensures that only functional, non-autoreactive T cells leave the 
thymus. The thymic seeding progenitors do not express TCRα and TCRβ and are double 
negative for CD4 and CD8. In the first step, the β-chain is rearranged. If the rearrangement 
was successful, a pre-TCR, composed of CD3, β-chain and an invariant pre-TCR α-chain is 
expressed and pre-TCR signalling is initiated (Böhmer 2005). The cells start to express CD4 
and CD8 (double positive T cells) and the α-chain is rearranged. Mature T cells are selected 
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for the recognition of self-peptide-MHC complexes presented on cortical thymic epithelial cells 
(cTEC, positive selection). Missing interactions induce death by neglect. However, a high 
affinity of the TCR induces apoptosis, to prevent autoreactivity (negative selection). Only T 
cells with intermediate affinity differentiate to mature, single positive T cells (Klein et al., 2014).  
1.2.4 Antigen recognition of T cells 
T cells can only recognize their antigens in association with MHC, in human called human 
leucocyte antigen (HLA). The highly variable CDR3 region of the TCR binds to the peptide 
presented on the MHC, and CDR1 and CDR2 mainly to the MHC (Rudolph et al., 2006).  
However, a single TCR is able to recognize more than one peptide-MHC-complex. Thus it is 
assumed that one TCR can recognize up to 1.3ˣ106 peptides (Wooldridge et al., 2012). The 
highly degeneracy of TCRs is called cross-reactivity. It ensures that most possible peptides 
presented by MHC are covered. 
Additionally, one in 103-104 T cells are able to recognize peptides presented on allogeneic 
MHC (Felix and Allen 2007). During T cell development in the thymus, T cells cannot be 
selected for their ability to bind to all HLAs which are not expressed by the individual. 
Alloreactivity especially plays a role after transplantations and bone marrow transplantation. In 
this so called graft-versus-host disease, donor T cells recognize peptides presented on 
recipient cells.  
1.3 Major Histocompatibility complex 
MHC play an important role in the adaptive immune system as well as in the recognition of self 
and foreign molecules.  
MHC-I molecules are expressed on all nucleated cells in the body. They are composed of a 
MHC-I heavy chain and an invariant subunit, the β-2-microglobulin (β2m). The heavy chain is 
encoded by three different polymorphic genes: human leukocyte antigen HLA-A, -B and -C. 
The heavy chain forms a binding groove, where cytosolic peptides bind and get presented on 
the cell surface to CD8+ T cells (Neefjes et al., 2011).  
In contrast to MHC-I, MHC-II molecules are only expressed on APCs (B cells, dendritic cells 
(DC) and macrophages). They are composed of one α and one β-chain, which forms a binding 
groove (Cresswell et al., 1987). These chains are encoded by three polymorphic genes, HLA-
DP, -DQ and -DR. APCs take up extracellular proteins by endocytosis. These proteins are 
degraded in the lysosome, loaded onto MHC-II molecules and presented to CD4+ T cells 
(Neefjes et al., 2011). 
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1.3.1 Comparison of MHC-I and MHC-II peptide loading 
Due to their different function, MHC-I and MHC-II molecules are loaded with their peptides in 
different cell compartments, illustrated in Figure 1-3.  
MHC-I molecules are folded in the endoplasmic reticulum (ER) by chaperons. The chaperone 
calnexin (CNX) performs the early folding of MHC-I molecules and binding of β2m. Calreticulin 
(CRT) stabilizes MHC-I molecules while ERp57 mediates the disulfide bond formation 
(Ellgaard and Frickel 2003).  
MHC-I molecules are loaded with cytosolic peptides, which have been degraded by the 
proteasome. After proteasomal cleavage, the C-terminus of the peptides are compatible with 
MHC-I binding, however the peptides are N-extended (Cascio et al., 2001). These precursors 
get trimmed in the ER by the ER aminopeptidase 1 (ERAP1, Saric et al., 2002).  
For peptide loading to MHC-I, it binds to the peptide loading complex (PLC). In the complex 
MHC-I/β2m is stabilized by CRT, ERp57 and Tapasin. Tapasin interacts with TAP1 and TAP2, 
which transport peptides of a length of 8-12 amino acids (AA) from the cytosol into the ER 
(Abele and Tampe 2004). After peptide binding, the peptide-MHC-I complex leaves the ER for 
presentation at the cell surface.  
Additionally, APCs, especially DCs, have the ability to uptake and present extracellular 
antigens on MHC-I. This presentation of non-cytosolic peptides on MHC-I is called cross-
presentation. This pathway is important for defence against tumor cells and viruses, which do 
not infect APCs (Kurts et al., 2010).  
The presentation of MHC-I can be modulated by Interferon gamma (INF-γ). INF-γ increases 
the expression of MHC-I, TAP, ERAP1 and the subunits of the immunoproteasome (Cascio et 
al., 2001).  
In contrast to MHC-I, MHC-II molecules are loaded with extracellular peptides in the MHC-II 
compartment (MIIC). To avoid peptide loading in the ER, the α- and β-chain of MHC-II 
associates with the invariant chain (Ii) in the ER (Cresswell et al., 1987). Ii is needed for the 
assembly of α and β-chain in the ER (Kvist et al., 1982). It blocks the binding groove of MHC-
II, and thereby prevents binding of cytosolic peptides (Roche and Cresswell 1990). 
Additionally, it targets the MHC-II to the MIIC by a targeting signal in the cytoplasmic tail 
(Lotteau et al., 1990). The targeting signal is recognized by the sorting adapters AP1, which is 
a trans-Golgi network adapter, and AP2, which is a plasma membrane adapter. This allows 
the complex to be targeted directly to the MIIC or it is targeted to the plasma membrane from 
where it is internalized by endocytosis and directed to MIIC (Neefjes et al., 2011). 
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Figure 1-3 Comparison of peptide loading on MHC molecules. (A) Loading of MHC-I with cytosolic 
peptides in the ER. The proteasome degrades cytosolic proteins. The peptides are transported via TAP 
into the ER where they are loaded onto MHC-I with the help of several chaperones. (B) The invariant 
chain (Ii) binds to MHC-II in the ER. The complex is transported to the MHC-II compartment (MIIC). Ii is 
degraded but CLIP still blocks the binding groove. HLA-DM exchanges CLIP with compatible peptides, 
which are degraded in the endosome by proteases (Modified from Neefjes 2011). 
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In the MIIC Ii is degraded by the proteases Cathepsin S and Cathepsin L, however the class-
II associated invariant chain peptide (CLIP) remains in the binding groove (Hsing et al., 2005). 
The binding of HLA-DM to MHC-II stabilizes MHC-II and prevents degradation. Additionally, 
HLA-DM catalyses the replacement of CLIP with exogenously supplied peptides. The 
dissociation of CLIP occurs best at a pH of 5.0 (Sloan 1995). HLA-DM acts as an editor. If the 
peptide-MHC complex is instable, the peptide is exchanged (Kropshofer et al., 1996). Only 
stable peptide-MHC-II-complexes are released for presentation on the cell surface. 
In contrast to MHC-I, the peptides that bind to MHC-II can protrude out of the binding groove 
at the N- as well as at the C-terminus (Rammensee 1995). Thereby, the size of the bound 
peptides is typically 13-17 AA (Rudensky et al., 1991). Shorter peptides can also bind to MHC-
II, however peptides shorter than 11 AA are removed by HLA-DM (Kropshofer et al., 1996). 
However, the part of the peptide in the binding groove, which interacts with the TCR, is usually 
9 AA long, with preferred anchor residues at position P1, P4, P6 and P9 (Rammensee 1995). 
Anchor positions of MHC-II as well of MHC-I can be used for T cell epitope predictions.  
1.4 Autoimmune diseases 
The immune system established several mechanisms to avoid autoreactivity, like clonal 
deletion of T cell clones as well as clonal anergy in the absence of a costimulation after the 
recognition of a peptide-MHC complex. Despite these mechanisms some self-reactive T cells 
can escape the control mechanisms (Wekerle 1992). However, potentially autoreactive 
lymphocytes can exist simultaneously without causing problems, if the antigen is not 
accessible, described as immunological ignorance. Additionally, they are controlled by 
regulatory T cells (Treg), which prevent their activation. However, if the self-tolerance controls 
fail, it leads to autoimmune diseases, whereby healthy tissue is attacked and destroyed.  
1.4.1 Multiple Sclerosis 
Multiple sclerosis (MS) is one of the most frequently neurological diseases in young adults. 
The disease is characterized by a chronic, inflammatory demyelination of the central nervous 
system (CNS) (Hartung et al., 2014). Although the etiology is not definite, MS is most likely an 
autoimmune disease. Lymphocytes pass the distorted blood-brain barrier and infiltrate into the 
brain and spinal cord, leading to demyelination, axon damage and neurological dysfunction 
(Vries et al., 2012). At the beginning, inflammation is transient in most patients and 
remyelination takes place. Later on, this relapse and remitting disease course changes to 
secondary progressive MS, whereby the disabilities accumulate (Compston and Coles 2008). 
Histological analysis of MS brains shows that MS can be differentiated into four patterns, with 
the common characteristic of inflammatory plaques (Lucchinetti et al., 2000).  
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CD4+ and CD8+ T cells, B cells, plasma cells, macrophages and activated microglia 
accumulate in several focal lesions, whereby the infiltration is often dominated by CD8+ T cells 
(Hohlfeld 2015). CD8+ as well as CD4+ T cells injure oligodendrocytes and neurons (Antel et 
al., 1994, Giuliani et al., 2003). A key player in animal models of MS are myelin specific CD4+ 
T cells (Hohlfeld et al., 2015). Often unconventional T cells are involved in MS. T cell repertoire 
analysis could show an expansion of a mucosal-associated semi-invariant T (MAIT) cells-
related TCR Vβ1+ T cell clone in active brain lesions at disease onset (Hohlfeld et al., 2016). 
Clonally expanded B cells and intrathecal expression of auto-antibodies can also be found in 
MS patients (von Büdingen et al., 2001, Obermeier et al., 2008, Brändle et al., 2016).  
Even though the cause of MS remains unclear, genetics and environmental factors are thought 
to trigger MS. The recurrence in families is higher than in the common population, especially 
for monozygotic twins (Compston 2008). Additionally, the expression of different HLA alleles 
influences the disease. The risk of MS is increased by the expression of different MHC-II 
molecules, like HLA-DRB1*15:01. On the other hand, the expression of protective class I 
alleles, like HLA-A*02:01, reduces the risk (Moutsianas 2015). Environmental factors, like 
lifestyle and infection with Epstein-Barr virus increase the risk for MS (Compston and Coles 
2008, Levin et al., 2003). A reason therefore might be molecular mimicry, whereby viral 
antigens share sequences with self-antigens in the CNS, and thereby trigger autoimmunity 
(Cusick et al., 2012, Hohlfeld et al., 2015).  
1.4.2 Paraneoplastic neurological diseases 
Paraneoplastic neurological diseases (PND) are a subgroup of encephalitis. Encephalitis are 
acute inflammations of the brain associated with neurological dysfunctions. The disease is 
often caused by viral (e.g. herpes simplex virus) or other infections. It can also be antibody-
associated, as it is the case for PNDs. However, often the encephalitis is idiopathic (Tunkel et 
al., 2008, Granerod et al., 2010).  
PNDs occur as a result of tumor immunity, whereby anti-neuronal antibodies are found in the 
serum and/or in the CSF of the patient. The disease is often associated with specific tumors, 
like small-cell-lung cancer (SCLC), thymoma, lymphoma, breast- and ovarian cancer and 
neuroendocrine tumors (Höftberger et al., 2015). The antibodies are specific for neuronal 
antigens, which are also expressed in the tumor. PNDs can be classified into two sub-groups: 
antibody-mediated PND and T cell mediated PND. 
In the antibody-mediated PND, the antibodies target cell-surface antigens, like N-methyl-D-
aspartate (NMDA) receptors or γ-aminobutyric acid type B (GABAB) receptors. Thus they are 
directly pathogenic. Although the expression of the antibodies is often associated with tumors, 
they can also occur without cancer (Dalmau and Rosenfeld 2008).  
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In the T cell mediated PND, the expressed antibodies are targeted against intra-cellular 
antigens. The disease is mediated by T cells which are probably targeted against the same 
antigens, which are recognized by the antibodies, as it was observed in patients with anti-Yo 
(also called cdr2) and anti-Hu antibodies (Albert et al., 2000, Benyahia et al., 1999). 
Additionally, a high infiltration of oligoclonal cytotoxic T cells (CTL) is found in the brain as well 
as in the tumor and the treatment of only the humoral immunity is not promising (Dalmau and 
Rosenfeld 2008). 
The diagnosis of PND is difficult, because the first symptoms often occur before cancer is 
diagnosed. The disease can be classified by classic syndromes combined with the expression 
of paraneoplastic antibodies. Additionally, inflammation of the CSF can be observed. However, 
atypical symptomes, the presence of poorly characterized antibodies and the missing 
determination of a tumor can impede the diagnosis (Dalmau and Rosenfeld 2008).  
The comparison of the TCR repertoire in the tumor and the CNS can deliver insights into the 
pathology of the disease. Pellkofer et al. (2009) could detect identical T cell clones in the tumor, 
CSF and the blood of a patient with paraneoplastic encephalomyelitis with adrenal 
neuroblastoma. This indicates a shared antigen between the tumor and the affected CNS 
tissue, opening new strategies for therapies. PNDs are usually treated by removing the tumor 
in combination with immunotherapy and plasmaphereses, to eliminate the antibodies 
(Höftberger et al., 2015).  
1.4.3 GABAA receptors in diseases 
The GABAA receptor is involved in various diseases. Differences in the expression pattern of 
GABAA receptors subunits and point mutations in the different subunits play a role in different 
types of epilepsy, anxiety and schizophrenia (Moehler 2006).  
A new disease pattern was first described by Petit-Pedrol at al., 2014. They detected 
antibodies against GABAA receptor α1 and β3 subunits in the serum and CSF of patients who 
suffer from encephalitis with refractory seizures and status epilepticus. The antibodies 
selectively reduce the expression of GABAA receptor clusters at synapses, which causes 
refractory seizures. Patients with high antibody titres showed behaviour changes and cognitive 
deficits combined with extensive cortical and subcortical brain MRI abnormalities. The seizures 
were refractory to anti-epileptic treatment, however some patients responded to 
immunotherapy. Anti-GABAA antibodies can appear in combination with antibodies against 
intracellular antigens, like glutamic acid decarboxylase 65 (GAD65), as well as antibodies 
against surface antigens, like NMDA or GABAB receptors (Petit-Pedrol et al., 2014, Ohkawa et 
al., 2014, Pettingill et al., 2015).  
In another study by Pettingill et al, 2015 IgG1 antibodies against the α1 and γ2 subunits were 
identified. Additionally, IgM antibodies against GABAA receptor without subclass specificity 
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were found in patients with low antibody titres. Only 47 % of the patients suffered from seizures, 
however other symptoms like memory impairment (47 %), hallucinations (33 %) and anxiety 
(20 %) were observed (Pettingill et al., 2015).  
Even though the disease has similarities with PNDs, an underlying tumor was not frequently 
found. In the study of Petit-Pedrol at al., 2014 one patient out of 18 was observed with a 
thymoma. Ohkawa et al., 2014 also described two patients with invasive thymoma in 
combination with the expression of antibodies against GABAA receptor β3 subunit. Simabukuro 
et al., 2015 could even show by staining of tissue sections that the tumor tissue of a patient, 
with thymoma and GABAA receptor antibodies, expresses GABAA receptors. These findings 
indicate a linkage of GABAA receptor associated encephalitis and thymoma. This linkage 
shows that the disease presumably is paraneoplastic. However, because the disease pattern 
is quite new, more patients need to be screened for antibodies against GABAA receptor to 
verify the linkage.  
1.4.3.1 Diagnosis Index patient 2 
The case Index patient 2 (IP2) was one of the index patients described by Petit-Pedrol et al., 
2014. IP2 was a 51-year-old male, in whose serum and CSF antibodies against α1, β3 subunit 
of GABAA receptor were detected. The patient showed behavioural changes, depressions and 
psychosis, followed by clonical seizures and epilepsy, resulting in status epilepticus. The 
patient was treated with anticonvulsants and immunosuppressants, however after 10 weeks 
the status epilepticus persisted and the patient died of a sepsis (Petit-Pedrol et al., 2014). 
E. Beltrán (Institut für klinische Neuroimmunologie, Ludwig-Maximilians-Universität München, 
AG Dornmair) cloned the antibody from CSF and could show, in cooperation with J. Dalmau 
(August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain) that it binds 
to the α1 subunit (unpublished data). IP2 suffered from a synaptic reduction of GABAA 
receptors, caused by antibody-mediated internalization of the receptor.  
Even though the availability of auto-antibodies and their antigens are described, the 
pathogenesis of the disease is still unclear. Is the disease paraneoplastic, associated with a 
thymoma? And which role do the T cells play in the diasease? The fact that antibodies against 
GABAA α1 subunit were found in the patient, already indicates an involvement of CD4+ T cells, 
which are crucial for a humoral immune response. For other PNDs it was shown that CD8+ T 
cells have a key role, with the presence of cross-reactive T cells in the tumor tissue as well as 
in the CSF, indicating a shared antigen (Pellkofer at al., 2009). Which role do CD8+ and CD4+ 
T cells play in GABAA receptor encephalitis? 
Thus, it is indispensable to uncover disease related T cells and their antigens for a better 
understanding of the disease pattern, as well as for a specific therapy.  
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1.4.3.2 Structure and function of γ-Aminobutyric acid type A receptor 
γ-Aminobutyric acid type A (GABAA) receptors are ligand gated ion channels, which belong to 
the Cys-loop superfamily (Connolly and Wafford 2004). They are responsible for fast inhibitory 
transmission in the CNS (Schofield et al., 1987). The heteropentameric structure is formed by 
a combination of different subunits (α1-6, β1-3, γ1-3, δ, ε, θ, π, ρ1-3) (Barnard et al., 1998, 
Mehta and Ticku 1999), however a combination composed of two α1, two β2 and one γ2 
subunits is most abundant (Sieghart and Sperk 2002). One subunit consists of an extracellular 
domain and four transmembrane (TM) domains connected by an intracellular loop between 
TM3 and TM4 (Karlin and Akabas 1995, Figure 1-4). The subunit composition determines the 
properties of the receptor, such as the affinity for ligands, it’s conductance as well as the 
kinetics (Gonzalez 2013).  
 
 
Figure 1-4 Illustration of GABAA receptor. (A) Model of the side view of GABAA receptor (adopted 
from Campagna-Slater 2007), illustrating the transmembrane domain (bottom) and the extracellular 
domain (top). (B) Model of one subunit of GABAA receptor, composed of an N-terminal extracellular 
domain with disulfide bridge and four transmembrane domains, connected with an intracellular loop 
between TM3 and TM4. (C) Illustration of the formation of a GABAA receptor by 5 subunits forming a 
pore in the membrane.  
GABAA receptors contain two GABA binding sites located at the interface of α and β subunits 
(Sigel et al., 1992, Amin and Weiss 1993). Binding of agonistic GABA leads to a conformational 
change, which results in an opening of the pore and, thereby, chloride and bicarbonate ions 
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can pass through the pore (Kash et al., 2004). The influx of Cl- results in an inhibitory 
hyperpolarization (Goetz et al., 2007).  
As all members of the Cys-loop superfamily, GABAA receptors can be allosterically modulated 
by zinc ions. Zinc ions can bind to three allosteric sites, one site in the ion channel and two 
sites at the α and β interface, and thereby inhibit the receptor function. However, the zinc 
sensitivity depends on the subunit composition of the receptor (Hosie et al., 2003). Additionally, 
pharmaceutical drugs, like benzodiazepines, barbiturates, picrotoxin and anesthetical steroids 
can modulate receptor activity, by binding to allosterical binding sites (Olsen and DeLorey 
1997).   
GABAA receptors are localized at inhibitory synapses as well as outside of synapses (Somogyi 
et al., 1989) in different regions of the brain, including the hippocampus (Sieghart and Sperk 
2002). 
Although the GABAA receptor is most abundant in the brain, other peripheral tissues as well 
as the immune system, also express GABAA receptors (Akinci and Schofield 1999, Alam et al., 
2006).  
1.5 Identification of disease related TCR  
Autoreactive T cells play a key role in autoimmune diseases. In psoriasis it was shown that an 
antigen expressed in melanocytes triggers CD8+ T cell response (Arakawa 2015). In several 
autoimmune diseases, like MS and GABAB receptor limbic encephalitis, an infiltration of 
lymphocytes is observed (Hohlfeld et al., 2016, Golombeck et al., 2016). However often the T 
cell repertoire, their antigens and their role in the disease remain unknown. For the better 
understanding of the pathogenesis of autoimmune diseases, as well as for the development 
of convenient therapies, it is essential to identify disease related TCR and their antigens.  
To distinguish disease relevant T cells from bystander T cells, the morphology of the T cells, 
especially their location in the lesion is important. Close contact with target cells is a possible 
hint for autoreactivity. Secondly, the expression of activation markers and oriented expression 
of lytic granular, like perforin and granzyme B, indicate disease related T cells in the lesion. 
Last but not least the analysis of the TCR repertoire can show if the T cell population is 
polymorphic or if a clonal expansion of one or more T cell clones is present in the lesion, 
indicating a proliferation after antigen stimulation (Dornmair et al., 2003).  
The TCR α- and β-chains can be identified by a clone-specific approach, combining CDR3 
spectratyping of the β-chain, staining of tissue sections for corresponding TCR Vβ regions and 
laser microdissection of the cells. After RT-reaction and pre-amplification of the chains, the β-
chain is amplified with clone-specific primers and the α-chain with a universal primer set (Seitz 
et al., 2006). However, this technique is limited to the availability of antibodies for the Vβ-
chains. An improved approach by Kim et al. (2012) allows the analysis of both, the α-chain as 
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well as the corresponding β-chain at once. This unbiased multiplex RT-PCR combines the 
described universal primer set for the amplification of the α-chain (Seitz et al., 2006) with an 
unbiased primer set to amplify all possible β-chains. This allows analysis of both, the α-chain 
as well as the corresponding β-chain of a single cell (Kim et al., 2012).  
A new strategy to analyse the T cell repertoire is by next generation sequencing (NGS). This 
technique allows thousands of sequences to be obtained in a single run (Ruggiero et al., 2015, 
Held et al., 2015). By the usage of a unique molecular identifier (UMI), expanded T cells clones 
can be distinguished from PCR amplificates, and thereby a quantification of the T cell clones 
is possible (Shugay et al., 2014). However, NGS only shows the expansion of different α- and 
β-chains, but the matching chains cannot be assigned. Only because one α-chain shows up 
for example 20 times, it is still not proven, that it pairs with the β-chain which also shows up 20 
times. Thus, to concomitantly identify pairs of α- and β-chains, single cell analysis is still 
required.  
1.6 Identification of TCR antigens 
The antigen identification of disease related TCR is challenging. For the correct presentation 
of peptides, the proteins have to be processed correctly in the cell and loaded onto MHC 
moleucles. Additionally, TCRs have a low affinity for peptide-MHC-complexes. Thereby, the 
usual biochemical methods, which are based on affinity and are applied in the antigen search 
of antibodies, like immunoprecipitation, are out of the question (Dornmair et al., 2003).  
The usage of cDNA libraries from affected tissue, presented on melanoma cells can be used 
for the antigen screening (van der Bruggen et al., 1991). This approach assumes the 
availability of patient material, which is not always the case. Furthermore, a correct antigen 
processing is required.  
Antigen screening with synthetic peptide libraries (Gundlach et al., 1996) can overcome the 
antigen processing problems. However, the more complex these libraries are, the more diluted 
is the correct antigen, and might not activate the TCR anymore. Additionally, they cannot be 
recovered by cloning (Siewert et al., 2012).  
Moreover, the MHC repertoire in one individual is polymorph as well as polygenic (Neefjes et 
al., 2011). Usually, one individual is heterozygote for MHC alleles. Thereby, different MHC 
molecules are expressed on the cell surface and the MHC-restriction of the disease related 
TCR is unknown. 
The detection of cytokines, like INF-γ, by enzyme linked immunosorbent assay (ELISA) are 
often used as read-out for T cell activation (Fujii et al., 2001).  However, this read-out is not 
sensitive enough for antigen screenings with libraries.  
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1.6.1 Methods for the Identification of CD8+ T cell receptor mimotopes 
To overcome these problems, Siewert et al., 2012 designed an unbiased method for the 
identification of CD8+ T cell mimotopes with plasmid-encoded combinatorial peptide libraries 
(PECPL). Mimotopes are peptides, which mimic the antigen. Thereby they are recognised by 
the immune system.  
For the screening of CD8+ T cell antigens, COS-7 cells are co-transfected with plasmids 
coding for MHC-I and PECPL. The short peptides are loaded onto MHC-I molecules and get 
presented on the cell surface. These cells are overlaid with 58-/- cells, which are transfected 
with hCD8αβ and the TCR α and β-chain of interest. The advantage of 58-/- cells is, that they 
are negative for TCR α- and β-chain. Thereby they do not express a TCR on the cell surface 
but possess the signalling machinery for T cell activation. Thereby, they do not form chimeric 
TCR with the transfected chains (Blank et al., 1993). The transfected α- and β-chain associate 
with the murine CD3 and show up on the cell surface (Figure 1-5). Additionally, the cells are 
transfected with sGFP under the control of the NFAT-enhancer. After the binding of the TCR 
to the correct peptide-MHC complex, the signal cascade triggers sGFP expression causing the 
cell to fluorescence green (Figure 1-5).  
By transfection with PECPL, no antigen processing is required. Short peptides are directly 
expressed and loaded onto MHC-I molecules. In addition, no knowledge about the possible 
antigen is necessary. The cells are kept in physical contact by gravity, thus high affinity is not 
needed. The detection system, based on single cell activation is highly sensitive, and the 
correct peptides can be detected among millions of irrelevant peptides. In contrast to peptide 
libraries, the plasmids can be easily recovered by PCR (Siewert et al., 2012).  
New candidate antigens of a presumably autoreactive, CD8+ TCR from a MS patient were 
identified using this screening approach (Rühl et al., 2016). Moreover, melanocytes expressing 
ADAMTS-like protein 5 (ADAMTSL5) were identified as a target of a psoriatric, autoreactive 
TCR (Arakawa et al., 2015).  
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Figure 1-5 Unbiased identification of CD8+ T cell antigens with plasmid-encoded combinatorial 
peptide libraries. A eukaryotic cell detection system is used for the antigen identification of the TCR of 
interest. 58-/- T hybridoma cells are transfected with TCRα and TCRβ-chains. Additionally, hCD8αβ and 
sGFP under the NFAT-enhancer are transfected. In parallel, COS-7 cells are transfected with MHC-I 
and a plasmid-encoded combinatorial peptide library (PECPL). COS-7 cells express the peptide library, 
which are loaded onto MHC-I molecules and presented on the cell surface. The two cell lines are 
cocultivated for 16 h. After binding of the TCR of 58-/- to the correct peptide-MHC-complex, sGFP 
synthesis is triggered. The underlying COS-7 can be isolated with a capillary via a micromanipulator and 
recovery PCR is performed. Modified from Siewert et al. 2012.  
1.6.2 Methods for the identification of CD4+ TCR mimotopes 
The method established by K. Siewert et al. (2012) is only useable for the detection of CD8+ 
T cell antigens. Other trials were made for the identification of CD4+ t cell antigens. Sanderson 
et al. demonstrated 1995 that fusion proteins with the invariant chain successfully enter the 
MHC-II presentation pathway, and hence are efficiently presented by MHC-II molecules on the 
cell surface. These Ii derivates showed an enhanced T cell stimulation compared to native or 
recombinant proteins (Malcherek et al., 1998). However, comparable to CD8+ T cell antigens, 
the cells have to uptake the proteins, process them and load them correctly onto MHC-II 
molecules.  
For library screening, fibroblast cells expressing library peptides covalently fused to the N-
terminus of the β-chain of MHC-II can be used and cocultivated with hybridoma cells 
expressing the TCR (Boen et al., 2000). However, new libraries have to be generated for every 
HLA.  
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Another possibility is the application of a vector, coding for the invariant chain, in which CLIP 
can be substituted by antigenic peptides or a library (Fujii et al., 2001). However, the read-out 
system with the detection of INF-γ in the supernatant of the cells is not sensitive enough for 
library screening  
In this study the detection system established by K. Siewert et al. (2012) for the identification 
of CD8+ T cell antigens is modified to allow the detection of CD4+ T cell antigens. Some parts 
of the detection method can be adopted, like the detection system. Other parts, like the 
libraries, have to be designed for the usage for the identification of CD4+ T cell antigens.  
In the CSF of IP2 antibodies against the GABAA receptor were detected. This indicates an 
involvement of CD4+ T cells in the disease, because CD4+ T cells are crucial for most humoral 
immune responses. The new established antigen screening system for CD4+ T cell antigens 
could be applied to possible disease related CD4+ T cells in GABAA receptor encephalitis. The 
identification of CD4+ T cell antigens could contribute to a better understanding of the 
pathology of GABAA receptor encephalitis.  
Moreover, the new screening system for the detection of CD4+ T cell antigens could also be 
applied for other autoimmune diseases with involved CD4+ T cells, like MS. The knowledge of 
the antigens does not only contribute to a better understanding of the diseases, but also opens 
new ways for possible therapies. 
1.7 Aim of this study 
Patients with GABAA receptor encephalitis suffer from a synaptic reduction of GABAA 
receptors, caused by antibody-mediated internalization of the receptor. Even though auto-
antibodies and their antigens were described, nothing is known about the role of T cells in 
these patients. Thus, for a better understanding of the disease pathogenesis, as well as for a 
future specific therapy, it is indispensable to uncover disease related T cells and their antigens. 
The presence of antibodies against GABAA α1 subunit already indicate the existence of CD4+ 
T cells, which are crucial for most humoral immune responses. Moreover, CD8+ T cells often 
play a key role in autoimmune diseases.  
For the better understanding of the role of T cells in the disease, disease related T cells have 
to be distinguished from bystander T cells in the TCR repertoire. For interesting, expanded 
clones, the disease related TCR, their HLA-restriction, and antigenic peptides must then be 
analysed. Although a sensitive method is available for the identification of CD8+ T cell 
antigens, no method is available to identify CD4+ T cell antigens among millions of bystanders.  
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The aim of this study was therefore focused on:  
 
The CD4+ and CD8+ TCR repertoire of IP2 should be analysed in the CSF, the hippocampus 
and the lateral sulcus. To concomitantly identify matching α- and β-chains of the TCR, single 
cells are analysed. The repertoire is analysed using the following methods:  
- Identification of matching α- and β-chains from single cells of the CSF of IP2 
- Immunohistochemistry (IHC) for the infiltration of CD8+ and CD4+ T cells in the 
brain 
- Single cell analysis of TCRs from brain sections isolated by laser microdissection  
- Bulk cell analysis by a clone-specific approach and by next generation sequencing 
in cooperation with E. Beltrán 
The identified disease related, presumably auto-reactive TCR of IP2 should then be analysed 
for their antigens. To this end, expanded T cell clones should be expressed in vitro and 
possible candidate antigens should be screened for T cell activation. Additionally, possible 
expanded CD8+ T cell clones should be analysed by the application of the unbiased PECPL 
method. Based on the expression of autoreactive antibodies in IP2, we expect to also identify 
expanded CD4+ T cell clones. To identify antigens of such possible CD4+ T cell candidates, 
the PECPL method should be modified to allow screening of MHC-II peptides. Following points 
should be established in parallel to the repertoire studies for the screening of CD4+ T cell 
antigens:  
- Design and generation of new libraries 
- Confirmation of the functionality of the system by the application of the well 
characterised, MS derived model T cell clone “Bbc9” as proof of concept  
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2 Material and Methods 
2.1 Material 
2.1.1 Instruments 
Balance Entris (Sartorius, Göttingen, Germany) 
PioneerTM PA214CM (Ohaus, Greifensee, Switzerland) 
Centrifuges Sprout (Heathrow Scientific LLC, Illinois USA) 
5417 R (Eppendorf, Hamburg, Germany) 
HaraeusTM MultifugeTM X3R (Thermo Scientific, Waltham, 
Massachusetts, USA) 
Avanti JXN-26 Rotor JA10 (Beckman Coulter, Krefeld, Germany) 
Cell counting chamber Neubauer (Carl Roth GmbH, Karlsruhe, Germany) 
Cryotom CM 1950 (Leica, Wetzlar, Germany) 
Electroporation Gene Pulser (Bio-Rad, Munich, Germany) 
4D NucleofectorTM Core Unit (Lonza, Basel, Switzerland) 
4D NucleofectorTM X Unit (Lonza) 
ELISA reader  Wallac VICTOR² 1420 Multilabel Counter, (Perkin Elmer, Waltham, 
Massachusetts, USA). 
Flow Cytometer BD FACSVerseTM  (Beckton Dickinson, Franklin Lakes, New Jersey, 
USA) 
BD FACSAria TM Ilu (Beckton Dickinson) 
Incubator APT.LineTM BD (E2) (Binder, Tuttlingen, Germany) 
New BrunswickTM Innova 44 (Eppendorf) 
New BrunswickTM Galaxy 170S and 170R (Eppendorf) 
Imager AlphaiIagerTM (Biozym Scientific, Oldendorf, Germany) 
Odyssey Fc (LI-COR, Lincoln, Nebraska, USA) 
Laser CryLaS FTSS 355-50 (Zeiss, Oberkochen, Germany) 
Microscope 
 
 
     Objectives 
 
 
      Filter 
 
      CCD Camera 
      Lamp 
Wilovert S (Wilhelm Will KG, Wetzlar-Nauborn, Germany) 
DM IL LED (Leica) 
Axiovert 200 M (Zeiss)  
Plan-Apochochromat® 5x/0.16; ∞/0.17 (Zeiss) 
Plan-Apochochromat® 10x/0.45 (Zeiss) 
Plan-Apochochromat® 20x/0.8 (Zeiss) 
sGFP: 472/30 nm, 520/35 (BrightLine Flourescence Filter, Semrock) 
and Cy3: 545/25 nm and 605/70 nm (Zeiss) 
CoolSNAP HQ2 (Photometrics, Tucson, AZ, USA) 
Fluoreszenz lamp HXP 120 (Visitron, Puchheim, Germany) 
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2.1.2 Plasmids 
Plasmid Size Resistance Gene Reference 
pHSE3’-HLA-DRA* 9.5 kb ampR, hygroR Section 2.4.5.5 
pHSE3’-HLA-DR1* 10.0 kb ampR, neoR Section 2.4.5.5 
 
     Objectives 
 
 
 
      Filter 
 
      CCD Camera 
      Lamp 
 
     Objectives 
 
      Filter 
 
      CCD Camera 
      Lamp 
AxioObserver.Z1 (Zeiss)  
Plan-Apochromat® 5x/0.16 (Zeiss) 
Plan-Apochromat® 10x/0.45 (Zeiss) 
EC Plan-Neofluar® 20x/0.5 (Zeiss) 
EC Plan-Neofluar® 40x/0.75 (Zeiss) 
sGFP: ET525/50M and ET470/40; Cy3: ET630/75M and ET560/40X; 
(CHROMA, Olching, Germany) 
CoolSNAP HQ2 (Photometrics) 
Sola-SM Light Engines® (Lumencor, Inc.,  Beaverton, Oregon, USA) 
Axiovert 200 M (Lasermicrodissection) 
LD Plan-Neofluar 20x/0.40 Korr (Zeiss) 
LD Plan-Neofluar 40x/0.60 Korr (Zeiss) 
10x basic-Z FITC/GFP BP450-490 and BP515-565; Cy3: 20x basic 
BP546/12 and BP575-640 (Zeiss) 
HV-D30 (Hitachi KokusaiElectric America, Woodbury, NY, USA) 
Fluoreszenz lamp HXP 120 (Visitron) 
Microinjector Cell Tram Vario (Eppendorf) 
Micromanipulator LN25 Mini (Luigs und Neumann, Ratingen, Germany) 
pH meter pH521 (WTW, Weilheim, Germany) 
Pipetting Robot Janus Automated Workstation (Perkin Elmer, Waltham, 
Massachusetts, USA) 
Power Supply EPS 3501 XL (Amersham Pharamacia Biotech, Freiburg, Germany) 
LKB ECPS 3000/150 (Amersham Pharamacia Biotech) 
PowerPac300 (Bio-Rad, Munich, Germany)  
Robo Mover PALM Microlaser Technologies (Bernried, Germany) 
Spectrophotometer NanoDrop 2000 (Thermo Scientific, Waltham, Massachusetts, USA) 
UV-1600 PC Photospectrometer (VWR International GmbH, 
Darmstadt, Germany) 
Sterile Bench FlowSafe B-[MaxPro]2-160 (Berner, Elmshorn, Germany) 
Thermocycler T3 Thermocycler (Biometra, Göttingen, Germany) 
Bioer Genetouch Thermal Cycler (Biozym) 
Mastercycler gradient (Eppendorf) 
Master cycler pro vapo protect (Eppendorf) 
Water preparation MilliQ Advantage (Merck Millipore, Billerica, Massachusetts, USA) 
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pHSE3’-HLA-DR2a* 10.0 kb ampR, neoR Section 2.4.5.5 
pHSE3’-HLA-DR2b* 10.0 kb ampR, neoR Section 2.4.5.5 
pHSE3’-HLA-A*02:01* 10.2 kb ampR, neoR Section 2.4.5.2 
pHSE3’-HLA-A*23:01* 10.2 kb ampR, neoR Section 2.4.5.2 
pHSE3’-HLA-B*35:01* 10.2 kb ampR, neoR Section 2.4.5.2 
pHSE3’-HLA-B*44:03* 10.2 kb ampR, neoR Section 2.4.5.2 
pHSE3’-HLA-C*04:01* 10.2 kb ampR, neoR Section 2.4.5.2 
pHSE3’-HLA-C*16:01* 10.2 kb ampR, neoR Section 2.4.5.2 
pHSE3’-Blasticidin* 8.2 kb ampR, blsR Section 2.4.5.8 
pHSE3’-Blasticidin-largeT 
antigen* 
10.3 kb ampR, blsR Section 2.4.5.8 
pRSV-AV8S1* 6.1 kb ampR, hygroR Section 2.4.5.3 
pRSV-BV8S1* 6.1 kb ampR, neoR Section 2.4.5.3 
pRSV-AV22S1  6.1 kb ampR, hygroR G. Giegerich, K-Dornmair 
pRSV-BV9.1 6.1 kb ampR, neoR G. Giegerich, K-Dornmair 
pcDNA6/V5-HisA 5.1 kb ampR, blsR Invitrogen 
pcDNA-NFAT-sGFP 7.4 kb ampR, blsR K. Siewert, K. Dornmair 
pcDNArc-spacer  7.6 kb ampR, blsR K. Siewert, G. Rühl  
pcDNA-candidates IP2-8S1* 5.1 kb ampR, blsR Section 2.4.5.4 
pcDNA-N27 5.1 kb ampR, blsR G. Rühl 
pc-DNA-Ii-wt* 5.7 kb ampR, blsR Section 2.4.5.6 
pcDNA-delta-Ii* 5.7 kb ampR, blsR Section 2.4.5.6 
pcDNA-Ii-hMBP141-149* 5.7 kb ampR, blsR Section 2.4.5.6 
pcDNA-Ii-hMBP141-150* 5.7 kb ampR, blsR Section 2.4.5.6 
pcDNA-Ii-hMBP141-151* 5.7 kb ampR, blsR Section 2.4.5.6 
pcDNA-Ii-hMBP139-151* 5.7 kb ampR, blsR Section 2.4.5.6 
pcDNA-delta-Ii-hMBP141-149* 5.7 kb ampR, blsR Section 2.4.5.6 
pcDNA-delta-Ii-hMBP141-150* 5.7 kb ampR, blsR Section 2.4.5.6 
pcDNA-delta-Ii-hMBP141-151* 5.7 kb ampR, blsR Section 2.4.5.6 
pcDNA-delta-Ii-hMBP139-151* 5.7 kb ampR, blsR Section 2.4.5.6 
pcDNA-Ii-ECPL-N27* 5.7 kb ampR, blsR Section 2.4.5.7 
pcDNA-Ii-ECPL-N27-M1,9* 5.7 kb ampR, blsR Section 2.4.5.7 
pcDNA-Ii-ECPL-N33* 5.7 kb ampR, blsR Section 2.4.5.7 
pcDNA-Ii-ECPL-N33-M2,10* 5.7 kb ampR, blsR Section 2.4.5.7 
pcDNA-Ii-ECPL-N36-C* 5.7 kb ampR, blsR Section 2.4.5.7 
pcDNA-Ii-ECPL-N36-N* 5.7 kb ampR, blsR Section 2.4.5.7 
pcDNA-Ii-ECPL-N36-C-M2,10* 5.7 kb ampR, blsR Section 2.4.5.7 
pcDNA-Ii-ECPL-N36-N-M3,11* 5.7 kb ampR, blsR Section 2.4.5.7 
pcDNA-Ii-ECPL-N39* 5.7 kb ampR, blsR Section 2.4.5.7 
pcDNA-Ii-ECPL-N39-M3, 11* 5.7 kb ampR, blsR Section 2.4.5.7 
* constructed during this study 
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2.1.2.1 Plasmids expressing possible IP2-8S1 antigen-candidates  
Plasmid Size Resistance Gene Reference 
pcDNA-CLWAWILLL* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-GLGERVTEV* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-GLGERVTEV* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-ILSQVSFWL* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-TAMDWFIAV* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-FIAVCYAFV* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-LLFGIFNLV* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-LLYTMRLTV* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-YLPCIMTVI* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-IMTVILSQV* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-YAWDGKSVV* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-RLSRIAFPL* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-IAFPLLFGI* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-PLLFGIFNL* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-GIFNLVYWA* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-NLVYWATYL* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-TMPNKLLRI* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-HLEDFPMDA* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-VLTMTTLSI* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-AMDWFIAVC* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-EYVVMTTHF* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-TYLPCIMTV* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-WFIAVCYAF* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-CYAFVFSAL* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-FVFSALIEF* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-IVQSSTGEY* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-MDWFIAVCY* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-KPKKVKDPL* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-PVSDHDMEY* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-DAHACPLKF* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-LPCIMTVIL* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-WFIAVCYAF* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-IAVCYAFVF* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-MEYTIDVFF* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-IEFATVNYF* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-LEDFPMDAH* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-GEYVVMTTH* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-LLDGYDNRL* 5.1 kb ampR, hygroR Section 2.4.5.4 
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pcDNA-VFTRILDRL* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-KTDIFVTSF* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-PMDAHACPL* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-QYDLLGQTV* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-GYFVIQTYL* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-KPPEPKKTF* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-TYLNREPQL* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-MTVLRLNNL* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-YAYTRAEVV* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-FHLKRKIGY* 5.1 kb ampR, hygroR Section 2.4.5.4 
pcDNA-TATSYTPNL* 5.1 kb ampR, hygroR Section 2.4.5.4 
* constructed during this study 
2.1.3 Primer  
All primers were ordered at Metabion (Planegg, Germany) dissolved as 100 µM solution. For 
the synthesis of libraries, RT reaction and the touch down PCR of the multiplex single cell TCR 
PCR, primers were ordered HPLC purified. For other purposes primers were ordered desalted. 
Primer sequences see Section 5.1.  
2.1.4 Buffers and solutions 
2.1.5 Media and additives 
Ampicillin 0.1 mg/ml (Sigma, St. Louis, Missouri, USA) 
Blasticidin Invitrogen, Carlsbad, USA 
DNA loading buffer (6×) 10 mM Tris-HCl pH 7.5, 50 % (v/v) glycerin, 0.02 % (m/v) 
bromphenol blue, 0.02 & (m/v) xylenblue 
FACS Buffer PBS (pH 7.2), 1 % FBS 
Laemmli sample buffer 
(reducing, 3×) 
0.15 M tris-HCL pH 6.8, 7.5 % (w/v) SDS, 45 % glycerol, 0.01 % 
(w/v) bromphenol blue, 6 % (v/v) β-mercaptoethanol 
ELISA Wash PBS + 0.05 % (v/v) Tween 20 
MACS Buffer PBS (pH 7.2), 2 mM EDTA, 0,5 % FBS 
SDS running buffer 0.1 % (w/v) SDS, 0.02 M tris, 0.2 M glycine 
TBE Buffer 90 mM Tris-HCl, pH 8.0, 90 mM boric acid, 2 mM EDTA 
Tris-EDTA Buffer 10 mM Trizma base, 1 mM Titriplex, 0.05 % Tween-20 
Western Blot blocking buffer PBS + 5 % (w/v) Blotting grade blocker (Bio-Rad, Munich, 
Germany) 
Western Blot buffer anode 50 mM boric acid, 20 % (v/v) methanol, pH 9 
Western Blot buffer cathode 50 mM boric acid, 5 % (v/v) methanol, pH 9 
Western Blot washing buffer PBS + 0.05 % (v/v) Tween 20 
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Freezing media FBS + 10 % (v/v) DMSO 
Geneticin (G418) Sulfate Santa Cruz, Dallas, Texas, USA 
Hygromycin B 50 mg/ml (Invitrogen) 
Lysogeny broth media (LB) 0.1 % (w/v) Bacto Tryptone (Becton Dickinson, Franklin Lakes, 
New Jersey, USA) 
0.05 % (w/v) yeast extract (Becton Dickinson) 
0.1 % (w/v) NaCl (Sigma-Aldrich, St. Louis, Missouri, USA) 
LB plates LB media + 1.5 % Bacto Agar (Becton Dickinson) 
Puromycin Biomol, Hamburg, Germany 
RPMI complete RPMI 1640 (Sigma-Aldrich) 
10 % FBS (Biochmrom GmbH, Berlin, Germany)) 
100 U/ml Penicillin (Invitrogen) 
100 µg/ml Streptomycin (Invitrogen) 
1× MEM non-essential amino acids (Invitrogen) 
1 mM MEM sodium pyruvate (Invitrogen) 
2 mM L-Glutamin (Sigma-Aldrich) 
Trypsin Trypsin-EDTA Solution: 0.05 % Trypsin, 0.02 % EDTA (Sigma-
Aldrich) 
2.1.6 Enzymes, Kits and Reagents 
Cloning Kits TOPO® TA-Cloning (Invitrogen) 
pcDNATM 3.1 Directional TOPO® Expression Kit (Invitrogen) 
Co-precipitant Pellet Paint (Merk Millipore) 
DNA isolation kit QIAamp DNA Micro Kit (Qiagen GmbH, Hilden, Germany) 
Gel Extraction Kit MinElute (Qiagen GmbH) 
QIAquick (Qiagen GmbH) 
Glycogen for mol. Bio. 20 mg/ml (Roche, Mannheim, Germany) 
iProofTM  High-Fidelity DNA Polymerase 2 U/µl (Bio-Rad) 
Nucleofection AmaxanTM SE Cell Line 4D-NucleofectorTM X Kit (Lonza) 
PeqGreen DNA/RNA Dye (Peqlab Biotechnologie GmbH, Erlangen, 
Germany) 
PCR Purification Kit MinElute (Qiagen GmbH, Hilden, Germany) 
QIAquick (Qiagen GmbH) 
Plasmid purification QIAprep Spin MiniPrep Kit (Qiagen) 
HiSpeed Plasmid Maxi Kit (Qiagen) 
Pure YieldTM Plasmid Miniprep System (Promega, Madison, WI, 
USA) 
Rapid DNA Dephosphorilation 
and Ligation Kit 
Roche 
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restriction enzymes Aat-II, AgeI-HF, AscI, BamHI, KasI, NotI-HF (New England 
Biolabs, Ipswich, MA, USA) 
RT-PCR OneStep RT PCR Kit (Qiagen GmbH, Hilden, Germany)  
Superskript III, 200 U/µl (Invitrogen, Carlsbad, USA) 
T4 DNA Ligase  1 U/µl (Invitrogen) 
Taq DNA Polymerase 2,5 U/µl (Roche) 
Transfection Reagents FuGENE® HD Transfection Reagent (Promega, Madison, WI, 
USA) 
2.1.7 Antibodies 
Table 2-1 Primary antibodies 
Specificity Clone (Isotype) Lable Concentration 
[mg/ml] 
Company 
hCD3 Polyclonal (rabbit) - 0.6 Dako, Glostrup, Denmark 
mCD3e 145-2C11 (Hamster IgG) - 0.5 eBioscience, San Diego, USA 
mCD3e 145-2C11 (Hamster IgG) APC 0.2 eBioscience 
mCD3e 145-2C11 (Hamster IgG) FITC 0.5 eBioscience 
hCD4 RPA-T4 (mouse IgG1, κ) AF-488 - Becton Dickinson, Franklin 
Lakes, New Jersey, USA 
hCD4 4B12 (mouse IgG1, κ)  - 244 Dako 
mCD4 GK1.5 (Rat IgG2b, κ) PE 0.2 eBioscience 
hCD8 SK1 (mouse IgG1, κ) APC - BD Bioscience 
hCD8α LT8 (mouse IgG1) Cy3 (in-
house) 
1 AbD Serotec, Puchheim, 
Germany 
hCD8α C8/144B (mouse IgG1, κ)  157 Dako 
hCD74 PIN.1 (mouse IgG1) - 1 Abcam, Cambridge, UK 
hHLA-DR L243 (mouse IgG2a, κ) FITC 0.012 eBioscience 
hPerforin B-D48 (mouse IgG1) - 1 Abcam 
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Table 2-2 Secondary antibodies 
Specificity origin Lable Concentration 
[mg/ml] 
Company 
mouse IgG goat AF488 2 life technologies (Carlsbad, 
Carlifornia, USA) 
mouse IgG1 goat AF488 2 life technologies 
rabbit IgG goat AF594 2 life technologies 
mouse IgG (H+L) donkey IRDye800CW 1 LI-COR 
mouse Immunglobulins goat F(ab’)2 FITC 0.4 Dako 
 
Table 2-3 Isotype controls 
origin Lable Concentration 
[mg/ml] 
Company 
mouse IgG1 - 0.05 BD Bioscience 
mouse IgG1 - 0.5 life technologies 
mouse IgG2a κ FITC 0.2 eBioscience 
armenian hamster IgG APC 0.2 eBioscience 
hamster IgG2, λ1 FITC 0.5 BD Pharmingen 
mouse IgG1, κ APC 0.5 BD Pharmingen 
rabbit IgG - 0.5 BD Pharmingen 
mouse IgG1 κ - 0.5 BD Pharmingen 
mouse IgG1 Cy3 (in house) - BD Pharmingen 
2.1.8 Patient sample: Index patient 2 
Antibodies against the α1 subunit of GABAA receptor were detected in the CSF of IP2. We 
received a small amount of CSF of the patient and additionally frozen and paraffin embedded 
biopsy sections of the hippocampus (HC) and the lateral sulcus (LS) from our Spanish 
cooperation partern Dr. Josep Dalmau. 
2.1.9 Eucaryotic cell lines 
Cell line origin Media source 
Cos-7 African green monkey kidney 
fibroblast-like cell line 
RPMI complete ATCC 
58-/- Hybridoma-
cells 
TCR deficient mouse T 
hybridoma 
RPMI complete K. Dornmair (originated 
from H. von Böhmer 
and U. Welzien) 
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LTK- mouse fibroblasts RPMI complete ATCC 
LCL  B-lymphoblastoid cell line RPMI complete J. Mautner (Helmholtz 
Zentrum München) 
EBV B cells patient derived RPMI complete J. Mautner 
 
2.1.9.1 HLA-typing of LCL and EBV B cells 
Cell line HLA-A HLA-B HLA-Cw 
17490 02:01, A03:01 35:01, B40:01 03; 04:01 
#28 29:02, 30:01 42:01, 44:03 16:01, 17:01 
#36 24:03, 29:02 18:01, 44:03 12:03, 16:01 
#43 02:01, 23:01 18:01, 44:03 04:01, 07:01 
IBi 11:01, 24:02 18:01, 51:01 04:01, 07:01 
JM 02:01, 03:01 15:29,51:01 12:03,14:02 
KK 01:01, 23:01 50:01, 57:02 06:02, 18 
TG 23:01, 24:02 07:02, 07:05 07:02, 15:05 
Fe 01:01 08:01 07:01 
2.2 Isolation of T cells 
2.2.1 MACS Purification of CSF 
Cells from the CSF of patient IP2 were purified via MACS according to manufacturer’s 
instructions, briefly described below. After positive selection of CD4+ T cells, the flow-through 
was used to purify CD8+ T cells. 
In the first step, CSF was centrifuged for 10 minutes at 300x g at 4 °C. The supernatant was 
discarded, the cells washed twice with 1 ml MACS Buffer and resuspended in 80 µl MACS 
Buffer. 20 µl CD4 Micro Beads, human (Milteny Biotec) were added, mixed well and incubated 
for 15 min at 4 °C. After adding 2 ml MACS Buffer and centrifugation at 300x g at 4 °C, cells 
were washed with 2 ml MACS Buffer. The supernatant was discarded, cells resuspended in 
500 µl MACS buffer, and magnetic separation was performed with a MS column. The flow-
through was collected for further purification for CD8+ T cells. After washing 3 times with 500 
µl MACS buffer, the column was removed from the magnet and CD4+ T cell were eluted with 
1 ml MACS buffer.  
The flow-through was purified with CD8 MicroBeads, human (Milteny Biotec), as described. All 
steps were perfomed on ice.  
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2.2.2 Single Cell sorting of purified lymphocytes 
Single cells were isolated from the purified CD4+ and CD8+ T cells with a 20 µl pipette in a 
microscope. To this end, the cells were diluted with MACS Buffer in a 3.5 cm dish and the cells 
picked in 2 µl MACS Buffer into a PCR tube on dry ice.  
2.2.3 Isolation of single cells from cryosections by laser microdissection 
1.0 PET membrane slides (Zeiss) were prepared for cryosections. After baking the slides for 
4.5 hours at 180 °C, slides ware sprayed with RNaseZAP (Sigma-Aldrich) to remove RNase, 
and washed with H2O/DEPC. Slides were coated for one hour in a wet-chamber with poly-L-
lysine-hydrobromide (2 µg/µl, Sigma-Aldrich). Residuals were removed with H2O/DEPC and 
slides UV-irradiated for 30 minutes. 10 µm hippocampal sections and sections of the lateral 
sulcus of patient IP2 were cut in a cryotome and mounted on 1.0 PET foiled slides.  
To avoid mRNA degradation in the samples, laser microdissection (LMD) was performed in an 
UV-irradiated room, wearing protective clothing and all staining steps were performed in the 
presence of 1 U/µl Protector RNAse Inhibitor (Roche).  
10 µm hippocampal sections and sections of the lateral sulcus of patient IP2 on 1.0 PET foiled 
slides were used for laser microdissection. CD8+ and CD4+ T cells in the brain sections were 
stained in a short protocol. Thus slides stored in -80 °C were dried for one minute in an 
exsiccator and fixed with acetone. After washing with 100 µl DEPC H2O, cells were stained 
with 100 µl anti-CD4-AF488 (BD Bioscience, 1:100) for 5 minutes. After removing the first 
antibody by washing with DEPC H2O cells were stained with 100 µl anti-CD8-Cy3 (AbD 
Serotec, 1:50 in DEPC H2O) for 3 minutes. After washing, the tissue was covered with 250 µl 
2-propanol. The tissue was screened for 30 minutes with the Axiovert 200 M microscope for 
CD4+ and CD8+ T cells. Positive cells were marked in the program PALM Robo Software 
V3.2.0.11 (PALM Microlase Technologies). After 30 minutes the cells were cut out of the dried 
tissue via laser and collected in the oil covered lid of single PCR tubes. Tubes were stored on 
dry ice until RT-reaction was performed. 
The RT-reaction master mix was pipetted into the lid of the PCR tubes and tubes centrifuged 
for 3 minutes at 6,000×g. Unbiased single cell TCR PCR was performed (2.2.2).  
2.3 Immunohistochemistry 
For staining of frozen tissue sections, the slides, which were stored at -20 °C were dried for 10 
min at room temperature. Afterwards the tissue was fixed for 10 min in acetone. The sections 
were washed 3 times for 5 min with PBS and blocked by covering the tissue with 100 µl of 2 
% (m/v) BSA in PBS. 100 µl primary antibody (polyclonal anti-hCD3 (1:500), anti-hCD8α-Cy3 
(1:50), anti-hCD4-AF488 (1:100) or anti-hPerforin (1:100) were added and incubated for one 
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hour at room temperature. Double staining was performed by combining two antibodies. After 
washing three times for 5 min with PBS, the secondary antibody (goat anti-rabbit IgG AF488, 
1:1000 or anti-mouse IgG1 AF488) was added and incubated for 30 min at room temperature. 
The tissue was washed 3 times, whereby 4′,6-Diamidin-2-phenylindol (DAPI, 1:1000) was 
added in the third washing step. The tissue was embedded in Darko Flourescence embedding 
media and sealed with a cover glass.  
Paraffin sections were incubated twice for 10 min in Xylene for deparaffinization. Rehydration 
of the tissue was performed stepwise, started with incubation for 5 min in 50 % Xylene and 50 
% Ethanol, followed by 100 % Ethanol, 95 % Ethanol, 70 % Ethanol and 50 % Ethanol, each 
step incubated for 5 min. Afterwards, the slides were put in running cold tap water and 
remained in tap water until heat-induced epitope retrieval (HIER). HIER was performed in a 
steamer at 95 °C for 30 min in Tris-EDTA Buffer. After steaming, the slides were cooled down 
to room temperature in the Buffer for 20 min. The tissue was permeabilised for 5 min with PBS 
+ 0,05 % Triton and unspecific binding sides blocked for 1 h with PBS containing 1 % (m/v) 
BSA and 10 % (v/v) FBS. 200 µl primary antibody (polyclonal rabbit anti-hCD3 (1:50), anti-
hCD8 (Clone C8/144B, 1:50) or mouse anti-hCD4 (Clone 4B12) in PBS containing 1 % (m/v) 
BSA were incubated for 1 hour at room temperature. Double staining was performed by 
combining two antibodies. After washing three times with PBS, the secondary antibodies 
(mouse IgG1 κ and rabbit IgG) were incubated for 30 min at room temperature. The tissue was 
washed 3 times, whereby DAPI (1:1000) was added in the third washing step. The tissue was 
embedded in Darko Flourescence embedding media and a cover glass added.  
2.4 Molecularbiological Methods 
2.4.1 Unbiased multiplex single cell TCR PCR 
An unbiased protocol for single cell TCR polymerase chain reaction (PCR), based on Seitz et 
al., 2006 and Kim et al., 2012 was used to identify the T cell receptor α- and β-chains. The 
protocol was further improved by Q. Zhou (Institut für klinische Neuroimmunologie, Ludwig-
Maximilians-Universität München, AG Dornmair) during her PhD thesis (unpublished data) and 
utilized with her kindly permission in this study.  
In the first step, cDNA was created by reverse transcriptase (RT), from mRNA in the T cells. 
The RT reaction was followed by a touchdown PCR with primers for α- and β-chain of the TCR. 
Afterwards, for the β-chain, an anchor (UP) was added in a runoff reaction, followed by an 
anchor PCR. Alpha PCR was performed with the PCR product of the touch-down PCR and 
five different primer sets, covering all different Vα-chains. Primer sequences see Section 5.1.  
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2.4.1.1 RT-reaction 
The master mix for the RT-reaction was added to the picked single cells. 
5× one step RT-PCR buffer 4 µl     
dNTP (10 mM each)  0.8 µl     
Cα-RT-imp (100 µM)  0.06 µl (0.3 µM)   
Cβ-RT-2 (100 µM)  0.06 µl (0.3 µM)  
Enzyme Mix    0.8 µl    
RNase OUT   0.5 µl (20 units)   
H2O    13.78 µl   
𝚺20 µl/tube  
RT-reaction was performed at 50 °C for 30 minutes with a lid temperature of 52 °C. The product 
was stored at 4 °C for further usage.  
2.4.1.2 Touch-down PCR 
The master mix for the touch-down PCR was added to the RT-reaction. 
5× One step RT-PCR buffer  1 µl  
dNTP (10 mM each)   0.2 µl 
Vp-primer   (3 µM each)  0.6 µl (0.072 µM) 
Cα-out Cβ-mid4 pool (10 µM each) 0.2 µl (0.08 µM) 
Enzyme Mix     0.2 µl (when RT was frozen, add 1.0 µl) 
H2O     2.8 µl  
      𝚺 5 µl 
 
After activation of HotStar Taq DNA Polymerase at 95 °C for 15 min, Touch-down PCR was 
performed with 4 different annealing temperatures. Four cycles at 61 °C, 58 °C and 56 °C and 
forty cycles at 53 °C, followed by a final elongation step for 10 min.  
 
Activation of HotStar Taq DNA Polymerase  95 °C    15 min 
Denaturation      94°C    1 min 
Annealing      61 °C/ 58 °C / 56 °C/ 53 °C 1 min 
Extension      72 °C    1 min 
Final Extension     72 °C    10 min 
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2.4.1.3 Run-off reaction 
Run-off reaction was used to add an anchor (UP new) ahead of the Vβ-region.  In the next 
step the anchor can be used as a universal primer for all TCRβ V chains.  
10× buffer     2 µl  
dNTP      0.4 µl 
Vp+ pool (11.1 µM each)  0.2 µl (0.11 µM) 
Cβ-in (100µM)   0.02µl (0.1 µM) 
Taq DNA Polymerase  0.1 µl  
H2O     16.28 µl  
Product touch-down PCR  1 µl  
      𝚺 20 µl  
 
 Initial Denaturation  94 °C  2 min 
Denaturation   94°C  30 sec 
Annealing   56 °C  2 min 30 sec   3 cyles 
Extension   72 °C  15 min 
Final Extension  72 °C  10 min 
 
UP new-anchor was infixed in 3 cycles of denaturation, annealing and extension, followed by 
a final extension for 10 min.  
2.4.1.4 Anchor PCR  
All TCRβ-chains were amplified in 30 cycles of anchor PCR with the primers Cβ-in and UP 
new.  
10× buffer     2 µl  
dNTP      0.4 µl 
Cβ-in (100 µM)   0.1 µl (0.5 µM) 
UP new (100 µM)   0.1 µl (0.5 µM) 
Taq DNA Polymerase  0.1 µl  
H2O     16.3 µl  
Product run-off reaction   1 µl  
      𝚺 20 µl  
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Initial Denaturation  94 °C  2 min 
Denaturation   94°C  30 sec 
Annealing   58 °C  1 min  30 cycles 
Extension   72 °C  1 min 
Final Extension  72 °C  10 min 
2.4.1.5 Alpha PCR  
For the αTCR PCR five different primer sets were used in a touch down PCR (2.4.1.2 ), with 
an initial denaturation of 2 minutes.  
10× buffer    2 µl      
dNTP (10 mM each)   0.2 µl       
Cα-rev-in (100 µM)   0.1 µl (0.5µM) 
Vα-for-in pool (10 µM each)  1 µl (0.5µM) 
Taq      0.2 µl  
H2O     15.5 µl     
Product touch-down PCR  1 µl  
      𝚺 20 µl  
2.4.2 Clone-specific TCR PCR 
Clone-specific PCR for the clone IP2-8S1 was performed in three steps as nested PCR.  
Clone-specific PCR 1: 
5× One step RT-PCR buffer  1 µl  
dNTP (10 mM each)   0.2 µl 
Primer for (10 µM)   1 µl  
Primer rev (10 µM each)  1 µl  
Enzyme Mix     0.2 µl  
H2O     2.4 µl  
      𝚺 5 µl 
 
For the clone-specific PCR1 the primers Vα-8,21-for-out and Cα-out were used for the α-chain, 
or VP7 and Cβ-mid4 for the beta chain. 5 µl Master Mix were added after the RT-reaction. 
PCR protocol (Section 2.4.1.4). 
 
 
 
 
 
2 Material and Methods 
33 
Clone-specific PCR 2/3: 
10× buffer     2 µl  
dNTP      0.4 µl 
Primer-for (100 µM)   0.1 µl  
Primer-rev (100 µM)   0.1µl  
Taq DNA Polymerase  0.25 µl  
H2O     16.15 µl  
Product PCR 1/2   1 µl  
      𝚺 20 µl  
 
For clone-specific alpha PCR 2, the primers Vα8/1-for-in and Cα-rev-in were used. For clone-
specific alpha PCR 3 N05-13 Vα-8.1-spec-for and N05-13 Vα8.1-spec-rev. 
Clone-specific beta chain PCR2 was run as a semi-nested PCR with the primers VP7 and Cβ-
in. Afterwards a nested PCR with N05-13 Vβ-8.1-spec-for and N05-13 Vβ8.1-spec-rev was 
performed. All three clone-specific PCRs were run under the same conditions (Section 
2.4.1.4). 
2.4.3 Sample preparation for NGS 
NGS was performed in cooperation with E. Beltrán as described by Gerdes et al., 2016. For 
the quantification of the TCR repertoire, UMIs were added. (Shugay et al., 2014). cDNA was 
synthesized from frozen biopsy sections of the hippocampus and the lateral sulcus of IP2 with 
the SmartScribe Kit (Clontech Laboratories, Mountain View, CA). cDNA was incubated with 
uracil-DNA glycosylase (New England BioLabs, Ipswich, MA), followed by two nested PCRs 
with 27 cycles each. The used primers are listed in Section 5.1. The Ovation Ultralow System 
V2 (NuGENE, San carlos, CA, USA) was used to add adaptors and barcodes. The samples 
were analysed at IMGM Laboratories GmbH (Planegg, Germany).  
2.4.4 Standardising single cell PCR with the Janus pipetting robot 
The Janus pipetting robot was used to standardise single cell PCR (scPCR). Protocols were 
designed for the run-off reaction, the anchor PCR as well as the alpha PCR with the Janus 
pipetting robot. To avoid contaminations, the robot was UV-radiated for 30 min prior 
application. Additionally, it was UV-radiated after the run for another 30 min.  
The deck of the robot was arranged as shown in Figure 2-1. For the run-off reaction, as well 
as for the anchor PCR and clone-specific PCR2 and 3, 19 µl Master Mix were pipetted into a 
96 well plate on a plate adapter support tile. For the pipetting 175 µl conductive tips, for liquid 
tracking, were used. 8ˣ dispense per aspirate and all four tips of the tip adapter were used. 
Tips were changed after pipetting 32 samples. The waste mode was used for pipetting. The 
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performance files were set for high sensitivity of liquid level sense, with an aspirate speed of 
10 µl/s, an aspirate delay of 200 ms, a dispense speed of 5 µl/s and a dispense delay of 1000 
ms. No waste volume was used. A transport airgap of 3 µl was used, and a system air gap of 
15 µl. The slope was set to 1.011 µl/µl and the offset to -0.633 µl. Best settings were evaluated 
by pipetting and measuring of the tubes with a balance. With these values, the offset and slope 
were calculated according to manufacturer’s instructions, for precise pipetting. After pipetting 
the master mix into the well, the Tip Dip/Touch mode was used, to ensure that no liquid stays 
at the tip. The Tip Dip/touch was performed 15 mm above the well bottom and with an offset 
of 25 % of the well width. Thereby, drops which were outside at the tip go into the well. This 
step was important for precise pipetting of the master mix. 
 
 
 
 
 
Afterwards the PCR products were transferred into the master mix, either from 8-stripes on top 
of rack on a plate adapter support tile (run-off reaction) or from 96-well plate on plate adapter 
support tile (anchor PCR). 1 µl dispense volume was transferred in 25 µl non-conductive tips. 
Tip 
chute 
Figure 2-1 Janus deck arrangement for pipetting the run-off reaction. The program was designed 
in WinPREP. On the left side all pipetting steps are shown. On the right side the arrangement on the 
deck of the robot is shown. On the top the tips (25 µl non-conductive, 175 µl conductive and 1 ml non-
conductive tips) were placed. In second row the PCR productes (stripes) were placed. The Master Mix 
was pipetted from a 1.5 ml tube in position G7 to a 96 well plate (row 3), and 1 µl of PCR product was 
transferred from the 8-stripes to the 96-well plate.   
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To ensure no PCR product remain in the tips, blow out mode was used, with a blow out volume 
of 20 µl. All 4 tips of the adapter were used. The performance file was set to an aspirate speed 
of 100 µl/s with an aspirate delay of 200 ms and a dispense speed of 20 µl/s and a delay of 
200 ms. A transport air gap of 3 µl was used, to ensure, no liquid is lost during the moving of 
the tip adapter, and thereby avoid contaminations. The slope was set to 0.940 µl/µl and the 
offset to -0.740. A post-dispense mix with 10 µl for three times was added. After the pipetting, 
the tips were disposed at the tip chute.  
All plates stand on racks filled with ice, to avoid a warming of the master mix. After the start, 
the user was requested to fill all tip boxes with new tips. Additionally, here the user can select 
how many samples the robot should pipette.  
The designed programs were used to perform scPCR of the samples of LMD of the lateral 
sulcus.  
2.4.5 Cloning strategies 
2.4.5.1 TOPO-TA cloning 
TOPO-TA cloning was used for the cloning of small amounts of PCR products. The TOPO-TA 
cloning kit (Invitrogen) was used according to manufacturer’s instructions. Positive clones were 
selected by blue-white screening and colony PCR (Section 2.4.12).  
2.4.5.2 Cloning MHC-I alleles of IP2 
All MHC-I alleles of IP2 were cloned from mRNA of 2 different B-lymphoblastoid cell lines (LCL, 
from Josef Mautner, Helmholtz Zentrum München): LCL #28 and LCL #43. For this purpose, 
cDNA was synthesized from isolated mRNA (Section 0 and 2.4.7) and PCR performed with 
primers for HLA-A, -B and –C to add SalI and BamHI cleavage sites. The PCR products were 
cloned into pHSE3’-neo, as described for MHC-II constructs (Section 2.4.5.5).  
2.4.5.3 Cloning of TCR chains 
DNA encoding the α-chain (IP2-AV8S1) and the β-chain (IP2-BV8S1) of IP2-8S1, without the 
constant regions, were ordered at GeneArt (Invitrogen) in pMA-T. The sequences were 
ordered as non-optimized and flanked with the cleavage sites SalI and PvuII for the α-chain, 
and SalI and AvaI for the β-chain. Additionally, a silent mutation was added in the N(D)N region 
in the β-chain, to distinguish between contaminations and real PCR products in the repertoir 
studies. The cassette vectors pRSV-hygro and pRSV-neo, which already contain the constant 
regions for TCR α- or TCR β-chain, were used for cloning.  
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For the α-chain the PCR products and pRSV-hygro were cleaved with SalI and PvuII and 
ligated (Section 2.4.9 and 2.4.11). The β-chain was cloned into pRSV-neo by restriction 
digestion with SalI and AvaI.  
2.4.5.4 Cloning of possible antigen-candidates of GABAA-receptor alpha 1 
subunit 
Candidate antigens of the GABAA receptor α1 subunit for IP2-8S1 were selected using 
databases, which comprise HLA epitopes (NetMHC 4.0 Server, Andreatta and Nielsen 2016) 
and proteasomal cleavage predictions and TAP transport efficiency (IEDB NetCTL Prediction, 
Vita 2015), for HLA-A and HLA-B of IP2. To identify possible candidates of HLA-C*04:01 and 
HLA-C*16:01, for which no database exists, the sequence was analysed for anchor positions 
described by Rasmussen et al. 2014.  
Oligonucleotide linkers coding for candidate antigens of GABAA-receptor α1 subunit (for-linker) 
and the complementary reverse oligonucleotide linkers (rev-linker) were ordered at Metabion, 
so that after annealing the candidates have sticky ends, as after digestion with AscI and NotI 
(sequences see Section 5.1). For annealing 5 µM of the for-linker and of the rev-linker in 100 
µl were incubated at 95 °C for 5 min, followed by 75 °C for 5 min and room temperature for 5 
min. 1 µl of the insert was ligated with 52 ng of AscI/NotI digested pcDNA-V5HisA vector in 1× 
ligation buffer containing 1 U of T4 DNA ligase (Invitrogen) in a total volume of 20 µl. After 30 
min incubation at room temperature, heat shock (Section 2.5.2.1) was performed with 1 µl of 
the ligation product and 20 µl of TOP10 in 96 v-well plates. A list of all cloned plasmids 
expressing possible antigen-candidates are listed in Section 2.1.2.1.  
2.4.5.5 Cloning MHC-II chains in pHSE3’ 
MHC-II chains were cloned from pRSV as templates (Klaus Dornmair) into pHSE3’. pHSE3’ 
does not exhibit a SV40 origin, hence it will not get amplified in COS-7 cells in contrast to the 
library which are expressed in pcDNA.  
The α-chain HLA-DRA*0101, which is in common for all HLA-DR, was cloned into pHSE3’-
hygro, and the β-chains HLA-DRB1*010101 (DRB1), HLA-DRB1*15010101 (DR2b) and HLA-
DRB5*010101 (DR2a) were cloned into pHSE3’-neo.  
PCR was performed to add the cleavage sites SalI and BamHI to all constructs. PCR products 
and vectors were cleaved with SalI and BamHI and ligated (Section 2.4.11).  
2.4.5.6 Cloning of the invariant chain and positive controls 
The invariant chain wild-type (Ii-wt) was ordered at GeneArt (Invitrogen) in pMA-T, flanked by 
the restriction digestion sites AscI and BspeEI. However, restriction digestion with BspEI was 
blocked by methylated DNA. Thereby PCR with p33-wt-AscI-for and p33-wt-BspEI-rev was 
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performed (Section 2.4.8) and the PCR product digested with AscI and BspEI. pcDNArc-
spacer (rc: “rare cutter”, cloned by Katherina Siewert) was digested with AscI and AgeI. AgeI 
and BspEI have the same sticky-end overhangs, thereby after ligation, the cleavage site is 
silent. This is important for further cloning of the libraries with AgeI and KasI into Ii-wt.  
The nucleotide sequences coding for different length of hMBP in the invariant chain were 
ordered as positive control at GeneArt (Invitrogen) in pMA-T. Following sequences were 
ordered: Ii-hMBP(141-149), Ii-hMBP(141-150), Ii-hMBP(141-151) and Ii-hMBP(139-151). To 
avoid contaminations, the constructs were ordered at GeneArt instead of cloning them in 
house. Additionally, silent mutations were added, where the primer for the library screening 
usually anneals. Thereby the constructs will not be amplified by PCR when the libraries are 
screened (Section 2.9.2). The constructs were cloned into pcDNA as described above for Ii-
wt. 
The signal sequence was removed by restriction digestions of pcDNA-Ii-wt, and the positive 
controls, with AscI and ApaI. The oligonucleotides delta-p33-for and delta-p33-rev-new were 
annealed (2.4.5.4) and the sticky ends ligated with the digested vector (Section 2.4.11).  
2.4.5.7 Cloning of Invariant chain encoded combinatorial peptide libraries 
For the identification of CD4+ T cell antigens, libraries which are expressed in the invariant 
chain, were used. To this end, CLIP of Ii was exchanged by combinatorial peptide libraries 
encoded by different length of nucleotides with and without anchor positions. The resulting 
libraries are called Ii-encoded combinatorial peptide libraries (Ii-ECPL) 
The libraries were prepared of HPLC purified, single strand oligonucleotides (Metabion), 
flanked by restriction sites AgeI and KasI and filled up with CLIP-AgeI to double strands. 
Therefor 5 µM of oligonucleotide (CLIP-N27-AgeI/KasI, CLIP-M1,9-AgeI/KasI, CLIP-N33-
AgeI/KasI, CLIP-N33-Anker-M-AgeI/KasI, CLIP-N39-AgeI/KasI, CLIP-N39-Anker-M-
AgeI/KasI, CLIP-N36-C-AgeI/KasI, CLIP-N36-C-Anker-M-AgeI/KasI, CLIP-N36-AgeI/KasI, 
CLIP-N36-Anker-M-AgeI/Kas; sequences are listed in Section 5.1 in Table 5-17) and 5 µM 
CLIP-AgeI-for (for CLIP-N27-AgeI/KasI, CLIP-M1,9-AgeI/KasI) or CLIP-KasI-rev (rest) in 1x 
PCR buffer in 100 µl were denaturated for 5 min at 99 °C. After cooling down, 100 µl of 1x 
PCR buffer containing 400 µM dNTPs and 10 U Taq DNA Polymerase (Roche) were added. 
To generate double strands, the mixture was gradually heated at 60 °C for 4 min, 63 °C for 4 
min, 65 °C for 4 min and a final step at 68 °C for one hour.  
The products were precipitated (2.4.12) and resuspended in 50 µl EB (Qiagen). The constructs 
and the vector pcDNA-V5His-A-Ii-ECPL-wt were sequentially digested with AgeI-HF and KasI. 
After dephosphorylation of the vector the constructs were ligated at 42 °C for 16 h (2.4.11), 
preceptitated and E. coli transformed by electroporation (Section 2.5.2.2).  
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2.4.5.8 Cloning pHSE3’-Blasticidin-large T antigen 
The gene for Blasticidin resistence was cloned from pcDNA via PCR and introduced into 
pHSE3’ by digestion with AatII and NdeI followed by ligation (2.4.11). Afterwards the gene for 
large T antigen was amplified from mRNA of COS-7 cells by PCR. The PCR product was 
integrated into pHSE3’-Blasticidin by restriction digestions with SalI and BamHI and ligation 
(Section 2.4.9 and 2.4.11).  
2.4.6 Isolation of mRNA 
Messenger RNA (mRNA) was isolated from B-lymphoblastoid cell lines (LCL, from Josef 
Mautner) with TRIzol (Thermo Fisher Scientific). 15 ml cell suspension was centrifuged at 300× 
g for 5 min. The cell pellet was resuspended in 750 µl TRIzol and incubated for 5 min at room 
temperature. 750 µl chloroform were added, mixed, incubated for 5 min at room temperature 
and centrifuged at full speed (5417 R, Eppendorf) for 15 min. The upper, aqueous phase was 
transferred into a new 1.5 ml tube. 10 µl glycogen were added and vortexed. Afterwards 700 
µl of 70 % isopropanol were added, vortexed and incubated at -20 °C for 20 min. After 
centrifugation at full speed (5417 R, Eppendorf) for 20 min, the pellet was washed with 1 ml of 
80 % ethanol, and centrifuged again for 5 min at full speed. The supernatant was discarded 
and the pellet dried for 30 min. The pellet was resolubilized in 50 µl DEPC-H2O and stored at 
-80 °C.  
2.4.7 cDNA synthesis from mRNA 
Super Skript III reverse transcriptase (Invitrogen) was used for the synthesis of complementary 
DNA (cDNA) from mRNA.  
1 µg of RNA and 1 µl oligo (dt) primer (50 µM, Invitrogen) were filled up to a final volume of 12 
µl with ddH2O. The primer was annealed to the poly-a tail of the mRNA at 65 °C for 10 min. 1 
µl of dNTPs (10 mM each, Qiagen), 2 µl of dithiothreitol (DTT,100 mM) and 5 µl of 5× FS Buffer 
were added and incubated at 42 °C for 2 min. cDNA was synthesized at 42 °C for one hour 
after adding 1 µl of Super Script III (200 U/µl, Invitrogen). cDNA was stored at -20 °C.  
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2.4.8 PCR 
Polymerase chain reaction was used for the amplification of DNA fragments. The PCR mix 
was prepared as followed: 
10× buffer     10 µl  
dNTP      2 µl 
Primer-for (100 µM)   0.5 µl  
Primer-rev (100 µM)   0.5 µl  
Taq DNA Polymerase  1 µl   
Template    1 µl  
ddH2O      85 µl 
     ∑ 100 µl 
PCR was performed in 30 cycles of denaturation, primer annealing and amplification of the 
DNA. The annealing temperature was calculated depending on the GC/AT content of the 
primers. 4 °C were calculated for GC-pairs, 2 °C for AT-pairs. Elongation time depends on the 
length of the expected PCR product. Taq DNA Polymerse transcribes 1.000 nucleotides per 
minute.  
 
Initial Denaturation  94 °C  2 min 
Denaturation   94°C  30 sec 
Annealing   calculated 30 sec  30 cycles 
Extension   72 °C  calculated 
Final Extension  72 °C  10 min 
 
2.4.9 Restriction Digestion 
Restriction digestion of plasmids and PCR products was performed with restriction enzymes, 
purchased from New England Biolabs, under manufacture recommended conditions at 37 °C 
for 1 h to overnight digestion. Total glycerol concentration in the digestion mix was kept under 
5 % to avoid star activity. Double digestion was performed if the same buffer was compatible 
for both enzymes, and the restriction sites were more than 100 bp apart from each other. For 
sequential double digestion the first enzyme was heat inactivated for 20 min at 65 °C before 
adding the second enzyme, if the same buffer could be used. Otherwise ethanol precepitaion 
was performed (2.4.15) to change the buffer.  
For electroporation of eukaryotic cells, the plasmids were linearised, either with AatII (pcDNA-
NFAT-sGFP, pHSE3’-HLA-DRβ), NdeI (pRSV-AV8S1, pRSV-BV8S1) or XmnI (pHSE3’-HLA-
DRA). Linearised plasmids were ethanol precipitated (Section 2.4.15).  
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2.4.10 Agarose gel electrophoresis 
DNA fragments were separated according to size by agarose gel electrophoresis. Depending 
on the size of the DNA fragment either 1 % (w/v) or 2 % (w/v) agarose in TBE Buffer with 1 
µg/ml Ethidumbromid or 1:25000 peqGreen (Peqlab) were used. Samples were mixed with the 
appropriate amount of 6× loading buffer and loaded on the gel. Additionally, either 5 µl of 1 kb 
ladder (New England Biolabs) or 50 bp DNA Ladder (Peqlab) were loaded. The gel was run 
for 30 minutes at 120 V in TBE buffer. DNA fragments were visualized under UV-light. Isolated 
DNA fragments were purified with the QIAquick® Gel Extraction Kit (Qiagen) and eluted in 50 
µl Elutionbuffer (EB) or with the MinElute® Gelextraction kit (Qiagen) and eluted in 12 µl EB.  
2.4.11 Dephosphoylation and Ligation 
To avoid religation, the digested vectors were dephosphorylated with the Rapid DNA 
Dephosphorilation and Ligation Kit (Roche) according to manufacturer’s instructions.  
For ligation T4 DNA Ligase (1 U/µl, Roche) was used. Ligation was performed in 20 µl reaction 
volume, containing 1 U T4 DNA ligase and a molar ration of 1:5 of DNA insert and vector. After 
ligation at room temperature for one hour or 16-48 h at 16 °C, depending on the acquired 
number of E. coli colonies. The ligation mix was ethanol precipitated before transfection 
(Section 2.4.15).  
2.4.12 Colony screening 
Colony PCR was performed with the grown bacteria to select for the positive clones. To this 
end, PCR with the clones as templates, was performed. In parallel the colonies were grown 
over night in 1 ml LB media containing 0.1 mg/ml ampicillin.  
2.4.13 Plasmid Preparation 
Plasmids were isolated from E. coli suspension cultures. For small scales of Plasmids, mini 
preparation was performed. To this end, 3 ml LB media containing 0.1 mg/ml ampicillin were 
inoculated with a positive clone and incubate over night at 37 °C and 150 rpm. Plasmids were 
isolated of 1-2 ml bacteria suspension with the QIAprep Spin Miniprep Kit (Qiagen) according 
to manufacturer’s instructions. DNA was eluted in 35 µl EB Buffer and stored at -20 °C.  
For higher DNA yields, HiSpeed Plasmid Maxi Kit (Qiagen) was used. To this end 250 ml LB 
media containing 0.1 mg/ml ampicillin were inoculated and grown over night at 37 °C and 150 
rpm. The next day DNA was isolated according to manufacturer’s instructions.  
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2.4.14 Sequencing 
DNA sequencing was performed at the Sequencing Service of Ludwig-Maximilians-Universität 
München (LMU). 5-10 ng DNA (100-200 bp), 10-40 ng DNA (200-500 bp) or 150-300 ng DNA 
(plasmids) were send for sequencing in a total volume of 7 µl containing 3,3 µM of primer. 
Sequences were analysed with Chromas.  
2.4.15 Ethanol precipitation of DNA 
For DNA purification ethanol precipitation was used. For this purpose, 10 % (v/v) NaAcetate 
(pH 5.2) was added to the DNA and vortexed briefly. Afterwards 250 % (v/v) Ethanol absolute 
was added and vortexed again. After incubation for > 1 h at – 80 °C the precipitated DNA is 
centrifuged for 1 h at 20,817x g and 4 °C. The supernatant was discarded and the pellet 
washed twice with 200 µl of 80 % (v/v) ethanol. The pellet was dried and solubilized in the 
desired volume of elution buffer. For the construction of libraries and for the library screening, 
full recovery of DNA is needed. Hence 2 µl of Pellet Paint (Merck) and 1 µl of Glycerol (20 
mg/ml, Roche) were added as carrier DNA.  
2.4.16 DNA Isolation of tissue 
Genomic DNA of IP2 was isolated with the QIAamp DNA Micro Kit (Qiagen). A 10 µm brain 
section was put in a 1.5 ml tube. The tissue was lysed and DNA isolated by manufacturer’s 
instructions for the isolation of genomic DNA from tissue.  
2.4.17 HLA-typing 
HLA typing was performed by the “Labor für Immungenetik und Diagnostik” at the Klinikum der 
Universität München. To this end 200 µl of DNA with a concentration of 27 ng/µl was send for 
HLA typing.  
2.5 Handling of prokaryotic cells 
2.5.1 Cultivation and freezing of E. coli cultures 
E. coli were cultivated at 37 °C either in LB media or on LB plates containing 0.1 mg/ml 
ampicillin (LBAmp). Cells were cultivated in flasks with 5-times the culture volume and with 180 
rpm for optimal aeration. Cell number was determined by spectrophotometry. To this end, 
OD600 was measured in the UV-1600 PC Photospectrometer (VWR), after blanking with LBAmp. 
For optimal measurement the OD600 should be between 0.1-0.5. If necessary, the samples 
were diluted. A bacteria suspension of OD600=1 is assumed to contain1ˣ106 bacteria per µl. 
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However, for exact colony numbers, a defined volume was spread on LB agar plates, grown 
at 37 °C and counted the next day.  
For glycerol stocks 50 % (v/v) autoclaved glycerol was added to the bacteria suspension, 
aliquoted into cryo tubes and frozen at -80 °C.  
2.5.2 Transformation of prokaryotic cells 
2.5.2.1 Transformation of E. coli by heat shock 
Chemical competent E. coli TOP10 were transformed by heat shock. For this purpose, the 
bacteria, which are kept at -80 °C, were thawed on ice. 1 µl plasmid or 10 µl ligation mix were 
added and incubated on ice for 30 min. The heat shock was performed at 42 °C for 30 seconds. 
To recover the cells were put on ice for 2 min. 250 µl SOC medium (Invitrogen) were added 
and the bacteria incubated for 1 h at 37 °C and 150 rpm shacking to produce β-Lactamase for 
ampicillin resistance.  
Afterwards 200 µl, 50 µl and the remains were streaked out onto agar plates containing 0.1 
mg/ml ampicillin. For blue-white screening the plates were pre-coated with 40 µl X-galactose. 
The plates were incubated over night at 37 °C.  
2.5.2.2 Transformation of E. coli by electroporation 
For the cloning of libraries and library screening high yields are essential, hence 
electroporation was used. 2 µl of ligation mix were pipetted in prechilled tubes. ElectroMAXTM 
DH10BTM T1 (Invitrogen) were thawed on ice and 20 µl (library screening) or 50 µl (cloning of 
libraries) bacteria were added to the ligation mix and transferred into a prechilled 0.1 cm 
electrode cuvette (Bio-Rad). Cells were electroporated with the Gene Pulser (Bio-Rad) with 
2,0 kV, 25 µF and 200 Ω. 1 ml SOC medium was added and incubated for 1 h at 37 °C and 
150 rpm shacking.  
For the production of libraries, 200 ml LBAmp were inoculated with the 1 ml bacteria. Serial 
dilutions were plated onto agar plates, to estimate the magnitude of the libraries.  
For the library screening, 50 µl of a 1:50 dilution was plated onto LBAmp agar plates to calculate 
the number of different plasmids of the library. 20 ml LBAmp were inoculated with the rest of 
bacteria.  
2.6 Handling of eukaryotic cells 
2.6.1 Cultivation and freezing of eukaryotic cells 
All eukaryotic cell lines were cultivated in different tissue culture vessels in RPMI complete 
media at 37 °C and 5 % CO2. For stable transfected cells the appropriate amount of antibiotic 
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was added. At a density of 80 % cells were splitted. To this end, adherent cells were washed 
twice with PBS and incubated for 5-10 min with Trypsin-EDTA (Invitrogen). The reaction was 
stopped by adding RPMI + 10 % FBS. Detached cells were centrifuged at 300× g for 5 min, 
resuspended in 10 ml media and seeded as required.  
Suspension cells were splitted by centrifuging them at 300× g for 5 min, resuspending the cells 
in 10 media and seed them as required.  
The cell number per milliliter was calculated in a Neubauer counting chamber. Therefor, 20 µl 
of cell suspension was diluted with 20 µl trypanblue, for the staining of dead cells. 4 big squares 
of the Neubauer counting chamber were counted and the number of cells per milliliter 
calculated be the average cell number (n) per square multiplied be the dilution coefficient (dc) 
and 104.  
ccells = nˣdcˣ104 
For freezing the centrifuged cells were resuspended in FBS containing 10 % DMSO. The 
cryovials were frozen in boxes containing isopropanol for slowly freezing to -80 °C.  
2.6.2 Transfection of eukaryotic cells by FuGENE® 
For library screening 500.000 Cos-7 cells were seeded in 3 ml RPMI complete in a 3.5 cm 
dish. After the cells adhered they were transfected. For this purpose, 2 µg DNA in 100 µl RPMI 
were mixed with 7 µl pre-warmed FuGENE® (Promega, Madison, Wisconsin, USA). The mix 
was vortexed and incubated for 10 min at room temperature. The mix was dropped onto the 
cells. The transfected cells were further incubated at 37 °C and 5% CO2 until needed.  
For screening of subpools 150,000 were seeded in 1 ml RPMI complete in a 24-well plate. 500 
µg DNA were filled up to a final volume of 25 µl with RPMI. 1,75 µl pre-warmed FuGENE® was 
added and transfection proceeded as described above.  
The amount of DNA was used half for the transfection of the library or positive control and half 
for the transfection of HLA, if there were no stabile transfected COS-7-HLA available.  
2.6.3 Transfection of eukaryotic cells by GenaxxoFect-plus 
Mouse fibroblast cells were transfected via GenaxxoFect-plus (Genaxxon bioscience GmbH, 
Ulm, Germany). 1 µl of GenaxxoFect-plus was diluteted in 40 µl Dilution Buffer. 300 ng DNA 
were filled up with Dilution Buffer to 40 µl. Both liquids were combined and mixed by pipetting 
several times. After incubation for 20 min at room temperature, 150.000 cells in 350 µl RPMI 
complete without Pen/Strep were added. The mix was seeded into one well of a 24-well plate 
and incubated under usual conditions.  
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2.6.4 Transfection of eukaryotic cells by nucleofection 
For nucleofection 1ˣ106 Cos-7 cells were centrifuged for 10 min at 100× g. The supernatant 
was discarded and the cells resuspended in 100 µl SE solution (Lonza) containing 82 µl 
solution, 18 µl of supplement and 1 µg DNA. Cos-7 cells were pulsed with the program CM130. 
The pulsed cells were incubated 10 min at room temperature. 500 µl pre-warmed RPMI 
complete was added, incubated for 10 min at room temperature and the cells transferred in 
3.5 cm dishes containing 2.5 ml pre-warmed RPMI compete. The transfected cells were further 
incubated at 37 °C and 5 % CO2.  
2.6.5 Transfection of eukaryotic cells by electroporation 
For stabile transfection of eukaryotic cells electroporation was used. 4-7ˣ106 cells were 
centrifuged and washed twice with RPMI. The cells were resuspended in 800 µl RPMI and 
transferred into a pre-cooled 4 mm electroporation cuvette (Eppendorf). 30 µg linearized and 
precipitated DNA (2.4.9 and 2.4.15) was resuspended in 60 µl RPMI and added to the cuvette. 
After incubation for 10 min on ice cells were pulsed with 280 V and 960 µF (Bio-Rad 
Genepulser). The cells were put on ice for 10 min and afterwards incubated in 10 ml pre-
warmed RPMI complete for 30 min at room temperature. Subsequently the cells were 
transferred into a 175 cm2 cell culture bottle and filled up to 70 ml with RPMI complete. The 
cells were incubated at 37 °C and 5 % CO2 for two days, before continuing with antibiotic 
selection.  
2.6.6 Single clone selection of stabile transfected cells 
48 h after electroporation, the transfected cells were set on antibiotic selection. For this 
purpose, cells were seeded in 24-well plates in half conditioned and half fresh RPMI complete 
containing three different antibiotic concentrations (Table 2-4).  
Table 2-4 Overview of antibiotic concentrations for the selection of transfected cell lines 
Cell line Plasmid Antibiotic Stock 
[mg/ml] 
Selection 
[µg/µl] 
Maintenance 
[µg/ml] 
58-/- pcDNA-NFAT-sGFP Blasticidin  10 3-5 3 
 pRSVhygro TRAV Hygromycin 50 300-500 300 
 pRSV.neo TRBV G418 100 2000-3000 1500 
Cos-7 pHSE3’ HLA-DRα Hygromycin 50 300-500 300 
 pHSE3’ HLA-DRβ G418 100 2000-3000 1500 
LTK- pHSE3’ HLA-DRα Hygromycin 50 150-300 150 
 pHSE3’ HLA-DRβ G418 100 300-500 300 
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To reduce the amount of spontaneously activated hybridoma cells and to get a clone with high 
sGFP expression, single cell dilution of stable clones of 58-/- TCRαβ-CD8-NFAT-sGFP cells 
and 58-/- TCRαβ-NFAT-sGFP cells was performed. An average of 0.3 cells/well were seeded 
in 200 µl into a 96-well vessels, wrapped into cling wrap to avoid evaporation and incubated at 
37 °C, 5 % CO2. 10-14 days later single clones were screened for CD3 activation and 
spontaneously activated cells (Section 2.8.1).  
Table 2-5 Stable transfected cell lines 
Cell Line Transfected plasmids Application 
58-/-   
IP2-8S1 pRSV-IP2-AV8S1 
pRSV-IP2-BV8S1 
pcDNA-NFAT-sGFP 
pLPC-hCD8α-IRES2-hCD8β 
TCR expression for antigen screening 
Bbc9 pRSV-AV22S1  
pRSV-BV9.1 
pcDNA-NFAT-sGFP 
TCR expression for antigen screening 
COS-7   
COS-7-DR1 pHSE3’-HLA-DRA 
pHSE3’-HLA-DRB1 
Antigen presenting cell 
COS-7-DR2a pHSE3’-HLA-DRA 
pHSE3’-HLA-DR2a 
Antigen presenting cell 
COS-7-DR2b pHSE3’-HLA-DRA 
pHSE3’-HLA-DR2b 
Antigen presenting cell 
LTK-   
LTK-DR1 pHSE3’-HLA-DRA 
pHSE3’-HLA-DRB1 
Antigen presenting cell 
LTK-DR2a pHSE3’-HLA-DRA 
pHSE3’-HLA-DR2a 
Antigen presenting cell 
LTK-DR2b pHSE3’-HLA-DRA 
pHSE3’-HLA-DR2b 
Antigen presenting cell 
 
2.6.7 MACS purification of stable transfected cells 
After stable transfection, some cells may be antibiotic resistant but do not express the protein 
of interest. To eliminate these cells, MACS purification was used. To purify CD8-transfected 
58-/- hybridoma cells, CD8 MicroBeads, human (Milteny Biotec GmbH, Bergisch Gladbach, 
Germany) were used. To increase the expression of HLA-DR of stable transfected COS-7 
cells, Anti-HLA-DR MicroBeads, human (Milteny Biotec GmbH) were used. 
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For the purification, the cells were trypsinised if necessary (COS-7) and centrifuged at 300× 
for 10 min. The cells were resuspended in 10 ml MACS Buffer and counted in a Neubauer 
counting chamber (2.6.1). After centrifugation, the cells were resuspended in the required 
amount of MACS Buffer, the appropriate amount of MACS Beads (20µl/107 cells) was added 
and the purification proceeded according to manufacturer’s instructions.  
2.7 Flow cytometry 
2.7.1 Detection of surface expression 
Flow cytometry was used to verify the expression of surface proteins on different cell lines. 
250,000 cells were washed twice with FACS Buffer. Surface proteins were detected with -
FITC, -PE or –APC-labelled antibodies (Section 2.1.7). Antibodies were diluted 1:50 in FACS 
buffer, added to the cells and incubated for 30 minutes on ice in the dark. Isotype controls were 
added in the same concentration as the antibodies and proceeded in the same way. After 
washing twice, the cells were resuspended in FACS Buffer + Topro (1:6000) or FACS Buffer 
+ propidium iodide (PI, 1:500). Results were analysed with FlowJo V9 (Tree Star, Ashland, 
USA).  
2.7.2 Fluorescence-activated cells sorting 
To increase the surface expression of HLA-DR on stable transfected COS-7 cells, 
fluorescence-activated cell sorting (FACS) was used. Cells were labelled with a FITC-labled 
antibody against human HLA-DR as described in section 2.7.1. FACS was performed with the 
FACSAria (BD) at the Max Planck Institute of Biochemistry by Dr. Markus Moser. The best 10 
% of the population expressing HLA-DR was sorted and cultivated for further experiments.  
2.7.3 Detection of intracellular expression 
The expression of the invariant chain (Ii, CD74) and MHC-II libraries based on the invariant 
chain, were detected by intracellular flow cytometry. All steps were performed at room 
temperature.  
Transient transfected Cos-7-DRB1 were trypsinised and centrifuged for 5 min at 300xg. The 
cells were fixed in 80 % (v/v) methanol for 5 min. After washing with PBS, cells were 
permeabilized with PBS + 0.01 % (v/v) Tween for 20 min and unspecific binding sites were 
blocked with PBS containing 10 % (v/v) goat serum and 0.3 % (m/v) glycine for 15 min. The 
cells were centrifuged at 300× g for 5’ and resuspended in 50 µl of 20 µg/ml anti-CD74 (abcam) 
or equivalent amount of isotype control. The antibody was incubated for 30 min. Successive 
the cells were washed twice with PBS and resuspended in 50 µl of 0.08 µg/µl polyclonal goat 
anti-mouse Immunoglobolins/FITC Goat F(ab’)2 (Dako, 0,4 g/l). Before FACS analysis the 
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cells were washed twice with PBS to remove unbound secondary antibody. Results were 
analysed with FlowJo V9 (Tree Star, Ashland, USA). 
2.8 T hybridoma activation assay 
As readout for T cell activation, sGFP-expression was observed by fluorescence microscopy 
or flow cytometry (Section 2.8.5). Additionally, IL-2 release was measured by ELISA (2.8.6). 
2.8.1 CD3 activation of T hybridoma cells 
CD3 activation assay of T hybridoma cells served as a positive control. 150 µl of anti-mCD3ξ 
(1 µg/ml in PBS, clone 145-2C11, eBioscience) was coated on a 96-well microtiter plate. After 
3 h of incubation at 37 °C the solution was removed, 150 µl of T hybridoma cells added and 
incubated for 16 h.  
2.8.2 Activation of T hybridoma cells by synthetic peptides 
Synthetic peptides were dissolved in ddH2O with a concentration of 10 mM. 1 µl of the peptide 
solution was added to 30,000 stable transfected COS-7 cells expressing HLA-DR in 96-well 
plate and incubated for 3 h prior adding 50,000 T hybridoma cells. The T hybridoma cells were 
incubated for 16 h.  
2.8.3 Activation of Bbc9 T hybridoma cells by Ii encoded positive control 
Bbc9 T hybridoma cells were activated with Ii encoded positive controls (Ii-hMBP), to test, if 
the screening-system with libraries expressed in the invariant chain instead of CLIP is working 
for MHC-II library screening. To this end, COS-7 stably expressing HLA-DR were transfected 
with pcDNA-Ii-hMBP (141-149, 141-150, 141-151 and 139-151, 2.4.5.6) and pcDNA-delta-Ii-
hMBP (141-149, 141-150, 141-151 and 139-151, 2.4.5.6) in 24-well plates (Section 2.6.2). 
250,000 Bbc9 T hybridoma cells were overlaid and incubated for 16 h at 37 °C and 5 % CO2. 
2.8.4 Cocultivation with LCL cells 
150,000 LCL cells (Fe, 17490, #28, #36, #43, AJo, IBi, JM, KK, TG) in 100 µl RPMI complete 
in a 96-round bottom plate were stimulated with 100 U/ml and 500 U/ml of INF-γ. After 
incubation for 24 h, 50,000 IP2-8S1 T hybridoma cells were added, centrifuged shortly, so that 
the cells accumulate at the bottom, and incubated for 16 h. Activation of hybridoma cells was 
screened by FACS (Section 2.8.5).  
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2.8.5 Detection of sGFP expression in 58-/- αβ cells after activation 
As a read out of activation of hybridoma cells, the cells were stably transfected with pcDNA- 
NFAT-sGFP. Thereby after activation the cells express sGFP. Fluorescence can be detected 
either by fluorescence microscope, or by flow cytometry.  
For flow cytometry the cells were transferred into a v-bottom plate. After centrifugation for 5’ at 
300× g the cells were washed twice with PBS. If necessary, cells were additionally stained for 
CD3+ (Section 2.7.1). Finally, resuspended in 150 µl FACS Buffer + Topro (1: 6,000). Results 
were analysed with FlowJo V9 (Tree Star, Ashland, USA). 
2.8.6 IL-2 ELISA 
IL-2 ELISA was used as a second read out for the activation of hybridoma cells. The murine 
IL-2 in the supernatant of activated cells was detected with the IL-2 ELISA Ready-SET-Go kit 
of eBioscience (San Diego, USA). ELISA was performed on 96-well MaxiSorb Nunc Immuno-
plates (Thermo Scientific) according to manufacturer’s instructions. Standard curves were 
performed with IL-2 in a range between 2 pg/ml and 200 pg/ml. Absorption was measured at 
450 nm in the Wallac VICTOR21420 Multilabel Counter (Perkin Elmer).  
2.9 Unbiased identification of TCR antigens 
2.9.1 Mimotope screening with plasmid-encoded combinatorial peptide 
libraries 
Library screening for CD8+ TCR antigens with PECPL was performed as described by Siewert 
et al. 2012. The workflow is illustrated in Figure 2-2. Adherent Cos-7 cells, expressing HLA 
molecules and PECPL, are overlaid with soluble 58-/- expressing the TCR of interest and sGFP 
under the control of the NFAT-enhancer as read out. After activation, 58-/- turn green, and the 
underlying COS-7 cell can be isolated. The plasmids are recovered by PCR and screened for 
reactivation.  
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Figure 2-2 Workflow unbiased Identification of CD8+ T cell antigens. For the library screening, 
COS-7 cells are transfected with a plasmid coding for MHC-I and PECP library and cocultivated with T 
hybridoma cells. The cells are screened with a fluorescence microscope for the expression of sGFP. 
The underlying COS-7 cells are isolated with a micromanipulator, recovery PCR is performed and the 
PCR products cloned into pcDNA3.1TM/V5-His-TOPO®. E. coli are transformed with the plasmids, the 
plasmids isolated and screened for reactivation. Positive clones are enriched in several steps of 
subpooling. In the last step, positive single clones are sequenced.  
 
For the library screening COS-7 cells, which served as APC were co-transfected with a plasmid 
coding for HLA and PECPL via FuGENE® transfection (Section 2.6.2) or nucleofection (Section 
2.6.4) and incubated at 37 °C and 5 % CO2. 32 h or 56 h after transfection, the cells were over-
laid with 1.5 ˣ 106 58-IP2-8S1 cells. After cocultivation for 16, the cells were screened for sGFP 
expression.  
If clusters of ≥ 2 activated 58-IP2-8S1 cells were detected, the underlying COS-7 cells was 
isolated with the help of a micromanipulator and a 14 µm capillary. The isolated cell was 
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transferred into a prechilled 200 µl PCR tube containing 7 µl H2O/DEPC. The tube was kept 
on ice until the plasmids were recovered by PCR.  
The peptide-encoding region of the plasmids of the picked COS-7 cell were amplified by PCR. 
50 µl of 2x iProofTM High Fidelity Master Mix, 0.5 µl pcDNA-2nd-for-TOPO (100 µM) and 0.5 µl 
pcDNA-rev3 (100 µM) were added to the picked cell and filled up to 100 µl with H2O/DEPC.  
After an initial denaturation at 98 °C for 3 min, PCR was performed in 40 cycles of denaturation 
for 20 s at 98 °C, annealing for 20 s at 56 °C and elongation for 30 s at 72 °C, followed by a 
final elongation at 72 °C for 10 min. The PCR products were kept at -20 °C.  
The PCR products were purified with the QIAquick® PCR purification kit (Qiagen), diluted to 1 
ng/µl and cloned into pcDNA3.1TMD/V5-His-TOPO® with the pcDNATM 3.1 Directional TOPO® 
Expression Kit (Invitrogen) according to manufacturer’s instructions. The samples were ligated 
for 30 min at room temperature followed by 16 °C over night. The DNA was precipitated 
(Section 2.4.15) and solubilized in 2 µl Elution Buffer (EB, Qiagen). E. coli Electro Max DH10B 
(Invitrogen) were transformed with the ligation constructs by electroporation (Section 2.5.2.2). 
The next day, the number of different plasmids were calculated from the agar plates, and DNA 
was isolated. 
2.9.2 Mimotope screening with Invariant chain-encoded combinatorial 
peptide libraries 
For the identification of CD4+ T cell mimotopes with Ii-ECPL, COS-7 cells stably expressing 
HLA-DR1 or HLA-DR2a molecules were employed as APC. The cells were transfected with Ii-
ECPL of different length via FuGENE® transfection (Section 2.6.2) or nucleofection (Section 
2.6.4) and incubated for 32 h or 56 h. The cells were overlaid with 1.5 ˣ 106 58-Bbc9 cells and 
incubated for 16 h. The cells were screened for activation and the underlying COS-7 cell picked 
as described in section 2.9.1.  
Recovery PCR was performed with p33-lib-for and p33-lib-rev, using standard PCR protocol 
(Section 2.4.8) running 40 cycles with an annealing temperature of 58 °C and an elongation 
time of 45 s. PCR products were kept at - 20 °C.  
PCR products were purified with the QIAquick® PCR purification kit (Qiagen). Afterwards the 
PCR products and pcDNA-Ii-33 were digested with AgeI and KasI (Section 2.4.9). The 
digested vector was dephosphorylated and 100 ng of dephosphorylated vector was ligated 
with the PCR products at 16 °C over night (Section 2.4.11). After precipitation (Section 2.4.15), 
the DNA was resolubilized in 2 µl EB and transformed into E. coli Electro Max DH10B 
(Invitrogen) by electroporation (Section 2.5.2.2). The next day, the number of different 
plasmids were calculated from the agar plates, and plasmids isolated.  
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2.9.3 Reactivation and enrichment by subpooling 
COS-7 cells were seeded in 24 well plates and transfected in duplicate with the purified 
plasmids (Section 2.9.1 and 2.9.2) by FuGENE® (Section 2.6.2). Either COS-7 cells stably 
expressing the appropriate MHC molecules were used, or plasmids coding for MHC alleles 
were co-transfected. 32 h and 56 h after transfected, the cells are overlaid with 250,000 T 
hybridoma cells and cocultered for 16 h. The wells were screened in a fluorescence 
microscope by hand, or by using the scanning program ZEN Pro (Zeiss), establishes by G. 
Rühl (Institut für klinische Neuroimmunologie, Ludwig-Maximilians-Universität München, AG 
Dornmair). The bacteria stock of the positive well contains the positive clone besides the 
calculated number of bystander plasmids (Section 2.5.2.2). For subpooling, the original stock 
was diluted 1/10 and 30 ˣ 1.25 ml LBAmp were inoculated with the bacteria. The bacteria were 
grown overnight and plasmids were purified the next day. The samples were screened for 
reactivation as described before.  
Positive reactivation was also used for a second round of picking, to enrich the positive clone.  
2.10  SDS-Page 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by Western Blot was used 
to analyse if the transfected Cos-7 cells express the invariant chain Ii-ECPL-wt with the correct 
size.  
For SDS-Page 8-20 % Tris-Glycine gels (NuPage) were used. 50,000 cells were resuspended 
in 75 µl 1× Laemmli sample buffer (reducing). The proteins were denatured at 95 °C for 5 min. 
25 µl of the samples and 7.5 µl of full range rainbow marker (Amersham) were loaded onto the 
gel. The gel was run with a constant voltage of 130 V for 90 min. Afterwards the gel was used 
for Western Blot (Section 2.11) 
2.11  Western Blot 
Western Blot was used to detect CD74 expression of the transient transfected cells.  
For this purpose, the proteins which were separated by SDS-Page were blotted onto a 
polyfinylidenfluorid (PVDF) membrane in a semi-dry blotter. Whatman paper were saturated 
with anode or cathode buffer and the PVDF membrane activated with methanol. The gel and 
the membrane were assembled in the transfer cell between 3 Whatman papers. The proteins 
were blotted with a constant current of 35 mA per gel for 3 h. Unspecific binding sides were 
blocked with blocking buffer for 1 h at room temperature or over night at 4 °C. For protein 
detection anti-CD74 [PIN.1] (abcam) was diluted 1:1,000 in blocking buffer, added to the 
membrane and incubated for one hour at room temperature in the dark. After washing the 
membrane 3 times for 5 min with washing buffer the detection antibody donkey anti-mouse 
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IRDye800CW (1:10,000 LI-COR, Lincoln, NE, USA) was added and incubated for one hour at 
room temperature. The membrane was washed again 3 times for 5 min. Signals were detected 
with the Odyssey Fc (LI-COR). The marker was detected at 700 nm for 0.5 min, the detection 
antibody at 800 nm for 10 min.   
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3 Results 
3.1 IP2: Identification of disease relevant T cell receptors 
GABAA receptor encephalitis is a new autoimmune disease pattern, first described by Petid-
Pedrol et al. 2014. Patients indicate high titre serum antibodies against the α1/β3 subunits, 
causing a reduction of synaptic GABAA receptors. Subsequently the patients develop seizures 
or refractory status epilepticus (Petit-Pedrol et al., 2014). Although, the antibody derived 
immunity is described, it is not known which role T cells play in the disease. However, T cells 
often have a key role in autoimmune diseases, like Psoriasis, MS or inflammatory myopathies, 
by infiltration of autoreactive T cells into the target tissue. Additionally, the presence of 
antibodies against GABAA α1 subunit indicate the existence of CD4+ T cells, which are crucial 
for most humoral immune responses 
To analyse the role of T cells in GABAA encephalitis, the T cell repertoire in the CSF (Section 
3.1.1), the hippocampus (Section 3.1.2) and the lateral sulcus (Section 3.1.3) of IP2 was 
characterised with different methods like IHC, LMD and NGS. All isolated TCR were 
designated according to Arden (Arden 1995).  
3.1.1 T cell repertoire from the CSF of IP2 
The T cell repertoire of the CSF of IP2 was analysed by an unbiased multiplex single cell TCR 
PCR (Section 2.4.1), which allows to analyse the matching α- and β- chain of single T cells. 
To this end, a universal α- and β-chain primer pool (Seitz et al., 2006; Kim et al., 2012), which 
was further improved by Q. Zhou (personal communication), was used. 
250 µl CSF were sorted via MACS beads (Section 2.2.1). Firstly, the CSF was positively sorted 
for CD4+ T cells, followed by a positive selection for CD8+ T cells of the flow-through. Single 
cells were isolated with a pipette at the microscope. RT-reaction and unbiased TCR PCR were 
performed.  
40 CD4+ T cells and 48 CD8+ T cells were isolated from the CSF of IP2. 15 β-chains of the 40 
CD4+ T cells were obtained. Hereof 12 corresponding α-chains could be identified, including 
one cell which expresses two different α-chains, but only one β-chain (Table 3-1).  
The identified TCR of the CD4+ T cells in CSF of IP2 show a high variety. Every cell is unique. 
There is no clonal expansion of any CD4+ T cell in the CSF. The CD4+ T cells in the CSF of 
IP2 are polyclonal.  
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Table 3-1 TCR chains of single CD4+ T cells from CSF of IP2. TCR β-chains and if detected, 
corresponding α-chains are listed, with their TRV and TRJ chains, their peptide sequence of the V-
CDR3-Joining regions, and the frequency, how often the TCR was detected in CSF. 
TCR 
no. 
Chain TRV TRJ Peptide Sequence 
V-CDR3-Joining 
Frequency 
(Total: 15) 
1 β 7S3 1-1 CASS-LKTGGYL-NTEAFFGQG 1 
 α 18S1 45 CAF-MG-GGGADGLTFGKG 1 
2 β 17S1 1-1 CASS-WPGQG-NTEAFFGQG 1 
 α 23S1 58 CAVR-VV-ETSGSRLTFGEG 1 
 α 3S1 12 CATD-Q-MDSSYKLIFGSG 1 
3 β 13S3 1-1 CASS-SLQGSPRG-NTEAFFGQG 1 
 α 2S3 44 CAVV-SP-TGTASKLTFGTG 1 
4 β 13S1 1-2 CAS-RSGD-NYGYTFGSG 1 
 α 18S1 41 CA-FPGR-SGYALNFGKG 1 
5 β 6S2 2-1 CASS-IKNP-YNEQFFGPG 1 
 α 1S5 53 CAV-SAR-GGSNYKLTFGKG 1 
6 β 5S1 1-1 CASS-FGAR-TEAFFGQG 1 
7 β 9S1 1-1 CASS-QGSWARM-NTEAFFGQG 1 
 α 2S1 54 CAM-RL-QGAQKLVFGQG 1 
8 β 3S1 1-5 CASS-IEG-NQPQHFGDG 1 
 α 8S2 4 CAEN-P-GGYNKLILEQGPG 1 
9 β 8S1 2-5 CAS-TLRGT-ETQYFGPG 1 
10 β 8S1 2-1 CASS-FRLAGY-YNEQFFGPG 1 
11 β 25S1 1-4 CASSQ-PLAGS-TEKLFFGSG 1 
 α 14S1 27 CAYRS-GP-AGKSTFGDG 1 
12 β 13S6 1-2 CASS-YTEAS-YGYTFGSG 1 
 α 4S2 20 CIV-SV-SNDYKLSFGAG 1 
13 β 8S1 2-3 CASS-WGV-TDTQYFGPG 1 
 α 2S2 21 YLC-VMRG-NFNKFYFGSG 1 
14 β 3S1 1-2 CAS-TLRDS-YGYTFGSG 1 
15 β 13S1 1-2 CAS-TDSTGTGA-NYGYTFG 1 
 α 2S1 49 CAV-TP-NTGNQFYFGTG 1 
 
Furthermore, the β-chains of 13 cells of the 48 picked CD8+ T cells were identified in total. Six 
of these 13 cells expresses the same β-chain.  
The matching α-chains of 11 cells were obtained, whereof one cell expressed two functional 
α-chains. All of the six CD8+ T cells with the same β-chain, also expresses the same α-chain 
(Table 3-2).  
In contrast to the CD4+ T cells, which are all unique in CSF, the accumulation of one CD8+ T 
cell clone indicates that the CSF contains an expanded CD8+ T cell clone. The β-chain of this 
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expanded clone is expressed in 46 % of all β-chains of CD8+ T cells found in CSF. The 
expanded clone (TCR no. 16, Table 3-2) was termed IP2-8S1.  
Table 3-2 TCR chains of single CD8+ T cells from CSF of IP2. TCR β-chains and if detected, 
corresponding α-chains are listed, with their TRV and TRJ chains, their peptide sequence of the V-
CDR3-Joining regions, and the frequency, how often the TCR was detected in CSF. 
TCR no. Chain TRV TRJ Peptide Sequence 
V-CDR3-Joining 
Frequency 
(Total: 13) 
16 (=IP2-8S1) β 8S1 2-3 CASS-AGG-DTQYFGPG 6 
 α 8S1-A1 49 CAAS-WG-TGNQFYFGTG 6 
17 β 8S1 1-6 CASS-FLDK-NSPLHFGNG 1 
 α 19S1 48 CAV-IGRGP-NFNEKLTFGTG 1 
18 β 5S1 1-5 CASS-QGPQ-SNQPQHFGDG 1 
 α 24S1 5 CAVVS-AE-DTGRRALTFGSG 1 
19 β 6S4 1-4 CAS-TVA-TNEKLFFGSG 1 
 α 2S2 20 CAMS-VD-DYKLSFGAG 1 
20 β 6S5 2-5 CASS-PGQG-QETQYFGP 1 
21 β 6S2 1-5 CASSL-AEGY-SNQPQHFGDG 1 
22 β 8S2 2-6 CASS-LSSD-GANVLTFGAG 1 
 α 1S4 30 CAVGA-P-NRDDKIIFGKG 1 
23 β 9S1 1-6 CASSQ-DTGR-SPLHFGNG 1 
 α 2S1 4 CAVN-SQ-GGYNKLIFGAG 1 
 α 25S1 53 CA-AS-SGGSNYKLTFGKG 1 
 
3.1.2 T cell repertoire analysis of the hippocampus of IP2 
3.1.2.1 Analysis of infiltrated T cells in the hippocampus by IHC  
IP2-8S1 was clonally expanded in the CSF of IP2 (Section 3.1.1). Biopsy sections of the 
hippocampus of IP2 were used to analyse, whether there is also an infiltration of T cells into 
the brain. Furthermore, it was analysed, if the infiltrated T cells are also activated.  
First, IHC for CD3, CD4 and CD8 was performed with paraffin-embedded biopsy sections of 
the hippocampus. Staining of the hippocampus demonstrated a much higher infiltration of 
CD8+ T cells, compared to CD4+ T cells (Figure 3-1). An average of 77 CD3+ T cells were 
detected per cm2 in the hippocampal region, from which 13 % were double positive for CD3 
and CD4 and the remaining 87 % double positive for CD3 and CD8. IHC showed that CD8+ T 
cells in the hippocampus were predominantly parenchymal, whereas CD4+ T cells were mostly 
perivascular (Figure 3-1). In the hippocampus regions with an infiltration of many CD8+ T cells 
were found and less infiltration of CD4+ T cells. Thereby, the disease exhibit great analogies 
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to other immune diseases, like MS, where also CD8+ T Cells were far numerous compared to 
CD4+ T cells in the analysed MS lesions (Babbe et al., 2000).  
 
 
 
 
 
To distinguish between bystander CD8+ T cells, which are attracted by cytokines, and 
activated CD8+ T cells, IHC for activation markers were used. Activated CD8+ T cells express 
cytotoxic granules, composed of perforin and granzymes (Pipkin and Lieberman 2007). For 
this purpose, staining of CD8, perforin and DAPI of frozen brain sections was performed and 
visualized by fluorescence microscopy (Figure 3-2).  
This IHC showed that activated CD8+ T cells are present in the hippocampus. Around 50 % of 
the CD8+ T cells express perforin.  
3.1.2.2 T cell repertoire of the hippocampus  
For the analysis of the TCRs in the brain, firstly bulk cells of the hippocampus were used to 
isolate mRNA, transcribe it to cDNA and perform a clone specific PCR for the expanded T cell 
clone IP2-8S1. The presence of the α-chain IP2-AV8S1 of the expanded T cell clone was 
Figure 3-2 Potential pathogenic role of CD8+ T cells in the hippocampus (HC) by the expression 
of activation markers Sections of the HC were costained for the expression of CD8 (red, A), perforin 
(green, B) and DAPI (C) and afterwards merged (D) The staining demonstrates expression of perforin, 
and thereby the presence of activated CD8+ T cells in infiltrated regions of the hippocampus. Scale bar: 
20 µm. 
Figure 3-1 Infiltration of T cells in the hippocampus (HC) of patient IP2. Hippocampal paraffin 
sections of brain biopsy of IP2 were stained for CD3 (red, A, E), CD8 (green B), DAPI (blue, C; G) and 
CD4 (green, F), merged (D, H) represent matched colors. (A-D) CD8+ T cells in the HC. (E-H) CD4+ T 
cells in the HC. Scale bar: 25 µm.  
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verified in the hippocampus of IP2 by PCR. This suggests an infiltration of the expanded CD8+ 
T cells to the brain. The β-chain IP2-BV8S1 was not detected. 
Due to the fact that IP2-BV8S1 did not show up during bulk cell analysis, and that bulk cell 
analysis does not show how often the expanded clone occurs in the inflammatory brain regions 
of IP2, single cells were isolated by LMD from hippocampal sections. The cells were analysed 
in parallel by unbiased multiplex TCR PCR and by clone-specific PCR.  
179 single T cells were isolated by LMD of the hippocampus (Figure 3-3). 177 of them were 
positive for CD8+ and two of them were positive for CD4+. The isolated cells were analysed 
by unbiased multiplex TCR PCR. No TCR chain was identified of the CD4+ T cells. However, 
three other β-chains of CD8+ T cells were identified in the hippocampus, which were not 
detected in CSF. One of them was detected in three CD8+ T cells of the hippocampus (TCR 
no. 24). No corresponding α-chain was identified (Table 3-3).  
 
In parallel, clone-specific PCR was performed with the samples of the isolated CD8+ T cells. 
The β-chain IP2-BV8S1 (TCR no. 16), which was clonally expanded in CSF, was detected in 
22 CD8+ T cells from the hippocampus by clone-specific PCR The corresponding α-chain IP2-
AV8S1 was found in 19 of the 22 cells (Table 3-3).  
Figure 3-3 Laser microdissection of single cells in HC sections of brain biopsy. 10 µm 
hippocampal sections on PET foil were stained with a Cy-3 labeled antibody against human CD8 (A) 
and a AF488 labeled antibody against CD4 (B). Positive cells were marked and controlled in transmitted 
light (C). Single cells were isolated by LMD (D). Scale bar: 25 µm. 
(A) (B) 
(C) (D) 
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(A) 
This provides clear evidence that IP2-8S1 is expanded in the CSF of IP2 and that it is also 
present in infiltrated brain regions. Furthermore, it is also strongly expanded in the 
hippocampus. 19 cells out of 177 of all isolated CD8+ T cells from the hippocampus (11 %) 
express IP2-8S1, and 22 out of 27 β-chains in the hippocampus (81 %) are IP2-BV8S1. 
Additionally, CD8+ T cells also express perforin, indicating the presence of activated CD8+ T 
cells in the hippocampus (Section 3.1.2.1).  
Table 3-3 TCR chains of single CD8+ T cells of the hippocampus of IP2. TCR β-chains and if 
detected, corresponding α-chains are listed, with their TRV and TRJ chains, their peptide sequence of 
the V-CDR3-Joining regions, and the frequency, how often the TCR was detected in CSF. 
TCR no. Chain TRV TRJ Peptide Sequence 
V-CDR3-Joining 
Frequency 
(Total: 27) 
16 (= IP2-8S1) β 8S1 2-3 CASS-AGG-DTQYFGPG 22 
 α 8S1 49 CAAS-WG-TGNQFYFGTG 19 
24 β 6S3 2-7 CASSL-NGIS-SYEQYFGPG 3 
25 β 6S2 2-2 CASSL-APN-GELFFGEG 1 
26 β 8S1 1-6 CAS-RRA-NSPLHFGNG 1 
 
3.1.2.3 Validation of IP2-8S1 in the hippocampus by NGS 
Next generation sequencing (NGS) studies were performed in cooperation with E. Beltrán and 
the sequencing was performed at IMGM Laboratories GmbH (Planegg, Germany) to validated 
the presence of IP2-8S1 in the brain. Samples were prepared from bulk cells. To distinguish 
between PCR amplification and clonal expansion, a unique molecular identifier (UMI) was 
added during PCR. Only sequences with different UMI were counted for the quantification. 
IP2-AV8S1 was detected 236 times in the hippocampus. Together with one other α-chain, IP2-
AV8S1 was one of the most expanded α-chain (Table 3-4). The NGS reaction for the β-chains 
provided less chains than expected. Only three different beta chains were detected, not 
including IP2-BV8S1. Due to the low yield of beta chains in the hippocampus, the NGS 
sequencing reaction is repeated currently by E. Beltrán. The α-chain was detected in the same 
rate in the hippocampus by LMD compared to NGS. Thus we expect to detect IP2-BV8S1 with 
the same frequency in the next NGS reaction.  
Although NGS reaction for the β-chain is currently repeated, the results of the hippocampus 
validate the data of LMD, where it was shown that the expanded clone also shows up 
frequently in the infiltrated regions of the hippocampus (Table 3-4).  
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Table 3-4 Comparison of T cell repertoir analysis LMD and NGS of the HC.  The quantity of detected 
IP2-AV8S1 and IP2-BV8S1 in the HC detected in LMD and NGS are listed. (*) NGS reaction of the β-
chain is repeated at the moment, due to low yields in the first experiment.  
TCR no. Chain TRV TRJ Peptide Sequence 
V-CDR3-Joining 
LMD HC NGS HC 
16 (= IP2-8S1) β 8S1 2-3 CASS-AGG-DTQYFGPG 22 n.a.* 
 α 8S1 49 CAAS-WG-TGNQFYFGTG 19 236 
 
3.1.3 T cell repertoire analysis of the lateral sulcus of IP2 
3.1.3.1 Analysis of infiltrated T cells in lateral sulcus by IHC 
IHC of the hippocampus of IP2 showed a strongly infiltration of CD8+ T cells into the brain, as 
well as the presence of the expanded CD8+ T cell clone IP2-8S1 in the hippocampus. The 
lateral sulcus of IP2 was also inflamed. Biopsy sections of the lateral sulcus of IP2 were 
analysed by IHC. The TCR repertoire was analysed in bulk cells, single cells and by NGS.  
The T cell infiltration of the lateral sulcus of IP2 was analysed by IHC of paraffin sections for 
CD3, CD4 and CD8.The same infiltration pattern as in the hippocampus was also observed in 
the lateral sulcus (Figure 3-4).  
 
 
 
 
 
147 CD3+ T cells were detected per cm2. 80 % of them were CD8+ T cells, and 20 % CD4+ T 
cells. In contrast to the hippocampus, where many CD8+ T cells were parenchymal, CD8+ T 
cells in the lateral sulcus were predominantly perivascular. Comparable to hippocampal 
staining, CD4+ T cells were mostly perivascular.  
Figure 3-4 Infiltration of T cells in the lateral sulcus (LS) of patient IP2. Paraffin sections of the 
lateral sulcus of IP2 were stained for CD3 (red, A, E), CD8 (green B), DAPI (blue, C; G) and CD4 (green, 
F), merged (D, H) represent matched colors. (A-D) CD8+ T cells in the LS. (E-H) CD4+ T cells in the 
LS. Scale bar: 25 µm. 
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Staining for the expression of activation markers in CD8+ T cells was used to distinguish 
between activated CD8+ T cells and bystanders in the lateral sulcus. Frozen biopsy sections 
were stained for CD8, perforin, and DAPI and visualized by fluorescence microscopy (Figure 
3-5).  
IHC for perforin showed that activated CD8+ T cells are also available in the lateral sulcus. 
Around 80 % of the infiltrated CD8+ T cells express the activation marker perforin.  
 
 
3.1.3.2 T cell repertoire of the lateral sulcus 
Staining of the lateral sulcus also showed inflamed regions. To analyse if the expanded clone 
IP2-8S1 also occurs in the lateral sulcus, first bulk cells of frozen biopsy sections of the lateral 
sulcus were analysed by clone-specific PCR for IP2-8S1. For this purpose, mRNA was isolated 
from the biopsy sections, transcribed to cDNA and clone specific PCR for the expanded T cell 
clone IP2-8S1 was performed. Comparable to the hippocampus, IP2-AV8S1 was verified in 
the lateral sulcus of IP2 by PCR. This presumes an infiltration of the expanded CD8+ T cells 
to the lateral sulcus. IP2-BV8S1 was not detected. 
To analyse the T cell receptor repertoire of the lateral sulcus, single cells were isolated by LMD 
from frozen sections and unbiased as well as clone-specific PCR for the detection of IP2-8S1 
was performed in parallel. For this purpose, 10 µm sections of the lateral sulcus were stained 
for CD4 and CD8. Single T cells were isolated by LMD (Figure 3-6) and analysed by unbiased 
and clone-specific PCR. Pipetting of the PCR was performed with the Janus pipetting robot 
(Section 3.1.4).  
In total 111 T cells were isolated by LMD of the lateral sulcus. All isolated T cells were detected 
as CD8+. None of them were positive for CD4.  
Figure 3-5 Potential pathogenic role of CD8+ T cells in the lateral sulcus (LS) by the expression 
of activation markers Sections of the LS were costained for the expression of CD8 (red, A) perforin 
(green, B), and DAPI (C) and afterwards merged (D) The staining demonstrates expression of perforin, 
and thereby the presence of activated CD8+ T cells in infiltrated regions of the lateral sulcus. Scale bar: 
20 µm. 
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Figure 3-6 Laser microdissection of single cells in LS sections of brain biopsy. 10 µm sections of 
the lateral sulcus of IP2 on PET slides were stained with Cy3-labeled antibody against human CD8 (A) 
and AF488 labeled antibody against human CD4 (B). Stained cells were marked and controlled in 
transmitted light (C). LS section after the isolation of single cells LMD (D). Scale bar: 25 µm.  
 
No TCR chains were detected in the isolated single cells by unbiased multiplex TCR PCR and 
IP2-8S1 was not detected by clone-specific TCR PCR. However, two TCR β-chain were 
identified by clone-specific TCR PCR from the lateral sulcus. One of them showed up in two 
single isolated CD8+ T cells (Table 3-5). Both β-chain are also TRV-B8S1, but their CDR3 
region differs from IP2-8S1. Both chains were neither found in CSF nor in the hippocampus of 
IP2. The corresponding α-chains were not detected. 
Table 3-5 TCR chains of single CD8+ T cells from the lateral sulcus of IP2. TCR β-chains are listed, 
with their TRV and TRJ chains, peptide sequence of the V-CDR3-Joining regions, and the frequency, 
how often the TCR was detected in CSF. 
TCR no.  TRV TRJ Peptide Sequence 
V-CDR3-Joining 
Frequency 
(Total: 2) 
27 β 8S1 2-1 CASS-PGLAMD-YNEQFFGPG 2 
28 β 8S1 1.4 CAS-AG-TNEKLFFGSGT 1 
 
 
 
(A) (B) 
(C) (D) 
3 Results 
62 
3.1.3.3 Validation of IP2-8S1 in the lateral sulcus by NGS 
NGS studies of the lateral sulcus were performed in cooperation with E. Beltrán and run at 
IMGM Laboratories GmbH (Planegg, Germany), as described before (Section 2.4.3 and 
3.1.2.3), to validated the presence of IP2-8S1 in the lateral sulcus. Samples were prepared 
from bulk cells.  
IP2-AV8S1 was detected one time in the lateral sulcus and IP2-BV8S1 three times (Table 3-6). 
NGS validates the infiltration of IP2-8S1 in the lateral sulcus, shown by clone-specific PCR of 
bulk cells (Section 3.1.3.2). In comparison to the hippocampus, the infiltration of IP2-8S1 is 
less.  
Table 3-6 Comparison of T cell repertoir analysis LMD and NGS of the HC and the LS 
TCR no. Chain TRV TRJ Peptide Sequence 
V-CDR3-Joining 
LMD LS NGS 
NGS 
16 (= IP2-8S1) β 8S1 2-3 CASS-AGG-DTQYFGPG - 3 
 α 8S1 49 CAAS-WG-TGNQFYFGTG - 1 
 
3.1.4 Standardizing single cell PCR with Janus Pipetting Robot 
The Janus Pipetting Robot was used to standardize single cell PCR (sc PCR). To this end, two 
programs were designed during this thesis together with G. Rühl, and further adapted by M. 
Schönwetter (Institut für klinische Neuroimmunologie, Ludwig-Maximilians-Universität 
München, AG Dornmair). The protocols were optimized for perfect pipetting by adjusting the 
performance files for pipetting, like aspiration and dispension speed and so forth (Section 
2.4.4).  
The advantages in using the pipetting robot are, that the pipetting is standardised and it can 
be used for high-throughput experiments. Additionally, the robot was placed inside a box in a 
clean room. This reduces the risk of contaminations during sc PCR. The room as well as the 
inside of the box can be UV-irradiated, which further reduces the risk of contaminations.  
With these optimized protocols, it is now possible to use the robot for the pipetting of the run-
off reaction, the anchor PCR, as well as the alpha PCR (Section 2.4.1). Furthermore, it is also 
ready for pipetting of clone-specific PCR2 and 3 (Section 2.4.2). Precise and contamination-
free pipetting were tested for several PCRs. During this study, it was successfully utilized for 
pipetting of the PCRs of LMD samples of the lateral sulcus.  
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3.2 IP2-8S1 antigen search 
Clone IP2-8S1 could be detected not only in the CSF of IP2, but also in the hippocampus and 
the lateral sulcus. Additionally, the clone showed up several times, which is ascribed to a clonal 
expansion of CD8+ T cells. The clonal expanded CD8+ T cell also infiltrated the brain. This 
indicates an important role of IP2-8S1 in the disease. However, it is not known which antigen 
is recognized by the TCR.  
Several approaches were used to identify the HLA restriction of IP2-8S1 and to find the antigen 
of the receptor. Hybridoma cells expressing sGFP under control of the NFAT enhance and 
IP2-8S1 (58-IP2-8S1), were cocultivated with LCLs expressing the HLA alleles of IP2 to test if 
the TCR recognises an endogenous peptide (Section 3.2.3.2). Additionally, possible antigen 
candidates of the GABAA receptor α1 subunit were tested for their ability to activate 58-IP2-
8S1 cells (Section 3.2.4). Furthermore, library screening with PECPL and 58-IP2-8S1 cells 
was performed (Section 3.2.5).  
3.2.1 In vitro expression of recombinant IP2-8S1 T cell receptor 
IP2-AV8S1 and IP2-BV8S1, coding for the variable, N(D)N and joining region of the α- 
and β-chain of IP2-8S1 were ordered at Geneart and cloned into pRSV that already 
contained the constant region of the TCR. The expression vectors coding for the α- and 
β-chain were cotransfected into 58-/--CD8+-NFAT-sGFP cells (produced by K. Siewert and 
G. Rühl) by electroporation and set on antibiotics for the selection of clones stably 
expressing IP2-8S1 (Section 2.6.6)  
3.2.2 Detection of the expression of TCR, CD8 and NFAT-sGFP 
IP2-8S1 was successfully transfected into 58-/- hybridoma cells. Expression of murine CD3 and 
human CD8 in the received clones was detected by flow cytometry (Figure 3-7). The clone, 
showing highest expression levels was kept and used for further studies.  
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The expression of sGFP under the control of the NFAT-enhancer in hybridoma cells is used 
as a reporter for the mimotope screening. The cells were activated in vitro by CD3 cross-linking 
via a murine anti-CD3 antibody, to test their ability to express sGFP after activation. sGFP 
expression was detected by flow cytometry as well as by microscopy (Figure 3-8).  
3.2.3 HLA restriction of IP2-8S1 
TCRs are HLA restricted in their antigen recognition (Zinkernagel and Doherty 1974). For the 
library screening of IP2-8S1 it is indispensable to know which HLA molecules were expressed 
by IP2.  
Figure 3-8 Expression of sGFP in 58-IP2-8S1 cells after CD3 activation. (A) Fluorescence 
microscopy of CD3 activated 58-IP2-8S1, scale bar 200 µm. (B) Flow cytometry of CD3 activated 58-
IP2-8S1 cells, gated on living cell population. 
Figure 3-7 Detection of surface expression of TCR and CD8 of transfected 58-/- hybridoma cells 
by flow cytometry. The expression of TCR in 58-/- transfected with IP2-AV8S1 and IP2-BV8S1 was 
detected with a FITC-labeled antibody against murine CD3ξ (purple). 58-/- do not express CD3 (A). After 
transfection with IP-AV8S1 and IP-BV8S1 CD3 expression of the cells is detected by flow cytometry (B). 
The expression of CD8 was detected with an APC-labeled antibody against human CD8 (C). 
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3.2.3.1 HLA typing of IP2-8S1 
For HLA typing, genomic DNA was isolated of a 10 µm hippocampal section of IP2 with the 
QIAamp DNA micro kit (Section 2.4.16). The isolated DNA was send to the “Labor für 
Immungenetik und Diagnostik” at the Klinikum der Universität München to perform HLA typing 
of IP2.  
IP2 is heterozygote in the expression of MHC-I and MHC-II alleles. The expressed HLA alleles 
are displayed in Table 3-7.  
Table 3-7 HLA typing of IP2 
MHC class Gene Allele 1 Allele 2 
MHC-I HLA-A *02:01 *23:01 
 HLA-B *35:01 *44:03 
 HLA-C *04:01 *16:01 
MHC-II HLA-DQB1 *02:02 *05:03 
 HLA-DPB1 *02:01 *04 
 HLA-DRB1 *07:01 *14:54/14:01 
3.2.3.2 Cocultivation of IP2-8S1 with LCL 
One method to identify the MHC-restriction of TCRs is to incubate them with LCL expressing 
different HLA alleles. In case the TCR recognizes endogenous peptides, presented by the 
correct HLA molecule, the TCR gets activated. It was not possible to establish patient relevant 
LCL. Thus, LCL of other patients, covering all HLA alleles of IP2 were used for cocultivation. 
HLA typing of the different LCL are listed in Section 2.1.9.1. Cocultivated 58-IP2-8S1 cells 
were analysed for activation by flow cytometry, gated on living, CD3+ cells. It was not possible 
to analyse the cells by microscopy, because the cells are cultivated in round-bottom vessel, to 
enhance their contact. Thus, it cannot be focused well in the microscope. In addition, LCLs 
express sGFP as reporter gene, which was introduced during the generation of LCLs. Thereby, 
in the microscope it cannot be distinguished between sGFP-expressing LCLs and activated 
hybridoma cells. 
EBV B-cells from patient Fe and only the hybridoma cells IP2-8S1 were used as negative 
control. To enhance the peptide presentation in LCL cell lines, they were stimulated with 
different concentrations of INF-γ (100 Units (U) and 500 U, Section 1.3.1).  
Flow cytometry did not show an activation of IP2-8S1 by the cocultivation with LCL. The 
percentage of activated IP2-8S1 varied between 0.2-1.9%, which is only background. Also 
stimulation with INF-γ did not increase activation of IP2-8S1. As positive control, 58-IP2-8S1 
cells were activated by cross-linkage via anti-CD3 antibodies (Figure 3-9).  
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3.2.4 Analysis of possible antigen-candidates from GABAA receptor of HLA-
dependent epitope binding  
In the CSF of IP2, antibodies which recognizes the GABAA receptor α-1 subunit were identified. 
The antibody was cloned from B cells of the CSF. In vitro studies confirmed the binding to the 
GABAA receptor α-1 subunit (E. Beltrán, J. Dalmau, unpublished data). The GABAA receptor is 
expressed in the hippocampus for mediating inhibitory synaptic transmission (Houser 1988, 
Schoch 1985). Simultaneously, an infiltration of the expanded CD8+ T cell IP2-8S1 was found 
in the hippocampus (Section 3.1.2) and the lateral sulcus (Section 3.1.3). This might indicate 
that the expanded TCR clone IP2-8S1 recognize an antigen of GABAA receptor α-1 subunit as 
well. To select possible antigen-candidates, databases, which comprise HLA epitopes 
(NetMHC 4.0 Server, Andreatta and Nielsen 2016) but also proteasomal cleavage predictions 
and TAP transport efficiency (IEDB NetCTL Prediction, Vita 2015) were used. Although the 
binding patterns and affinities for some HLA alleles of IP2 are characterized in detail, the 
databases did not include information for all MHC-I alleles of IP2, in particular for HLA-C*04:01 
and HLA-C*16:01. Therefore, databases analysis was only performed for HLA-A and -B with 
the amino acid (AA) sequence of GABAA receptor α-1 subunit. 9-meric peptides were analysed 
for their HLA-binding affinities, for their transport into the ER by TAP, and additionally for their 
potential proteasomal cleavage. Antigen-candidates which fulfil these criterial were selected 
for the screening. To identify some candidates presented by HLA-C*04:01 and HLA-C*16:01, 
for which no database search exists, the sequence was analysed for anchor positions, 
described by Rasmussen et al. 2014. For HLA-C*04:01 they described a preferred aspartic 
acid at position three and a leucine, isoleucine or phenylalanine at position nine. For HLA-
Figure 3-9 Cocultivation of IP2-8S1 with LCL. 58-IP2-8S1 cells were cocultivated with different LCLs 
without and after stimulation with 100 Units (U) and 500 U of INF-γ. IP2-8S1 alone or cocultivated with 
Fe served as negative controls. Activation of 58-IP2-8S1 cells via CD3 antibody was used as positive 
control. Activation varied between 0.2-1.9 %, which represent background.  
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C*16:01 an alanine at position 2, an arginine at position 5 and also a leucine, isoleucine or 
tyrosine at position 9 is preferred.  
DNA coding for 48 antigen-candidate peptides (Section 2.1.2.1) were cloned (Section 2.4.5.4), 
and co-transfected into COS-7 cells together with plasmids coding for the HLA alleles. 58-IP2-
8S1 cells were overlaid, and after 16 h screened for activation in the fluorescence microscope, 
using the scanning system (Section 2.9.3). Every candidate peptide was tested with all six 
different HLA alleles. However, no activation was found with any candidate. Thereby, HLA-
restriction of IP2-8S1 and its peptide antigens are still unknown.  
3.2.5  Library Screening IP2-8S1 with PECPL 
To identify possible antigens of IP2-8S1 PECPL-N27 was used. PECPL-N27 is coding for a 
random, nine AA long peptide. For the screening of possible antigens COS-7 cells were 
cotransfected with PECPL-N27 and HLA alleles, either by FuGENE® transfection or 
nucleofection. The screening was performed under different conditions. Either all six HLAs of 
IP2 were screened individually, or HLA-A (HLA-A*02:01 and HLA-A*23:01), HLA-B (HLA-
B*35:01 and HLA-B*44:03), HLA-C (HLA-C*04:01 and HLA-C*16:01) or all six HLA alleles 
were pooled. Additionally, either 1 µg or 0.1 µg of PECPL were transfected.  
Furthermore, a HLA-specific PECPL (A2-269) was used for the screening with HLA-A*02:01. 
The library expresses fixed anchor positions, composed of an isoleucine at position two, a 
valine at position six and a leucine at position nine. The anchor positions are specific for HLA-
A*02:01 whereby the binding to the HLA molecule is facilitated.  
The screened areas, the number of detected clusters and the number of activated 58-IP2-8S1 
cells (= cluster size) using the different screening approaches are listed in Table 3-8. In 
general, K. Siewert, G. Rühl and A. Niedl (Institut für klinische Neuroimmunologie, Ludwig-
Maximilians-Universität München, AG Dornmair) observed that the presence of activated 
clusters indicates the presence of the TCR antigen in the transfected COS-7 cell (Siewert et 
al., 2012, Rühl et al., 2016). In clusters composed of a higher number of activated hybridoma 
cells, the probability of antigen-specific activation is increased. Thereby, variations in the 
cluster size and cluster frequency in the different approaches, can also give a hint for HLA-
restriction.  
For the screening of all HLA alleles individually two clusters of the size of four activated 58-
IP2-8S1 cells were detected with HLA-C*04:01 (Table 3-8 and Figure 3-10 (D)). With the other 
HLA alleles, no activated 58-IP2-8S1 cells were detected.  
In the approach, where all six HLAs were pooled, no cluster of activated 58-IP2-8S1 was 
detected (Table 3-8).  
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Table 3-8 Overview library screening IP2-8S1. For the library screening, two different libraries were 
analysed. Different amounts of the library were transfected, in combination with IP2-specific HLA alleles. 
The area which was screened, the number of detected clusters and the cluster size of n activated 58-
IP2-8S1 cells are listed.  
Library Transfected 
amount [µg] 
HLA Area [cm2] Cluster  
 
Cluster size  
[n activated cells] 
N27 1 A*02:01 93.6 - - 
N27 1 A*23:01 93.6 - - 
N27 1 B*35:01 93.6 - - 
N27 1 B*44:03 93.6 - - 
N27 1 C*04:01 93.6 2 4 
N27 1 C*16:01 93.6 - - 
N27 1 A*02:01 and 
A*23:01 
140.4 4 3-4 
N27 1 B*35:01 and 
B44*03 
140.4 3 3-4 
N27 1 C*04:01 and 
C*16:01 
152.1 4 3-5 
N27 1 all six HLAs 46.8 - - 
A02-269 1 A*02:01 23.4 - - 
N27 0.1 A*02:01 23.4 - - 
N27 0.1 A*23:01 23.4 - - 
N27 0.1 B*35:01 23.4 - - 
N27 0.1 B*44:03 23.4 - - 
N27 0.1 C*04:01 23.4 - - 
N27 0.1 C*16:01 23.4 - - 
 
In the approaches where HLA-A, -B or -C were pooled, clusters of activated 58-IP2-8S1 cells 
were detected in all samples expressing different HLA alleles (Table 3-8 and Figure 3-10 A-
C). The clusters were detected with the same frequency and the same cluster size of activated 
58-IP2-8S1 cells. No differences were observed concerning the different HLA-pools. Thereby, 
HLA restriction could not be resolved.  
For all detected clusters, the underlying transfected COS-7 cell were picked, plasmid recovery 
PCR was performed and cloned into pcDNA3.1D/V5-His-TOPO (Section 2.9.1).  
For one sample of the HLA-A pool, one sample of the HLA-C pool and one sample of the HLA-
C*04:01, reactivation was observed. However, the reactivation signal was not reproducible 
during the subpooling procedure. Thus, the underlying COS-7 after reactivation was isolated 
again, and proceeded as described before. However, no reactivation was observed anymore.  
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Figure 3-10 Cluster of activated 58-IP2-8S1 cells. COS-7 cells were transfected with PECPL N27 and 
pooled HLA-A (A), pooled HLA-B (B), pooled HLA-C (C) of IP2 and HLA-C*04:01 (D). The transfected 
cells were cocultivated with 58-IP2-8S1 cells. The green cells represent 58-IP2-8S1 cells, expressing 
sGFP after activation, indicating the presence of an antigen recognized by 58-IP2-8S1. Scale Bar: 100 
µm.  
3.3 Identification of MHC-II mimotopes 
We expected to detect an expanded CD4+ T cell clone in IP2, mediating CD4+ T cell help for 
the humoral immunity in GABAA receptor encephalitis. Although we then detected a CD8+ T 
cell clone, we wanted to create the opportunity to screen for CD4+ T cell antigens. Therefor, 
as a second project, a method to identify MHC-II mimotopes was established. To this end, the 
method to identify CD8+ T cell antigens of K. Siewert et al. (2012) was modified to allow the 
identification of CD4+ T cell antigens.  
As described in Section 1.3.1, the peptide loading of MHC-I and MHC-II molecules is different. 
Therefore, new libraries for MHC-II were designed (Section 3.3.1). The functionality of the 
system was tested with the model TCR Bbc9, for which the HLA restriction and the peptide 
antigen are known. Stable COS-7 cells expressing HLA-DR and 58-Bbc9 hybridoma cells 
expressing the TCR Bbc9 and sGFP under the control of the NFAT-enhancer were generated 
(Section 3.3.3 and Section 3.3.4). The ability to activate 58-Bbc9 cells in a HLA-restricted 
manner was analysed with hMBP-derived peptides of different length. The ability to express Ii-
ECPL in COS-7 cells was determined by Western Blot and intracellular flow cytometry (Section 
3.3.5). Furthermore, the functionality of the system was confirmed with the positive control Ii-
hMBP, expressing hMBP-derived peptides of different length in Ii (Section 3.3.7). In addition, 
58-Bbc9 cells were screened for antigens with different Ii-ECPL presented by HLA-DR1 and 
HLA-DR2a (Section 3.3.9). 
An overview over the established system for the identification of MHC-II mimotopes is depicted 
in Figure 3-11. For the MHC-II libraries, CLIP of Ii-wt was changed to a randomised library 
sequence (Figure 3-11 A). These Ii-encoded combinatorial peptide libraries (Ii-ECPL) are 
cotransfected with pHSE3’ expressing HLA-DRα and HLA-DRβ into COS-7 cells (Figure 3-11 
B). COS-7 cells expressing HLA-DR molecules, which are complexed in the ER with the Ii-
ECPL. Thus MHC-II molecules are already loaded in the ER with the library peptides (Figure 
3-11 C). Depending on the signal sequence, these complexes are either targeted directly to 
the cell surface, or to the MIIC by the N-terminal signal sequence of the Ii-ECPL. Here Ii is 
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degraded, the peptides of the library remain in the binding groove and the complex gets 
transported to the cell surface, where the peptides of the library are presented to 58-/- 
hybridoma cells. As a read out for T cell activation, the same detection system as for MHC-I 
library screening is used. The expression of sGFP under the control of the NFAT-enhancer in 
hybridoma cells is supposed to be more sensitive than the measurement of the cytokines in 
the supernatant by ELISA.  
 
3.3.1 Design of MHC-II Libraries 
The design of MHC-II libraries is illustrated in Figure 3-12. MHC-II libraries are cloned in 
pcDNA-Ii-wt. Hereby CLIP of Ii is replaced by (NNN)9-13 or by (NNK)9-13 . N stands for a random 
nucleotide, K for a nucleotide of the keto-group (guanine or thymin). The application of K at the 
Figure 3-11 Library presentation on MHC-II molecules. (A) For Ii-ECPL, CLIP of Ii is exchanged by 
a random library. (B) pHSE3’ encoding HLA-DRα and –DRβ and pcDNA-Ii-ECPL are co-transfected into 
COS-7 cells. (C) COS-7 cells express HLA-DR molecules which are loaded in the ER with the library 
expressed in Ii. Depending on the N-terminal signal sequence of Ii, the complex can either be 
transported directly to the cell surface or to MIIC, where the invariant chain is degraded and the library 
loaded on MHC-II molecules is transported to the cell surface. At the cell surface, the library is presented 
by HLA-DR molecules to hybridoma cells which express TCR and sGFP under the NFAT-enhancer for 
the detection of activation. 
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third position reduces the risk of Stop-codons in the library. X represents a random AA in the 
library. Libraries with a methionine (M) at position X and X+8 as anchors for binding at MHC-
II molecules, were also designed. The libraries were named by the length of the random 
nucleotide sequence (N) and the position of the methionine-anchor in the peptide (M, Table 
3-9). An overview of the cloned Ii-ECPL is shown in (Table 3-9).  
 
The number of different plasmids of the libraries vary between 7.5ˣ107 - 7ˣ109 clones (Table 
3-9).  
30 single clones were picked and send for sequencing. 50 - 70 % of the sequences code for a 
correct library without stop codon. Around 30 % of the sequences contain stop-codons. For 
some sequences, Ii had a deletion after the restriction site KasI, whereby Ii was not coded 
correctly anymore after KasI, due to the restriction digestion. The remaining number of different 
plasmids cover a broad spectrum of possible peptides.  
 
 
Figure 3-12 Design of MHC-II libraries. For the MHC-II libraries CLIP in the invariant chain (Ii) was 
exchanged by a random sequence (A). Electropherogramm of Ii-ECPL-N39 (B) and Ii-ECPL-N39-
M3,11, which codes for methionine anchors at AA position 3 and 11 (C). 
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Table 3-9 Overview of the cloned Ii-ECPL and the number of different plasmids of the libraries. 
CLIP of Ii was replaced by different library constructs to receive Ii-encoded combinatorial peptide 
libraries (Ii-ECPL). N describes the nucleotide length of the library, M the position of the methionine in 
the peptide.  
Library Aminoacid sequence No. of different plasmids 
Ii-ECPL-N27 -PVSKXXXXXXXXXQALP- 7ˣ109 
Ii-ECPL-N27-M1,9 -PVSKMXXXXXXXMQALP- 7.7 ˣ 108 
Ii-ECPL-N33 -PVSXXXXXXXXXXXALP- 2 ˣ 108 
Ii-ECPL-N33-M2,10 -PVSXMXXXXXXXMXALP- 5.5ˣ108 
Ii-ECPL-N36-C -PVSXXXXXXXXXXXXLP- 2ˣ108 
Ii-ECPL-N36-N -PVXXXXXXXXXXXXALP- 7.5ˣ107 
Ii-ECPL-N36-C-M2,10 -PVSXMXXXXXXXMXXLP- 1.4ˣ108 
Ii-ECPL-N36-N-M3,11 -PVXXMXXXXXXXMXALP- 2,9ˣ108 
Ii-ECPL-N39 -PVXXXXXXXXXXXXLP- 3.6ˣ109 
Ii-ECPL-N39-M3,11 -PVXXMXXXXXXMXXLP- 3ˣ108 
 
3.3.2 Bbc9 as proof of concept 
For the establishment of a system to identify CD4+ T cell antigens, the T cell receptor Bbc9 
was used as a proof of concept. It recognizes hMBP139-153 presented by HLA-DRB1*01:01 
(DR1) and HLA-DRB5*01:01 (DR2a), however it does not recognize the same peptide 
presented by HLA-DRB1*15:01 (DR2b) (Giegerich et al., 1992). Because the HLA restrictions 
and the antigen of the TCR Bbc9 are described well, it can be used as a proof of concept for 
the MHC-II library screening system.  
3.3.3 Expression of TCR, CD4 and NFAT-sGFP in 58-/- T hybridoma cell line 
For the library screening 58α-β- T hybridoma cells were transfected with the α- and β-chain of 
Bbc9 in pRSV (Giegerich et al., 1992). The TCR α- and β-chain of Bbc9 associate with the 
murine CD3 and thereby shows up as a chimeric TCR on the cell surface (Blank et al., 1993). 
58-/- cells also express human CD4 (Blank et al., 1993). Surface expression of murine CD3 
and human CD4 was analysed by flow cytometry (Figure 3-13 A, B).  
Clones of 58-Bbc9 cells with strong surface CD3 expression were additionally transfected with 
pcDNA-NFAT-sGFP, coding for sGFP under the NFAT-enhancer (Siewert et al., 2012). Upon 
activation the cells express sGFP (Figure 3-13 C, D). Stable transfected clones were screened 
for highest level of sGFP expression after CD3 activation and lowest rate of spontaneously 
activated cells. 
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Figure 3-13 Flow cytometry and fluorescence microscopy of 58-Bbc9 cells. The expression of TCR 
in stable transfected 58-Bbc9 cells was detected with an APC-labeled antibody against murine CD3ξ 
(A) and the expression of CD4 with a PE-labeled antibody against human CD4 (B). The expression of 
sGFP in 58-Bbc9 cells after CD3-linkage, was detected by flow cytometry, gated for living cells (C), and 
by fluorescence microscopy (D). Scale bar: 200 µm.  
3.3.4 Expression of HLA-DR molecules in COS-7 cells 
COS-7 cells were used for the presentation of Ii-ECPL on HLA-DR. To this end, HLA-DRA, 
DRB1, DR2a and DR2b coding sequences were cloned into pHSE3’. In contrast to pRSV, 
pHSE3’ does not contain an SV40 origin. Thus it does not get amplified in COS-7 cells. 
COS-7 cells, which do not express HLA-DR (Figure 3-14), were cotransfected with pHSE3’-
HLA-DRA and pHSE3’-HLA-DR1 or pHSE3’-HLA-DR2a or pHSE3’-HLA-DR2b. After single 
cell isolation, almost all cells of COS-7-DR1 expressed HLA-DR. However, the expression of 
COS-7-DR2a was low and almost no cells expressed HLA-DR2b (Figure 3-14). To increase 
the amount of HLA-DR+ cells, the cells were purified via MACS Beads for HLA-DR (COS-7-
DR2a and COS-7-DR2b) and sorted by FACS (COS-7-DR1 and COS-7-DR2a). For FACS, the 
best 10 % of the population were sorted and cultivated further. Comparison of HLA-DR 
expression of the cells before and after FACS, showed only a little increase of HLA-DR 
expression in COS-7-DR1. However, the expression of HLA-DR2a in COS-7-DR2a cells was 
increased. The surface expression of HLA-DR2b was increased successfully by several 
rounds of MACS purification (Figure 3-14). 
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3.3.5 Detection of Ii-ECPL expression in COS-7-DR1 cells 
To detect whether COS-7 cells express Ii-ECPL, the cells were transfected with pcDNA-Ii-
ECPL-N39. Ii-ECPL was detected with an antibody against the N-terminal signal sequence of 
Ii (CD74). Detection was visualised by Western Blot and intracellular flow cytometry.  
3.3.5.1 Detection of Ii-ECPL expression by Western Blot 
Expression of Ii-ECPL was detected by Western Blot. COS-7-DR1 cells were transfected with 
1 µg pcDNA-Ii-N39 by nucleofection and the cells were harvested after 48 h. Non-transfected 
COS-7-DR1 cells served as negative control.  
Untransfected COS-7-DR1 did not show a signal for CD74 in Western Blot (Figure 3-15 lane 
1), which proves that COS-7 cells do not express the invariant chain. After transfection of COS-
7-DR1 cells with Ii-ECPL, a strong signal showed up in Western Blot, with the molecular weight 
of Ii (33 kDa, Figure 3-15 lane 2). This shows that Ii-ECPL is expressed in COS-7 cells after 
transfection 
Figure 3-14 Expression of HLA-DR in stable transfected COS-7 cells. Expression of HLA-DR in 
COS-7 cells was detected by flow cytometry with a FITC-labeled anti-hHLA-DR antibody. Non-
transfected COS-7 cells do not express HLA-DR (A). Expression of HLA-DR in COS-7 cells co-
transfected with pHSE3’-HLA-DRA and pHSE3’-HLA-DR1 (B), pHSE3’-HLA-DR2a (C) and pHSE3’-
HLA-DR2b (D). To increase the expression of HLA-DR, COS-7-DR1 (E) and COS-7-DR2a (F) were 
purified via FACS and COS-7-DR2b purified via MACS beads (G).  
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3.3.5.2 Detection of Ii-ECPL expression in by intracellular flow cytometry  
To find the best transfection conditions for the expression of Ii-ECPL in COS-7 cells, 
intracellular flow cytometry was performed. COS-7-DR1 cells were transfected by 
nucelofection and by FuGENE® with two different amounts (1 µg and 100 ng) of pcDNA-Ii-
ECPL-N39, whereby the total transfected DNA amount was kept constant at 1 µg by adding 
fish sperm DNA. Intracellular FACS was performed 48 h and 72 h after transfection. COS-7-
DR1 cells transfected with 1 µg fish sperm DNA served as negative control.  
COS-7-DR1 cells only transfected with fish sperm DNA, did not express CD74 (Figure 3-16). 
After transfection, either with FuGENE® or by nucleofection, COS-7-DR1 expressed Ii-ECPL. 
The expression level for both transfection methods are higher for 1 µg of transfected pcDNA-
Ii-ECPL compared to the transfection of 100 ng. The expression level after nucleofection is 
much higher compared to FuGENE® transfection, especially for the transfection of small 
amounts of DNA. However, the expression level 72 h after nucleofection is lower than after 48 
h, presumably explained by degradation of DNA (Figure 3-16). For FuGENE® transfection no 
difference in the expression level is observed 48 h and 72 h after transfection (Figure 3-16).  
The results show that nucleofection should be the method of choice for the library screening.  
 
Figure 3-15 Western Blot showing expression of Ii-N39 in COS-7-DR1 cells transfected with 
pcDNA-Ii-N39. Lane 1: untransfected COS-7-DR1 cells. Lane 2: COS-7-DR1 cells transfected with 1 
µg pcDNA-Ii-N39 by nucleofection. The invariant chain was detected with an antibody specific for CD74 
(PIN.1). 
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3.3.6 Activation of Bbc9 by synthetic peptides 
In the first step, 58-Bbc9 cells were activated with diverse length of hMBP-derived synthetic 
peptides presented on COS-7 expressing HLA-DR. The synthetic peptides and their AA 
sequences are shown in Table 3-10.  
Table 3-10 Overview peptide sequences of hMBP-derived synthetic peptides 
peptide AA sequence source 
hMBP(141-149)    FKGVDAQGT K. Dornmair 
hMBP(140-149)   GFKGVDAQGT K. Dornmair 
hMBP(141-150)    FKGVDAQGTL K. Dornmair 
hMBP(140-150)   GFKGVDAQGTL K. Dornmair 
hMBP(139-153)  KGFKGVDAQGTLSKI K. Dornmair 
 
The activation with synthetic peptides were performed, to prove, if 58-Bbc9 cells are activated 
by peptides presented by HLA molecules on COS-7 cells as APC. It also shows which peptide 
can be used as a positive control expressed in Ii. Furthermore, it provides an evidence, which 
library length is reasonable for the identification of mimotopes. The vehicle (H2O) as well as 
hMBP(50-69, GAPKRGSGKDSHHPARTAHY) served as negative control. COS7-DR2b cells, 
expressing the irrelevant HLA-DR2b were additionally used as negative control. Activation of 
58-Bbc9 cells was detected by fluorescence microscopy (Figure 3-17 A-U), flow cytometry 
(Figure 3-17, V) and IL2-ELISA (Figure 3-17, W).  
Figure 3-16 Expression of the invariant chain library in COS-7-DR1. COS-7-DR1 cells were 
transfected with 0.1 µg Ii-ECPL-N39 + 0.9 µg fish sperm DNA (1), 1 µg Ii-ECPL-N39 (2) or with 1 µg fish 
sperm DNA (3). Intracellular FACS for CD74 was performed 48 h and 72 h after transfection.  
1 2 3 
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Figure 3-17 Activation of Bbc9 by variations of hMBP-derived peptides presented by HLA-DR. 
hMBP50-69 (B, I, P), hMBP141-149 (C, J, Q), hMBP140-149 (D, K, R), hMBP141-150 (E, L, S), 
hMBP140-150 (F, M, T), hMBP139-151 (G, N, U) or only the vehicle were added to COS-7 cells, stably 
expressing HLA-DR2a (A-G), HLA-DR1 (H-N) or HLA-DR2b (O-U). After 3 h incubation 58-Bbc9 cells 
were added and cocultivated for 16 h. The expression of sGFP was analysed by fluorescence 
microscopy (A-U). Scale bar: 200 µm. Additionally, the percentage of activated Bbc9 was determined 
by flow cytometry (V) and the IL-2 concentration in the supernatant was measured by IL-2 ELISA.  
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58-Bbc9 cells were strongly activated by hMBP(141-150), hMBP(140-150) and hMBP(139-
153), presented on COS-7-DR2a cells. Less activation was observed with the construct 
hMBP(140-149). No activation was observed by the shorter construct hMBP(141-149). Both 
negative controls did not activate Bbc9 (Figure 3-17). The activation of Bbc9 was additionally 
validated by the detection of sGFP expression by flow cytometry (Figure 3-17 V) and the 
detection of IL-2 in the supernatant by ELISA (Figure 3-17 W). Comparison of the sensitivity 
of the three detection methods showed that fluorescence microscopy is the most sensitive 
detection method. Clusters with only several activated 58-Bbc9 cells were visible by the 
presentation of hMBP140-149 by COS-7-DR2a cells (Figure 3-17 D), however no activation 
was detected neither in flow cytometry nor by ELISA (Figure 3-17 V, W).  
Almost the same activation pattern was observed for the synthetic peptides presented by COS-
7-DR1 cells, however, no activation at all was detected for hMBP140-149 (Figure 3-17, H-N).  
No activation was observed by any of the peptides presented on HLA-DR2b, neither in 
fluorescence microscopy nor by flow cytometry or Il-2 ELISA (Figure 3-17 O-W).  
The activation with the peptides hMBP(141-150) and hMBP(140-150) is stronger when 
presented by HLA-DR1 molecules compared to HLA-DR2a. However, for the longest peptide 
hMBP(139-153) the activation is more intense presented by HLA-DR2a molecules compared 
to HLA-DR1 (Figure 3-17 V, W). 
The results show that it is possible to specifically activate 58-Bbc9 cells with the correct peptide 
presented by the matching HLA-DR molecules on COS7 cells. The results also confirm the 
restriction of Bbc9 to HLA-DR2a and DR1, as observed before (Giegerich et al., 1992). 
Additionally, Bbc9 specifically recognizes an at least 10 AA long peptide of hMBP, which must 
include the phenylalanine (position 141) and leucine (position 150) for optimal activation. 
These results are in accordance with previous experiments, where also different length of 
peptides presented by HLA-DR1 and HLA-DR2a molecules were used to activate Bbc9 
(unpublished data K. Dornmair, E. Meinl, Institut für klinische Neuroimmunologie, Ludwig-
Maximilians-Universität München) detected with T cell proliferation as read-out (Meinl et al., 
1993). 
3.3.7 Activation of Bbc9 by hMBP-derived peptides expressed in Ii 
A positive control construct (Ii-hMBP) in pcDNA was cloned to test if 58-Bbc9 cells can be 
activated by the correct peptide expressed in the invariant chain in pcDNA. For this purpose, 
CLIP was replaced on DNA level by sequences coding for four hMBP-derived peptides of 
different length (hMBP(141-149), hMBP(141-150), hMBP(141-151) and hMBP(139-151)). The 
length was varied to test which construct can activate 58-Bbc9 cells most efficient. This 
evidence can be used for the decision which library length are useful for CD4+ T cell antigen 
screening. The transfected amounts of DNA were varied, to find the best concentration for 
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activating 58-Bbc9 cells and low cell death ratio of COS7-DR cells after transfection 
concomitantly.  
Additionally, the N-terminal signal sequence in the four constructs was removed (delta-Ii 
constructs). COS-7 cells are no professional APCs. Therefore, it is not known whether they 
may recognize the N-terminal signal sequence of the invariant chain (Figure 3-11). Ii-hMBP 
and delta-Ii-hMBP constructs were compared in matters of cellular viability after transfection 
and activation efficiency of 58-Bbc9 cells.  
After FuGENE® transfection of 500 ng pcDNA-Ii-hMBP(139-151) and pcDNA-delta-Ii-
hMBP(139-151) cellular viability of COS-7-HLA-DR cells was only 50 % after 48 h and 40 % 
after 72 h. Cellular viability is increased to 60 % (48 h) and 50 % (72 h) for the transfection of 
250 ng and to 80 % (48 h) and 70 % (72 h) for 100 ng (Figure 3-18). Cellular viability is 
decreased for all constructs 72 h after transfection compared to 48 h. However, there is no 
difference in cellular viability comparing the constructs with and without N’-terminal signal 
sequence (Figure 3-18).  
 
 
The results of activating 58-Bbc9 cells with the different pcDNA-Ii-hMBP and pcDNA-delta-Ii-
hMBP constructs, transfected by FuGENE®, are presented in Figure 3-19 and Figure 3-20. For 
fluorescence microscopy activation of 58-Bbc9 cells by Cos7-DR1 cells with six different 
constructs are exemplarily presented in Figure 3-19. Results of the activation of 58-Bbc9 cells 
by all constructs presented on COS-7 cells expressing different HLA-DR molecules detected 
by flow cytometry and IL-2 ELISA are presented in Figure 3-20. 
Activation of 58-Bbc9 cells was observed by Ii-hMBP constructs, presented on COS-7-DR2a 
and COS-7-DR1 (Figure 3-19 and Figure 3-20). No activation was observed with the negative 
Figure 3-18 Cellular viability of COS-7-HLA-DR cells 48 h (A) and 72 h (B) after transfection with 
pcDNA-Ii-hMBP(139-151) compared with pcDNA-delta-Ii-hMBP(139-151). COS-7-DR1 cells were 
transfected with 100 ng, 250 ng or 500 ng of pcDNA-Ii-hMBP(139-151) (plain) or pcDNA-delta-Ii-
HMBP139-151 (hatched). Cellular viability was detected by flow cytometry.  
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controls (pcDNA-Ii-wt and pcDNA-delta-Ii), nor by presentation of Ii-hMBP constructs by COS-
7-DR2b cells. This verify that the system for the presentation of CD4+ T cell antigens is 
functional. MHC-II molecules are loaded correctly with Ii including the peptide, and the complex 
is transported to the cell surface, where the antigen is presented to hybridoma cells. The 
activation of 58-Bbc9 cells by constructs with the N’-terminal signal sequence compared to the 
constructs without, showed higher activation levels (Figure 3-19 and Figure 3-20). This effect 
cannot be ascribed to differences in cellular viability after transfection (Figure 3-18). 
Presumably the transportation to the cell surface is more efficient for constructs with signal 
sequence.  
 
 
Figure 3-19 Activation of Bbc9 by Ii-hMBP constructs presented on COS7-DR1 cells. COS-7-DR1 
cells were transfected with 250 ng of the following constructs: pcDNA-Ii-hMBP(141-149) (A), pcDNA-Ii-
hMBP(139-151) (B), pcDNA-Ii-wt (C), pcDNA-delta-Ii-hMBP(141-149) (D), pcDNA-delta-Ii-hMBP(139-
151) (E) and pcDNA-delta-Ii using FuGENE® transfection. Scale Bar: 200 µm. 
 
The highest activation level of 58-Bbc9 cells was observed with the longest construct, 
expressing 13 AA in the invariant chain (Ii-hMBP(139-151)), followed by Ii-hMBP(141-151) and 
Ii-hMBP(141-150). Interestingly the nine AA construct expressed in the invariant chain Ii-
hMBP(141-149) also showed low activation of 58-Bbc9 cells. The synthetic peptide of the 
same length did not show any activation (Section 3.3.5).  
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Figure 3-20 Activation of 58-Bbc9 cells by Ii-encoded positive control (Ii-hMBP) presented on 
COS-7-HLA-DR. COS-7-HLA-DR cells were transfected with 100 ng (A, C, E, G) or 250 ng (B, D, F, H) 
pcDNA-Ii-constructs using FuGENE® transfection and analysed after 48 h (A, B, E, F) and 72 h (C, D, 
G, H). Activated 58-Bbc9 cells were analysed by flow cytometry, gated for living, CD3+ cells (A-D). The 
supernatant was tested for IL-2 concentration by ELISA (E-H). COS-7-HLA-DR cells were transfected 
with following constructs: pcDNA-Ii-hMBP(141-149) (1), pcDNA-Ii-hMBP(141-150) (2), pcDNA-Ii-
hMBP(141-151) (3), pcDNA-Ii-hMBP(139-151) (4), pcDNA-Ii-wt (5), pcDNA-delta-Ii-hMBP(141-149) (6), 
pcDNA-delta-Ii-hMBP(141-150) (7), pcDNA-delta-Ii-hMBP(141-151) (8), pcDNA-delta-Ii-hMBP(139-
151) (9) and pcDNA-delta-Ii (10).  
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3.3.8 Comparison of the sensitivity using different detection methods 
To analyse until which dilution the correct antigen is still detectable, and which detection 
method (fluorescence microscopy, flow cytometry or IL-2 ELISA) is most sensitive, a titration 
of pcDNA-Ii-hMBP(139-151) diluted in pcDNA-Ii-wt was performed. Therefore, COS-7-DR1 
cells, seeded in 24-well plates were transfected with the titration preparations by FuGENE® 
(Section 2.6.2). The cells were always transfected with 250 ng DNA, whereas the amount of 
pcDNA-Ii-hMBP(139-151) was reduced in a dilution series from 1:10 to 1:106. The transfected 
DNA was kept constant with 250 ng per sample by adding pcDNA-Ii-wt. The cells were 
incubated for 32 h and 56 h before adding 58-Bbc9 cells. The hybridoma cells were 
cocultivated with the transfected COS7-DR1 for 16 h. Afterwards, the cells were analysed by 
fluorescence microscopy for activated 58-Bbc9 cells. Additionally, the cells were analysed by 
flow cytometry. For this purpose, the cells were stained with an APC-labeled AB against CD3 
and PI for counterstaining. It was gated on living, CD3+ cells. Further, concentration of IL-2 in 
the supernatant was detected by ELISA.  
The analysis by fluorescence microscopy showed that until a dilution of 1:103 there were still 
several clusters composed of nine activated 58-Bbc9 cells visible (Figure 3-21 C, J). At a 
dilution of 1:104 at least one cluster composed of four (48 h) or seven (72 h) activated 58-Bbc9 
cells per well was detected. This also shows that the cluster size is enlarged for 72 h 
preparation compared to 48 h (Figure 3-21 D, K). At a dilution of 1:105 and 1:106 clusters of 
two activated 58-Bbc9 cells or no activated cells were visible (Figure 3-21 E, F, L, M). In the 
negative control, transfected with pcDNA-Ii-wt, no activation was visible.  
In flow cytometry, activated cells were still detectable until a dilution of 1:103 (Figure 3-21 O). 
For higher dilutions it was not possible to distinguish between background and activated cells, 
even there were still some clusters visible in the microscope.  
The expression of IL-2 by ELISA was also detectable until a dilution of 1:103 (Figure 3-21 P). 
For higher dilutions, the ELISA, which has a detection limit of 2 pg/ml, is not sensitive enough.  
The titration showed that compared to flow cytometry and IL-2 ELISA, fluorescence 
microscopy was the most sensitive method to detect activated 58-Bbc9 cells. Clusters of 
activated 58-Bbc9 cells were visible as immediate neighbours, indicating a specific activation. 
This close contact of a few activated cells can neither be visualized by flow cytometry nor 
detected by IL-2 ELISA. Activated 58-Bbc9 cells were still detectable until dilutions of 1:104-
1:105 by fluorescence microscopy in 24-well format. This should be sufficient enough to detect 
mimotopes, after the first isolation of cells from a 3.5 cm dish, to enrich the positive candidate. 
After cloning, it must be ensured that not more than 104-105  clones are screened per well of a 
24-well plate, otherwise, the positive clone is too diluted and thereby not detectable anymore.  
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3.3.9 Library Screening 58-Bbc9 cells with Ii-ECPL 
The experiments with Ii-hMBP constructs showed that peptides expressed in the invariant 
chain are loaded to MHC-II molecules in the ER and hybridoma cells can be activated by the 
presentation on the cell surface (Section 3.3.7). 58-Bbc9 cells were screened with different 
MHC-II libraries and different MHC-II alleles (HLA-DR1 and HLA-DR2a) for activation. Different 
transfection methods and DNA concentrations (Table 3-11) were used, to determine 
Figure 3-21 Comparison of the sensitivity of different detection methods. COS-7-DR1 cells were 
transfected with a dilution series of pcDNA-Ii-hMBP(139-153) diluted in pcDNA-p33-wt. 58-Bbc9 cells 
were added 32 h or 56 h after transfection. The cells were screened by fluorescence microscopy 48 h 
(A-G) and 72 h (H-N) after transfection. Scale bar: 200 µm. 58-Bbc9 cells were additionally analysed by 
FACS, gated on CD3+, living cells (O) and the supernatant was analysed by ELISA (P).  
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differences in the frequency of the presence of activated 58-Bbc9 cells as well as differences 
in the number of activated cells per cluster.  
Table 3-11 Library Screening Bbc9. Bbc9 was screened with Ii-ECPL expressed in COS-7 cells 
expressing either transiently (t) or stably (s) HLA-DR2a or HLA-DR1 molecules. Different Libraries were 
transfected with different amount of DNA and by FuGENE® (F) or by nucleofection (N). The number of 
clusters and the cluster sizes, by the number of activated 58-Bbc9 cells in the cluster, detected in the 
viewed area are displayed.  
Library (pcDNA) Transfected 
library [µg] 
HLA Area [cm2] Cluster 
 
Cluster size 
[n act. cells] 
Ii-ECPL-N27 1 µg, F DR1 (t) 140.4 16 2-4 
Ii-ECPL-N27 1 µg, F DR2a (t) 110 - - 
Ii-ECPL-N33-M2,10 2 µg, F DR2a (s) 374.4 15 3-4 
Ii-ECPL-N33-M2,10 0.1 µg, N DR2a (s) 70.2 - - 
Ii-ECPL-N33 2 µg, F DR1 (s) 140.4 4 2-3 
Ii-ECPL-N33 1 µg, N DR1 (s) 140.4 3 15-17 
Ii-ECPL-N39 2 µg, F DR1 (s) 351 18 2-5 
Ii-ECPL-N39 1 µg, N DR1 (s) 257.4 12 3-17 
Ii-ECPL-N39 0.1 µg, N DR1 (s) 198.9 2 5-7 
Ii-ECPL-N39 1 µg, N DR2a (s) 11.7 - - 
Ii-ECPL-N39 0.1 µg, N DR2a (s) 11.7 - - 
Ii-ECPL-N39-M3,11 2 µg, F DR2a (s) 163.8 - - 
 
In contrast to FuGENE® transfection, a higher cellular viability was determined by 
nucleofection, also after the transfection of high amounts of DNA, visualised in a transmitted 
microscope.  
Both, for HLA-DR1, as well as for HLA-DR2a clusters of activated 58-Bbc9 cells were detected 
by fluorescence microscopy. However, the experiments showed a high variability in the cluster 
size of activated 58-Bbc9 cells, depending on the length of the library and the transfection 
method. Clusters of 2 to 4 activated Bbc9 were observed with the short library Ii-ECPL-N27 
and by transfection with FuGENE®. Larger cluster sizes were observed with longer libraries. 
The biggest clusters were found after nucleofection of pcDNA-Ii-ECPL-N33 and pcDNA-Ii-
ECPL-N39 with up to 17 activated 58-Bbc9 cells (Table 3-11 and Figure 3-22).  
The underlying COS-7 cells were isolated with a micromanipulator and plasmids recovered by 
PCR. Samples were analysed for reactivation.  
For some isolated samples of all Ii-ECPL reactivation was observed. Further subpooling did 
not lead to a mimotope of Bbc9. The reactivation of 58-Bbc9 cells during the subpooling was 
not reproducible. During the subpooling procedure the COS-7-HLA-DR cells often died after 
transfection with FuGENE®. However, nucleofection, where the cells had a higher viability was 
not usable for many samples, due to low DNA quality and high costs. A second round of library 
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screening followed by DNA isolation and recovery, using the plasmids of the first round, was 
performed to futher enrich the positive clone. However, no reactivation of 58-Bbc9 cells was 
observed after cloning. 
 
Figure 3-22 Comparison clusters of activated Bbc9 using different libraries and transfection 
methods. COS-7-DR1 were transfected with Ii-ECPL-N39 (A, B) or Ii-ECPL-N33 (C) using FuGENE® 
transfection (A) or Nucleofection (B, C).  
3.3.10 LTK- cells as APCs as alternatives to COS-7 cells 
It was possible to activate 58-Bbc9 cells with Ii-hMBP constructs expressed in COS-7-HLA-
DR cells (Section 3.3.7). However, it was tested, if the mouse fibroblast cell line LTK- might be 
more suitable for CD4+ TCR antigen screening, and thereby it can be used as alternative 
APCs to substitute COS-7 cells.  
LTK- cells were co-transfected with pHSE3’-HLA-DRA and pHSE3’-HLA-DR1/DR2a/DR2b by 
electroporation. Single clones were analysed for the expression of HLA-DR molecules on the 
cell surface by flow cytometry (Figure 3-23). Clones with highest expression levels were kept 
for further studies.  
 
 
Figure 3-23 Expression of HLA-DR on LTK- cells. The expression of HLA-DR molecules in LTK- cells 
was analysed by flow cytometry with a FITC-labeled antibody against human HLA-DR. LTK- cells were 
cotransfected with pHSE3’-HLA-DRA and pHSE3’-HLA-DR2a (A), pHSE3’-HLA-DR1 (B) and pHSE3’-
HLA-DR2b (C).  
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Transfection efficiency of LTK- cells with FuGENE® was very low. Thus, only 2 % of the cells 
expressed sGFP after the transfection of pcDNA-sGFP. Thereby a new transfection method, 
using GenaxxoFect-Plus (Genaxxon bioscience GmbH, Ulm, Germany), was established 
together with M. Schönwetter to improve the transfection efficiency.  
Additionally, it was observed that the transfection is much more efficient, if the cells are splitted 
the day before transfection. Thereby, the cells are in a good growth phase, and thereby the 
uptake of DNA is more efficient. Thus, it was possible to increase transfection efficiency over 
50 %.  
Cocultivation of 58-Bbc9 cells with LTK-HLA-DR2a cells and LTK-HLA-DR1 cells transfected 
with pcDNA-Ii-hMBP(139-151) and pcDNA-delta-Ii-hMBP(139-151) constructs, showed 
activation of 58-Bbc9 cells. In contrast to COS-7 cells, no difference in activation was observed 
comparing the constructs with N’-terminal signal sequence pcDNA-Ii-hMBP(139-151) and 
pcDNA-delta-Ii-hMBP(139-151), where the signal sequence was delted. The negative controls 
pcDNA-Ii-wt and pcDNA-delta-Ii did not show any activation of 58-Bbc9 cells, neither 
cocultivation with LTK- cells expressing HLA-DR2b (Figure 3-24).  
The activation of 58-Bbc9 cells by Ii-hMBP(139-151) and delta-Ii-hMBP(139-151) presented 
on LTK- cells show that LTK- cells are a possible alternative to COS-7 cells as APCs in 
screening of CD4+ T cell antigens. 
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Figure 3-24 Activation of Bbc9 by Ii-hMBP presented on LTK- cells. LTK- cells expressing HLA-
DR2a, -DR1 or -DR2b were transfected with pcDNA-Ii-hMBP(139-151) (1), pcDNA-delta-Ii-hMBP(139-
151) (2) and cocultivated with 58-Bbc9 cells. pcDNA-Ii-wt (3) and pcDNA-delta-Ii (4) served as negative 
controls. Activation was first detected by fluorescence microscopy. Scale bar is 200 µm (A). The 
percentage of activated 58-Bbc9 cells was measured by flow cytometry, gated on CD3+, living cells (B). 
The concentration of IL-2 in the supernatant was measured by ELISA (C). 
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4 Discussion 
GABAA receptor encephalitis is recently described disease pattern, whereby patients suffer 
from antibodies against the GABAA receptor, which causes refractory seizures (Petit-Pedrol 
2014). The antibodies bind specifically different subunits of the GABAA receptor, which causes 
an internalisation of the receptor, and thereby the inhibitory receptor function is lost, causing 
neurological and psychological symptoms. It is still unknown whether the disease belong to 
paraneoplastic neurological disorders, although association to thymomas was found in some 
patients (Ohkawa 2014, Simabukuro 2015). Further, similarities to neurological surface 
receptors, which are often involved in PNDs were found (Section 1.4.2).  
Even though the humoral immunity is described, nothing is known about the role of T cells in 
the disease. Uncovering the influence of T cells, their pathogenicity as well as their antigens, 
would give insights into the etiopathology of the disease. Additionally, it could smooth the way 
for new treatment options. Three connected questions were adduced. First, the T cell 
repertoire of IP2 was analysed, and the disease related CD8+ T cell clone IP2-8S1 was 
detected. IP2-8S1 was used to screen for possible antigens of the TCR. Additionally, CD4+ T 
cells are also involved in GABAA receptor encephalitis to perform CD4+ T cell help for the 
production of antibodies. To analyse antigens of CD4+ T cells, a new screening system was 
established during this study. Therefore, the antigen screening for CD8+ T cells (K. Siewert et 
al., 2012) was modified to allow the detection of CD4+ T cell antigens.  
4.1 Index patient 2 
To uncover the role of T cells in GABAA receptor encephalitis, the T cell repertoire of the CSF, 
the hippocampus and the lateral sulcus of IP2 (Petit-Pedrol et al., 2014) was analysed (Section 
4.1.1). Furthermore, the expanded clone IP2-8S1 was successfully cloned and analysed for 
HLA-restriction (Section 4.1.2) and antigen recognition (Section 4.1.3).  
4.1.1 T cell repertoire 
4.1.1.1 IHC of inflamed brain regions of IP2 
IHC analysis of brain sections showed a high infiltration of CD8+ T cells in the hippocampus 
and the lateral sulcus of IP2. In contrast to CD8+ T cells, CD4+ T cells were very rarely found 
in both areas. Such low numbers are surprising, since CD4+ T cells are involved in the antibody 
response and are found frequently in infiltrated brain regions in autoimmune diseases. For 
example, in acute lesions of relapsing and remitting MS CD4+ T cells are predominant (Raine 
1994). 
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Stainings for perforin proved that the CD8+ T cells are not only infiltrated into the brain, but 
they are also activated. The infiltration of CD8+ T cells in combinations with the expression of 
cytolytic granules prove an effector function of CD8+ T cells. The cells infiltrate into the brain, 
where they recognize their antigen and get activated. However, in IHC the target cell of the 
CD8+ T cells was not visible (Section 3.1.2.1, Figure 3-2 and Section 3.1.3.1, Figure 3-5). The 
nucleus of the target cell can be in a different layer of the biopsy section, and thereby it is not 
visible. Furthermore, the target could be localised on the axons of neurons, thus, the nucleus 
could be far away. To identify the target cell, costaining for different cell types in combination 
with staining for CD8 and perforin could be performed. An orientation of perforin to one cell 
type could indicate a possible target cell (Goebels et al., 1996). The stained target cells could 
eventually be isolated by laser microdissection and quantitative PCR (qPCR) with cell line 
specific primers could be performed, to identify the target cell.  
4.1.1.2 T cell repertoire of the CSF of IP2 
T cell analysis of the CSF of IP2 indicated about equal numbers of CD4+ and CD8+ T cells in 
the CSF. 40 CD4+ and 48 CD8+ T cells were isolated from 250 µl CSF.  
Single cell analysis of the T cells isolated from CSF of IP2 showed a polyclonal distribution of 
CD4+ T cells in the CSF. The β-chain of 15 CD4+ T cells were identified, additionally 11 
corresponding α-chains. Each TCR showed up only once. This polyclonal infiltration let 
suggest that the CD4+ T cells are only bystanders. Additionally, almost no CD4+ T cells were 
found in the inflamed region of the brain. Due to the humoral immunity with specific antibodies 
against the GABAA receptor α1 subunit, we expected to detect a clonal expansion of one or 
fewer CD4+ T cell clones, which might have been involved in the activation of B cells. CD4+ T 
cells are inevitable for the activation of B cells. They stimulation B cells for proliferation, somatic 
hypermutation as well as immunoglobulin class switching. However, in contrast to CD8+ T 
cells, CD4+ T cells do not need to be on-site of inflammation, for activation of B cells. The 
activation occurs in lymph nodes (Garside et al., 1998). Thereby, the analysis of the CD4+ T 
cell in CSF and brain sections is not sufficient for a complete repertoire analysis. For the 
detection of possible disease related CD4+ T cell clones, the T cells in lymph nodes and in the 
blood have to be analysed. This was not possible during this thesis, because of the lack of 
biopsy material.  
In contrast to CD4+ T cells, the TCR repertoire of CD8+ T cells in the CSF of IP2 had a strong 
bias to one particular clone. The TCR from six CD8+ T cells out of eleven identified TCRs were 
identical. All other TCRs showed up only once. Thereby, T cell repertoire studies for CD8+ T 
cells of the CSF of IP2 showed a clonal expansion of one TCR, which was called IP2-8S1. 
This clonal expansion indicates an effector function of the expanded clone, and thereby it could 
play a key role in the disease.  
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4.1.1.3 T cell repertoire of inflamed brain regions of IP2 
Bulk cell analysis of the hippocampus and the lateral sulcus of IP2 by clone-specific PCR 
showed the presence of IP2-AV8S1 in both infiltrated brain regions. IP2-BV8S1 was not 
detected. However, in sc PCR both chains were detected. These results indicate problems 
during the clone-specific PCR of the β-chain during bulk cell analysis. In contrast to sc PCR, 
higher cDNA concentrations are used. Probably the β-chain primers of the clone-specific PCR1 
bind unspecifically to a different DNA region, and thereby the primers for clone-specific PCR2 
cannot bind anymore to the PCR product and cannot amplify IP2-BV8S1.  
PCR on bulk cells already indicated the presence of IP2-AV8S1 in the brain. To further analyse 
the TCR repertoire in the brain, to quantify the presence of IP2-8S1 in the brain, and also to 
detect IP2-BV8S1, single cells were isolated by LMD of both infiltrated brain areas. The α- and 
β-chain were analysed by unbiased multiplex TCR PCR and in parallel by clone-specific TCR 
PCR.  
As already shown by IHC, almost no CD4+ T cells were detected in both brain areas, thereby, 
only two CD4 + T cells were isolated from the hippocampus, and none of the lateral sulcus. 
However, no TCR sequence was received from PCR. These findings are in accordance with 
the repertoire analysis of the CSF. Presumably the disease relevant CD4+ T cells are not in 
the CSF, but probably present in the lymph nodes, where they activate relevant B cells to 
produce antibodies against the GABAA receptor α1 subunit.  
Four different β-chains were identified from the 177 isolated CD8+ T cells of the hippocampus 
(Table 3-3). Two of the β-chains only showed up once and the third chains (clone 24) showed 
up three times in the hippocampus. However, the corresponding α-chains were not identified. 
The forth identified β-chain was the chain of the clonal expanded T cell from CSF: IP2-8S1. 
The β-chain of this clone was detected 22 times in the hippocampus. Furthermore, the 
corresponding α-chain of IP2-8S1 was identified in 19 of the 22 cells. IP2-8S1 was identified 
with clone-specific primers but not with the unbiased multiplex TCR PCR. This is due to the 
higher efficiency of clone-specific primers compared to the pool of the unbiased method 
(Dornmair 2003). The unbiased approach contains a lot of different primers covering all TCR 
chains. The primers have different PCR efficiency and might also interfere with each other. 
Thereby, the approach with clone-specific primers, where in each PCR step only one primer 
pair is used, is more efficient. The infiltration of IP2-8S1 was additionally validated by NGS, 
where it was also shown, that IP2-8S1 is expanded in the hippocampus (E. Beltrán).  
The presence of many CD8+ T cells which express the TCR IP2-8S1 in the inflamed region of 
the hippocampus shows that IP2-8S1 is not only expanded in the CSF, but also in the brain. 
The clonal expansion of IP2-8S1 in the CSF and the hippocampus set the clone apart from 
bystander T cells. It highly indicates the presence of the target antigen in the CNS. 
Furthermore, it ascribes a key role of IP2-8S1 in the disease.  
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Although bulk cell analysis proved the presence of IP2-AV8S1 in the lateral sulcus, the clone 
couldn’t be detected by single cell analysis of 111 CD8+ T cells, isolated by LMD. Only one 
new β-chain, but not the corresponding α-chain, was found in the lateral sulcus (Table 3-5). 
This result does not mean that IP2-8S1 is not present in the lateral sulcus. In fact, it shows that 
more single cells have to be isolated and analysed. Bulk cell analysis as well as NGS definitely 
proved the presence in the lateral sulcus. However, NGS showed that the rate of IP2-8S1 in 
the lateral sulcus is much lower compared to the hippocampus. The lower rates indicate, that 
the levels of the autoantigen of IP2-8S1 is increased in the hippocampus compared to the 
lateral sulcus. The lower rates also indicate that a lot more CD8+ T cells have to be isolated, 
to detect IP2-8S1 in the lateral sulcus. Additionally, the isolated single cells could have been 
derived from the wrong area in the biopsy section. Analysis of more single cells would validate 
the findings from bulk cell PCR and NGS. However, due to time limitations, it was not possible 
to isolate further cells during this thesis.  
The achievement to get PCR products from LMD, especially depends on the mRNA quality of 
the tissue. The sample is always stored at -80 °C, thawing is avoided and RNase inhibitors are 
used while staining and LMD. Although, a RNase inhibitor is used during LMD, the screening 
for T cells in the biopsy and their isolation by LMD is restricted to 30 min for marking cells and 
30 min for cell isolation. Otherwise the mRNA will be degraded by RNase. Thus, mRNA quality 
is not sufficient for RT-PCR. One method to overcome this problem would be to run the RT-
PCR in situ and isolate the cells afterwards (Bagasra 2007). Thereby, mRNA would already 
be transcribed to cDNA in the tissue. Afterwards the tissue can be stained and all T cells can 
be isolated by LMD without time pressure. However, the major problem could be the digestion 
of the tissue with proteinase K. This step is required for the digestions of membrane proteins, 
to facilitate the PCR master mix to penetrate the cells (Bagasra 2007). The digestion could 
destroy the antigens for IHC. However, the digestion could be adapted to the tissue, to avoid 
antigen destruction. Thereby it would be possible to isolate all the T cells from one brain section 
without wasting any of the valuable biopsy material. Additionally, with one staining a lot more 
T cells could be isolated, which would also safe time and costs for chemicals, like RNase 
inhibitors and ABs.  
Afterwards unbiased multiplex TCR PCR can be performed high throughput by the Janus 
pipetting robot. The robot was programmed during this thesis for the protocols for the run-off 
reaction, the anchor PCR, the alpha PCR as well as for clone-specific PCR. The protocols of 
the robot were adjusted for precise pipetting. The robot was put into a separated room and 
additionally into a box to avoid contaminations. UV radiation of the robot pre- and after usage 
lowers the contamination risk additionally. No contaminations were observed during the testing 
of the robot. Furthermore, it was successfully employed for the unbiased multiplex TCR PCR 
and the clone-specific PCR of samples isolated from the lateral sulcus. 
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By the application of the robot, the PCRs are standardized and optimized. Thereby the robot 
gives us the possibility for high throughput repertoire analysis of FACS sorted blood cells or 
CSF samples.  
4.1.2 HLA restriction IP2-8S1 
To analyse the disease relevant TCR IP2-8S1, it was successfully cloned into expression 
plasmids, which already contain the constant regions for TCR α- or TCR β-chain. To distinguish 
between contaminations and real PCR products in the repertoire studies silent mutations were 
added in the N(D)N region in the β-chain and in the α-chain. The plasmids coding for IP2-
AV8S1 and IP2-BV8S1, were stably transfected into hybridoma cells expressing CD8. 
Furthermore, as activation marker, sGFP under the control of the NFAT-enhancer, was 
transfected. Single cell dilution was performed to isolate the best clone, expressing high levels 
of sGFP after activation, and with only little spontaneous activation to reduce the background. 
The thereby generated cell lines specifically express the TCR IP2-8S1 and sGFP as well as 
IL-2 after activation. Both activation markers can be used for the detection of T cell activation 
in further experiments.  
To identify possible antigens of IP2-8S1 it would be helpful, to know the HLA-restriction of the 
T cell receptor. 
HLA sequencing of IP2 showed that the patient expressed six different MHC-I alleles as well 
as six different MHC-II alleles (Table 3-7). Cocultivation of 58-IP2-8S1 cells with LCL, covering 
all MHC-I alleles, did not lead to an activation of IP2-8S1. Consequently, IP2-8S1 does not 
recognise an endogenously presented antigen on MHC-I molecules.  
The antigens of the antibodies found in IP2 recognise an epitope of the GABAA receptor α1 
subunit as their antigen. Thereby it was presumed that IP2-8S1 might also recognise a GABAA 
receptor α1 subunit derived peptide presented on MHC-I. Possible candidates of the GABAA 
receptor α1 subunit were selected by their predicted affinity to HLA alleles, TAP transport and 
proteasomal degradation, and tested for their ability to activate IP2-8S1. However, none of the 
48 tested candidates was recognised by IP2-8S1. This absence of activation does not exclude 
the GABAA receptor α1 subunit as possible target, since only 48 candidates of the receptor 
were tested. The probability of a peptide to be presented on MHC-I molecules and thereby be 
recognised by a TCR is increased for peptides with high affinity for the MHC molecule, a high 
transport rate by TAP and the existence of large hydrophobic or basic residues for optimal 
cleavage after the residues by the immunoproteasome (Cascio et al., 2001). However, 
peptides with less optimal amino acids composition for all these criteria are also presented by 
MHC-I molecules, and thereby they could be a possible antigen of IP2-8S1. To exclude the 
GABAA receptor α1 subunit as possible antigen, all possible peptides have to be screened. 
However, this approach would be very time-consuming and expensive.  
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Another possibility would be to produce the GABAA receptor α1 subunit recombinantly and 
digest it with consumable 20S proteasome (Chen et al., 2013). Afterwards the digested protein 
can be added to COS-7 cells expressing MHC-I. After incubation, 58-IP2-8S1 cells can be 
added, cocultivated for 16 h and screened for T cell activation by fluorescence microscopy, 
flow cytometry or IL-2 ELISA. By the cleavage with the 20S proteasome, the subunit would be 
cleaved comparable to the natural cleavage in the body. This approach would be easier and 
cheaper for testing GABAA receptor α1 subunit as a possible antigen of IP2-8S1 than cloning 
all possible candidates or synthesising every peptide.  
4.1.3 Library Screening IP2-8S1 
The HLA-restriction could not be revealed. Thus, library screening for IP2-8S1 was performed 
with all six MHC-I alleles.  
In one set of experiments, all HLA alleles were screened individually with a N27 library. Only 
in the samples with HLA-C*04:01 two clusters were found. However, further subpooling of the 
recovered plasmids did not result in a mimotope, because no reactivation was visible. The fact 
that only in the samples with HLA-C*04:01 clusters were found, could indicate a restriction to 
HLA-C*04:01. However, in another set of experiments, HLA-A, HLA-B or HLA-C were pooled 
and cotransfected for library screening. For all the pooled HLA alleles, clusters of activated 58-
IP2-8S1 cells were found. The size and frequency of the clusters were comparable for all HLA-
pools. No obvious HLA-restriction, where the clusters were only found by the screening with 
one HLA-pool, was visible. Additionally, clusters were found with the same frequency in all 
samples. The cluster sizes were almost in the same ratio between 3 to 5 activated 58-IP2-8S1 
cells (Table 3-8). Thereby, HLA-restriction cannot be distinguished by the accumulation of 
clusters in one pool, compared to the others. If one pool would always show an increased 
cluster size compared to the other pools, it would indicate the HLA-restriction of IP2-8S1. 
Subpooling of the recovered plasmids did not lead to a mimotope, because either no 
reactivation was observed, or the reactivation was lost during the subpooling procedure.  
For finding a mimotope of IP2-8S1, larger areas have to be screened for each HLA allele. 
Useful for future experiments would be to generate COS-7 cells which stably express the 
different HLA alleles. Thereby, HLA molecules are always expressed and do not depend on 
the transfection efficiency of each experiment. Besides this, the cells are less stressed, if only 
the library is transfected and has to be expressed additionally. However, the problem is that a 
specific antibody is needed for the selection of transfected cells, because COS-7 cells also 
express MHC-I molecules. A specific antibody is only available for HLA-A*02:01.  
Library screening would be further eased with the application of HLA-specific libraries, as they 
were already used for HLA-A*02:01 (Section 3.2.5). MHC-I binding prediction tools can be 
used for the design of HLA-specific libraries (Rasmussen et al., 2014, Vita et al., 2015, 
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Andreatta and Nielson 2016). By the usage of these libraries it is ensured that the peptides 
have optimal binding properties for their MHC molecule. Thereby the presentation on the cell 
surface as well as the probability to find a mimotope is enhanced. Additionally, the libraries 
can be varied in the length between 8-11 AA for the antigen screening. It might be possible 
that longer or shorter peptides are recognized easier by IP2-8S1.  
If the target cell of the TCR IP2-8S1 could be identified by IHC and qPCR (Section 4.1.2), cell 
specific cDNA libraries could be designed for the library screening, comparable to cDNA 
libraries from tumor tissue (van der Bruggen et al., 1991). This would scale down the size of 
the library to peptides, which are expressed and presented by the target cell. A smaller area 
has to be screened to identify the antigen of IP2-8S1.  
Furthermore, it is still unsolved if GABAA receptor encephalitis is a PND. Often the disease is 
associated with thymoma (Ohkawa et al., 2014, Simabukuro et al., 2015). However, IP2 was 
not screened for a tumor. Additionally, in other PNDs tumors are also not always detectable, 
because the tumors can be tiny and thereby, they are easily missed (Dalmau and Rosenfeld 
2008). The analysis of the TCR repertoire of additional patients with thymoma could be helpful 
to solve this question. Possible expanded T cell clones could be screened for their antigens 
with tumor specific cDNA libraries. It would be interesting to see, if the target antigen of the 
expanded TCR is present in the tumor as well as in the CNS.  
The detection of mimotopes with PECPL established by K. Siewert et al. 2012 is still a new 
method. Although it was validated with two additional TCR (Rühl et al., 2016, Arakawa et al., 
2015), the method needs further optimization for higher efficiency. Already in the first step, the 
transfection of COS-7 cells with the library, an optimization could increase the efficiency of 
activated clusters and the following steps of subpooling. The transfection efficiency does not 
only depend on the cell cycle and condition of the cells, but also on the transfection method, 
as well as the amount of transfected DNA per cell. A quantification of the numbers of plasmids, 
which goes into one cell has to be adapted for the library screening. In the case that one cell 
takes up many different plasmids at once, the correct antigen might be too diluted to activate 
the TCR. In the other case, if only one or two plasmids go into the cell and are amplified by the 
large T antigen via the SV40 origin, the density of the correct antigen on the cell surface is 
high. However, a huge area has to be screened to find the correct antigen in a library of > 107 
clones. Thereby the plasmid number has to be optimized and standardized to a median, so 
that the signal can still be detected, and the areas, which have to be screened are not too 
huge.  
One explanation why sometimes no reactivation after plasmid recovery is observed, is that 
even though the method does not depend on high affinities of the TCR to the peptide-MHC-
complex, because the cells are kept together my gravity (Siewert et al., 2012), it might still 
happen that the hybridoma cells move after activation. Thereby, the activated cells might not 
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be directly superposed to the activating APC. This would lead to the isolation of the wrong 
COS-7 cell and thereby no reactivation will be visible after plasmid recovery. For the isolation 
of the correct cell, it would be helpful, if the COS-7 cell would also light up after activation.  
Another explanation that no reactivation is observed, is that the COS-7 cells can burst during 
the picking procedure. Thus, the plasmids can stick to the capillary, and the positive signal is 
lost.  
The signal loss of both, by picking the wrong COS-7 and by the burst of the cell, can be avoided 
by changing the dimension for the library screening from 3.5 cm dishes to 384 well format (G. 
Rühl, personal communication). The transfected cells can be pipetted into the 384 wells by the 
Janus pipetting robot, and the wells screened for activation by the scanning program “Zen pro”. 
All COS-7 cells of the activated well, can be transferred to a PCR tube after detaching the cells 
for 5 min on ice. To make sure, no cell is lost, the well can be additionally washed with the 
PCR master mix. By this procedure, a loss of the correct plasmid by the movement of the 
hybridoma cells, as well as by problems during the picking procedure, is avoided.  
Furthermore, the detection could be changed from the expression of sGFP controlled by the 
NFAT-enhance to the expression of luciferase under the control of the NFAT-enhancer. After 
the addition of the substrate luciferol to the media and activation of the hybridoma cells, the 
bioluminescence can be detected by an ELISA reader in 384 well plates. This would 
additionally safe a lot of time, because one plate can be detected much faster by an ELISA 
reader compared to the screening by fluorescence microscopy.  
Although single cell dilution of 58-IP2-8S1 cells was performed to reduce the background of 
spontaneously activated hybridoma cells, spontaneous activation cannot be completely 
excluded. The expression of sGFP under the control of the NFAT-enhancer is triggered by 
increased Ca2+ concentration in the cell. However, Ca2+ elevation is not only related to antigen 
recognition. T cells, which are not exposed to their antigens, also show short-lasting Ca2+ 
peaks (Mues et al., 2013). These Ca2+ peaks highly likely induce spontaneous activation of the 
hybridoma cells. Thereby it might happen that the COS-7 cell, which was isolated, does not 
carry the plasmid expressing the correct peptide. Furthermore, spontaneous activation can 
falsely be interpreted as positive signal. Thereby, in the next round, the signal seems to be 
lost, even though the signal was always just background. The background of spontaneous 
activated cells can be reduced, by single cell dilution and by keeping the cells in culture not 
longer than six weeks. After this time period a new vial should be thawed from the liquid 
nitrogen storage. 
Another reason, why no reactivation is visible, might be that the correct peptide is lost during 
cloning. Furthermore, the number of clones screened for reactivation might be too low, 
whereby the correct clone is not screened. The area which is screened to detect reactivation 
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in the subpools might also be not sufficient enough. By the optimization with the transfection 
of a definite number of plasmids per cell, this problem could be avoided.  
Another possibility why the correct antigens cannot be found, might be that the correct peptide 
is degraded in the cell by proteases. Thereby only a small amount of the correct peptide will 
be presented by MHC-I molecules on the cell surface. Depending on the degradation, the 
amount can be enough for T cell activation. However, the next time it is screened, the amount 
of remaining peptide is not enough anymore for T cell activation, and thereby, a once positive 
signal is lost. The same might be observed, after the formation of aptamers with the peptides 
in the cell. This formation leads to less available free peptide in the cell, which can be loaded 
on MHC molecules. Consequently, the correct peptide cannot be presented on the cell surface, 
resulting in a missing activation signal.  
Another possibility is that the correct peptide is in some way toxic for the cell. This results in a 
dying of COS-7 cells expressing the desired peptide. The correct peptide cannot be presented 
on the cell surface anymore, and no activation signal can be observed.  
These challenges, where the peptides are degraded, form peptide-aptamers in the cell or when 
the peptide is toxic for the cell, are not easy to solve. One possibility would be to replace COS-
7 cells as APC by another cell line. Other cell lines, especially derived from different species, 
have a different proteome. Thereby, there is the chance that the protease, which degrades the 
peptide, is not present. Hence, a T cell activation should be detectable.  
The method to identify TCR mimotopes by PECPL is limited to peptides as possible antigens 
of the TCR. However, there are several T cell subtypes which do not recognise peptides as 
antigens. Mucosal-associated invariant T (MAIT) cells, for example, recognise vitamin B 
derivatives presented by MHC-related protein 1 (MR1, Kjer-Nielsen et al., 2012). Another 
example is γδ TCRs, which can recognise conformational epitopes, lipids, carbohydrates or 
small molecules, alone or bound to CD1 (Dornmair et al., 2003). Hence the premise of the 
method is that the TCR recognises peptides presented by MHC-I molecules.  
Altogether, HLA-restriction and the target antigen of the expanded CD8+ T cell clone IP2-8S1 
is still unknown. By the optimization and standardization of the detection methods, and further 
screenings for antigens with additional libraries, it should be possible to identify the target 
antigen and thereby solve the role of T cells in GABAA receptor encephalitis.  
4.2 Detection of MHC-II mimotopes 
The identification of CD4+ T cell antigens is fundamental for a better understanding of 
autoimmune diseases and the interaction of the immune system. Additionally, the knowledge 
of CD4+ T cell antigens would lead the way for new therapeutic options of tumors, autoimmune 
diseases as well as vaccination strategies. In IP2, antibodies against the GABAA receptor were 
detected. CD4+ are crucial for most humoral immune response. Thus we expected to identify 
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an expanded CD4+ T cell clone in IP2. However, to identify the antigen of CD4+ T cells, a new 
screening system was required. With the so far establishes unbiased method, based on the 
screening for antigens with PECPL, it is only possible to identify CD8+ T cell antigens. Thus, 
the method was modified to allow screening of CD4+ T cell antigens. Though, in IP2 an 
expanded CD8+ T cell clone was then detected and not, as expected an expanded CD4+ T 
cell clone. However, the new established method can be used to identify antigens of expanded 
CD4+ T cell clones in other diseases. 
4.2.1 MHC-II libraries 
Due to the different loading of MHC-I und MHC-II (Section 1.3.1) new libraries, expressed in 
Ii, were designed for the screening of CD4+ T cell antigens. Ii-ECPL of different library length 
were successfully cloned and produced in E. coli. The number of different plasmids of the 
libraries varied between 7.5ˣ107 - 7ˣ109 clones. This yield of different plasmids per library is 
very good. However, it must be pointed out that around 30% of the clones contain a STOP 
codon in the library and are thereby not useful. The remaining number of different plasmids 
are nevertheless very high and cover a broad spectrum of possible antigens.  
By Western Blotting it was shown that empty COS-7 cells do not express Ii, but after 
transfection of pcDNA-Ii-ECPL, the cells express the libraries in Ii. The expression of Ii-ECPL 
in COS-7 cells was the first premise for further experiments. Intracellular FACS for CD74 after 
the transfection of different DNA concentrations with different transfection methods showed 
that nucleofection is the method of choice for library screening. In contrast to FuGENE® 
transfection, the expression of Ii-ECPL is much higher, especially for low DNA concentrations. 
The higher expression of CD74 after nucleofection compared to FuGENE® transfection is due 
to higher transfection efficiency by nucleofection. However, after 72 h the level of CD74 
decreases, especially after the transfection of higher DNA concentrations. This effect can be 
ascribed due to DNA degradation in the cell. Thereby, picking of activated clusters should be 
performed between 48-72 h.  
4.2.2 Bbc9 as proof of concept 
The well characterised TCR Bbc9 was chosen as proof of concept. Due to the knowledge of 
HLA-restriction, as well as the peptide specificity of the TCR, Bbc9 is well suitable as positive 
control, to test, whether the new established system for the identification of CD4+ T cell 
antigens is working accurately (Section 3.3.2).  
The α- and β-chain of Bbc9 were successfully transfected into 58-/- hybridoma cells, which 
already express human CD4 (Blank et al., 1993). Furthermore, pcDNA-NFAT-sGFP was 
transfected, and the clone expressing highest level of sGFP and lowest amount of 
spontaneously activated cells, was chosen for further experiments.  
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The specificity of the 58-Bbc9 cells to HLA-DR1 and -DR2a was proven by incubation of 58-
Bbc9 cells with hMBP-derived synthetic peptides presented on COS-7 cells stably expressing 
HLA-DR1, -DR2a and as negative control HLA-DR2b. A specific activation with an at least 10 
AA long peptide, including a phenylalanine (F) at position 1 (hMBP(141), F141) and a leucine 
(L) at position 10 (hMBP(150), L150), presented on HLA-DR1 and -DR2a was verified. The 
specificity of the system was confirmed by presentation of the peptides by an irrelevant HLA 
allele (HLA-DR2b) and by the presentation of an irrelevant peptide (hMBP(50-69)) by the 
correct HLA alleles. No signal was observed in any of the negative controls. The results are 
confirmed by fluorescence microscopy, flow cytometry as well as by IL-2 ELISA, all three 
methods reflecting the same specificity of Bb9.  
The peptides must have a minimum length of ten AA for activating Bbc9. Longer peptides 
(hMBP(139-153)) activated Bbc9 more efficiently. Natural peptides loaded on MHC-II are 13-
17 AA long (Rudensky et al., 1991). Shorter peptides than eleven AA are usually exchanged 
by HLA-DM (Kropshofer et al., 1996). Furthermore, the AA F141 and L150 are essential for 
the recognition by Bbc9. The 10 AA long peptide hMBP(140-149) only activates Bbc9 a little 
presented on HLA-DR2a but not at all on HLA-DR1, and less strong, than the also 10 AA long 
peptide hMBP(141-150). This shows how important the AA F141 and L150 are for an optimal 
activation of Bbc9.  
The experiments show that Bbc9 was specifically activated by hMBP. Furthermore, HLA-
restriction was ensured. No unspecific activation was detected. Thereby, the cell-based assay 
can be applied for CD4+ T cells for the measuring of TCR activation by the different synthetic 
peptides.  
Plasmids, coding for Ii-hMBP with diverse length of hMBP-derived peptides, demonstrated that 
an activation of 58-Bbc9 cells is also possible with these constructs. No activation was 
observed by the presentation of the constructs on HLA-DR2b molecules, proving that the HLA-
restriction is preserved with Ii-hMBP constructs. The activation of 58-Bbc9 cells with the Ii-
hMBP constructs, but not with the negative control Ii-p33-wt, presented by HLA-DR1 as well 
as by HLA-DR2a show a specific activation of Bbc9 by the Ii-hMBP constructs, restricted to 
the hMBP peptide. The invariant chain itself does not generate an unspecific activation of the 
TCR. Although no activation of 58-Bbc9 cells was observed with 9 AA long synthetic peptide 
hMBP(141-149), Ii-hMBP(141-149) showed weak activation of 58-Bbc9 cells. This activation 
can be ascribed to the binding properties of Ii. Although, nine AA long peptides, or even shorter, 
can also bind successfully to MHC-II molecules, natural bound peptides are usually longer 
(Rammensee 1995). The binding properties of a nine AA long peptide to MHC-II molecules 
are not good. However, expressed in the invariant chain, the peptide takes advantage of the 
AA residues of Ii, which bind to MHC-II molecules by non-specific interactions (Rammensee 
1995). Thereby, Ii-hMBP(141-149) can be loaded onto MHC-II molecules and can be 
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presented on the cell surface, hence it is anchored by the invariant chain to MHC-II. However, 
activation is still lower, compared to longer constructs, because L150 is missing. 
The expression of peptides with low affinity to MHC-II molecules in Ii can provide an opportunity 
to present these peptides on the cell surface and induce T cell activation, however with lower 
efficiency.  
The comparison in inducing activation in Bbc9 using Ii-hMBP constructs with and without N-
terminal signal sequence of Ii, showed that Ii-hMBP constructs activate Bbc9 more efficiently 
than delta-Ii-hMBP constructs. The more intense activation of Ii-hMBP constructs cannot be 
ascribed to differences in cellular viability after transfection, due to the fact that no differences 
in cellular viability were observed (Figure 3-18). Thus, the signal sequence must be recognised 
by COS-7 cells. The loaded MHC-II complex is targeted to the cell surface, where it can 
activate the TCR on hybridoma cells. All designed libraries contain the full length Ii chain, with 
signal sequence, due to the fact that the activation by Ii-hMBP constructs was much stronger 
with signal sequence, compared to constructs without.  
The experiments with Ii-hMBP constructs demonstrate that our designed system for the 
identification of MHC-II antigens is functional. COS-7 cells successfully expressed Ii-hMBP 
constructs. The constructs are loaded onto MHC-II molecules and are presented on the cell 
surface to TCR-expressing hybridoma cells. The TCR of these hybridoma cells can specifically 
and in an HLA-restricted manner be activated. The activation can be detected with different 
methods, using fluorescence microscopy, flow cytometry as well as IL-2 ELISA. Thereby, the 
system is ready to use for the screening of CD4+ T cell antigens.  
4.2.3 Comparison of the sensitivity of different detection methods 
Our cellular detection system enables us to screen TCR activation by three different ways: by 
fluorescence microscopy, by flow cytometry as well as by IL-2 ELISA. Siewert et al. 2012 were 
using fluorescence microscopy as method of choice, because it was the most sensitive method 
for the detection of CD8+ T cell antigens. The titration of pcDNA-Ii-hMBP(139-151) in pcDBA-
p33-wt showed that fluorescence microscopy is also the best choice for the detection of CD4+ 
T cell antigens. In titration, clusters with several activated 58-Bbc9 cells were still visible at 
dilutions of 1:104 in 24-well plates. In contrast, flow cytometry and IL-2 ELISA were only 
sensitive enough to detect dilution of 1:103. The difference is that in fluorescence microscopy, 
clusters of activated 58-Bbc9 cells can be visible close to each other. Even if no other cells are 
activated in the well, this close contact of a few activated cells indicate recognition of their 
antigen, and thereby presence of the plasmid expressing the correct antigen. However, in flow 
cytometry and IL-2 ELISA all cells, or the supernatant is analysed. The number of activated 
cells thereby must be much higher to yield an activation signal above background. This is 
further proved by the fact that the weak activation of hMBP(140-149) presented by HLA-DR2a 
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molecules was only detectable by fluorescence microscope. No activation was observed by 
flow cytometry neither by ELISA. Fujii et al. (2001) also designed a method for the detection 
of CD4+ T cell antigens, however, they were only able to identify the correct antigen out of 
1,000 irrelevant, due to the fact that INF-γ ELISA was used as read-out system.  
The number of different plasmids of Ii-ECPL vary between 7.5ˣ107 to 7ˣ109  clones, depending 
on the used library (Table 3-9). The plasmid expressing the correct antigen is enriched by 
isolating the underlying COS-7 cells and recovering the plasmids of the library by PCR. For 
reactivation it must be ensured that the number of different plasmids is not exceeding 104 - 105 
clones. Otherwise no reactivation can be detected in a 24-well plate, because the correct clone 
will be too diluted. However, if larger areas are screened, reactivation will still be detectable. 
Consequently, the area to be screened for the reactivation, is adjusted to the number of 
different plasmids after picking.  
4.2.4 COS-7 cells as antigen presenting cells 
COS-7 cells were chosen as antigen presenting cells, because they are easy to culture, the 
transfection efficiencies are high, they are adherent cells and because they worked well for the 
detection of CD8+ T cell antigens.  
However, COS-7 cells were not efficiently expressing HLA-DR molecules. Only after several 
transfection and several rounds of MACS purification and FACS, clones, with stable 
expression of HLA-DR molecules were received. Furthermore, COS-7-DR cells often died after 
the transfection of Ii-constructs. Both let suggest that COS-7 cells are overstrained with the 
presentation of MHC-II libraries. COS-7 cells are kidney cells, and thereby no professional 
APCs. One reason for the cell dying after transfection might be that COS-7 cells do not 
recognize the N-terminal signal sequence. Thereby the Ii-ECPL-loaded MHC-II molecules 
would get stucked in the ER and block the excretion machinery of the cell. However, the 
comparison of cellular viability after transfection of constructs with and without signal sequence 
did not differ. Cellular viability was comparable for both variants. 
Transfection of COS-7-DR cells with Ii-ECPL by nucleofection showed higher cellular viability 
as  compared to FuGENE® transfection. Nucleofection is more gentle to the cells compared to 
FuGENE® transfection. Furthermore, the transfection efficiency is increased and thereby also 
the expression levels of the library. Hence, nucleofection was the method of choice for the 
library screening.  
Although cell death is reduced after nucleofection of Ii-ECPL, during the subpooling procedure, 
DNA quality of the isolated plasmids is not sufficient to use nucleofection. Bacterial 
lipopolysaccharides (LPS), which are toxic for the cells, remain in the isolated DNA from E. 
coli. These LPS can penetrate the cells by nucleofection and thereby induce cell death. This 
can be avoided by using FuGENE® transfection. Another possibility would be to use a plasmid 
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isolation kit with additional endotoxin removal buffer, as it is provided by promega. Plasmid 
preparation with this kit and following nucleofection reduced the cell death remarkably. 
However, the costs for nucleofection of many subpooling samples must be considered. 
Although, nucleofection yields increased cellular viability after transfection, after reducing the 
transfected DNA amount from 500 ng to 250 ng, cellular viability was also increased with 
FuGENE® transfection (Figure 3-18), and the signal was still very good, which was shown with 
Ii-hMBP constructs (Figure 3-19 and Figure 3-20).  
Hence, nucleofection is the method of choice for the initial library screening and picking of 
cells. However, for all following transfections FuGENE® transfection is sufficient.  
As an alternative to COS-7 cells, it was shown that LTK- cells also have the ability to activate 
58-Bbc9 cells after transfection of Ii-hMBP(139-151). LTK- cells also fulfil all criteria for the 
application in the library screening. The cells are easy to culture, they can be transfected and 
they are adherent. LTK- cells were successfully stably transfected with HLA-DR1, -DR2a or -
DR2b. The expression levels of HLA-DR were higher as compared to stable COS-7 cells 
expressing HLA-DR, even without further purification via MACS beads or FACS.  
Although stable transfection with plasmids coding HLA-DR was successful, the transient 
transfection with FuGENE® was challenging. The transfection efficiencies were very low. 
However, transfection was improved by the usage of GenaxxoFect-Plus as transfection 
reagent and by splitting the cells the day before transfection. With this new established 
transfection method, it was possible to activate 58-Bbc9 cells with the positive control Ii-
hMBP(139-151). Comparable to usage of COS-7 cells as APCs, no activation was observed 
with the negative controls Ii-wt or delta-Ii. Furthermore, HLA-restriction is conserved and no 
activation was observed with the irrelevant HLA-DR2b allele.  
The experiments show that LTK- cells are a possible alternative to COS-7 cells as APCs for 
the library screening. Specific and HLA-restricted activation of TCRs is ensured. Furthermore, 
mouse fibroblast might even be more efficient than COS-7 cells for the activation of murine 
hybridoma cells. It was shown that 58-/- cells can be activated more efficiently by mouse 
fibroblasts than TCR-transfected human cell lines, presumably traced back to the expression 
of murine costimulatory factors (Dornmair et al., 2003). However, this has to be tested in further 
experiments.  
Another possibility would be to use a cell line which is derived from a professional APC, best 
from murine origin, because the used hybridoma cells are also from mouse. Possible cell lines 
would be the mouse microglia cell line SIM-A9 or mouse microglia cell line C8-B4. Both cell 
lines originated from spontaneous transformation and are adherent cell lines (Alliot et al., 1996, 
Nagamoto-Combs et al., 2014). The advantage of these cell lines compared to COS-7 cells 
would be that they are both of murine origin. Thereby, they express appropriate costimulating 
factors for the hybridoma cells. This could increase the activation of hybridoma cells during the 
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library screening. Additionally, they originated from professional APCs. The whole machinery 
of the expression of MHC-II molecules, the targeting to the MIIC as well as the loading with 
possible peptides and the presentation on the cell surface is optimized in these cell lines. 
Thereby, they might not be overtaxed after the transfection of Ii-ECPL, as it is the case for 
COS-7 cells.  
It is possible to use COS-7 cells for the detection of CD4+ T cell antigens, however, there might 
be other cell lines such as LTK- cells which are more appropriate for this purpose. Further cell 
lines have to be tested in further studies.  
4.2.5 Library screening Bbc9 
Library screening for the TCR Bbc9 was performed with two different HLA alleles, HLA-DR1 
and HLA-DR2a. Both HLA alleles are able to activate Bbc9, whereas the focus in this work 
was pointed to HLA-DR1. Comparison of the ability to activate 58-Bbc9 cells with different 
libraries, varying in the length, showed that the cluster sizes of activated 58-Bbc9 cells were 
bigger for longer libraries (Table 3-11). This result is in good accordance to the results of 
activation by Ii-hMBP constructs expressed in pcDNA (Figure 3-20). The best activation was 
also observed with the longest construct Ii-hMBP(139-151) expressed in pcDNA, which would 
be the equivalent to the Ii-N39 library. However, almost only low activation was found with Ii-
hMBP(141-149) expressed in pcDNA, which would be the equivalent to the Ii-N27 library. Both 
results show that library screening for CD4+ T cell antigens will be more efficient for longer 
libraries. According to the results of Ii-hMBP constructs the random sequence of Ii-ECPL 
should be at least 30 nucleotides (10 AA) long.  
COS-7 cells stably expressing HLA-DR molecules were transfected with Ii-ECPL by two 
different methods. On the one hand via nucleofection, and on the other hand by FuGENE® 
transfection. Comparison of the sizes of the activated clusters showed that after nucleofection 
up to 17 activated 58-Bbc9 cells can be found in one cluster, whereas after FuGENE® 
transfection only clusters of maximum five activated Bbc9 were found. One reason therefore 
is that after nucleofection the cellular viability is better. Thus cells will start growing earlier and 
more rapidly. Furthermore, the expression levels of Ii-ECPL are higher after nucleofection 
(Figure 3-16). Thus, more library-loaded MHC-II molecules are presented on the cell surface, 
and 58-Bbc9 cells can be activated more efficient.  
After transfection of less DNA per cell, the number of different plasmids per cell is reduced. 
Thereby, the cell can amplify each plasmid more often, and consequently, the correct antigen 
is presented more efficiently on the cell surface. Although, it was expected that the cluster 
sizes might increase after the transfection of less amount of DNA per cell, the cluster sizes 
were in fact smaller. After the nucleofection of 1 µg of pcDNA-Ii-N39 per 1ˣ106 COS-7 cells the 
clusters had a size of up to 17 activated 58-Bbc9 cells. In comparison, after the transfection of 
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0,1 µg of the same library per 1ˣ106 COS-7 cells, the size of the activated clusters was only 
composed of up to seven activated 58-Bbc9 cells. Although the number of activated 58-Bbc9 
cells is not increased after transfection of less DNA, the correct plasmid is amplified via the 
SV40 origin in higher copy number in the COS-7 cells. Thereby, the following steps of 
subpooling are facilitated. However, by the transfection of less DNA each cell expresses a 
lower number of different plasmids. Thereby, huge areas have to be screened, which is very 
time consuming. A balance has to be found. The change to 384-well plates instead of 3.5 cm 
dishes, as well as the change to the expression of luciferase under the control of the NFAT-
enhancer, already discussed in Section 4.1.3, can improve the library screening. The same 
amount of transfected cells can be screened for activation much faster. Thereby, the number 
of plasmids per cell can be adjusted much better, without a time loss.  
Although big clusters of up to 17 activated 58-Bbc9 cells were detected and isolated from the 
Ii-ECPL screening, no mimotope was detected jet. Often no reactivation was observed after 
the cloning of the PCR products back into Ii in pcDNA. All the reasons described in Section 
4.1.3 for MHC-I antigen search, like the bursting of the COS-7 cell during the isolation 
procedure, are also a challenge for the screening of CD4+ T cell antigens.  
Furthermore, the PCR products have to be digested with the restriction enzymes AgeI and 
KasI for cloning it into Ii. For the identification of CD8+ T cell antigens, no restriction digestion 
is necessary. The PCR product is straightforwardly cloned via the pcDNATM 3.1 Directional 
TOPO® Expression Kit (Invitrogen). By digestion with restriction enzymes, it might happen that 
the PCR product, coding for the positive antigen, also gets digested, and thereby it is not 
available anymore in the pool. Thus, no reactivation may be detected.  
Additional steps of DNA purification are required after the restriction digestion, compared to 
the cloning procedure for MHC-I antigen search. Each purification step increases the risk of 
losing the sequence coding for the positive candidate, leading to a lack of reactivation signal. 
In addition, the religation efficiency of the customised TOPO ligation kit might be higher and 
more convenient compared to the conventional cloning.  
Another challenge was the restriction digestions of the cloning vector pcDNA-Ii-wt, into which 
the PCR products were cloned. The vector has to be serial digested with AgeI and KasI. 
However, the insert is very small (55 bp). Thus, it is not trivial to separate completely digested 
vector from only partially digested vector. The undigested vectors may religate and increased 
the background. Thus, larger areas have to be screened for reactivation. One way to minimise 
the background would be to insert a bigger spacer into pcDNA-Ii-wt via AgeI and KasI (pcDNA-
Ii-spacer), comparable to pcDNArc-spacer, used for the cloning of PECPL. Another possibility 
to decrease the background would be to use different restriction sites, like AscI in combination 
with KasI. The only difficulty would be the increased error rate of the polymerase for the 
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generation of the longer PCR product. However, a proof-reading polymerase would reduce 
this risk.  
The calculation of how many clones have to be screened, to detect one mimotope is based on 
statistics. This calculation was established for CD8+ T cell antigens. However, CD4+ T cells 
have an even lower affinity to the peptide-MHC complex than CD8+ T cells (Cole et al., 2007). 
This lower affinity makes it more challenging to identify a CD4+ T cell antigen. No mimotope 
was detected jet for CD4+ T cell antigens by the new established method based on Ii-ECPL. 
One reason might be that the statistic might not be transferable to the screening of CD4+ T 
cell antigens. It might be that an exceeding number of clones and a larger area have to be 
screened for the CD4+ library screening.  
To facilitate the recognition of a possible mimotope by Bbc9, clone-specific libraries could be 
designed, composed of a random NNK-sequence, amplified by adding the anchors F and L for 
example at AA position 1 and 10 of the random peptide sequence, resulting in the library Ii-
ECPL-N30-F1,L10. The possibility of recognition by Bbc9 will be increase by adding these 
anchors, and thereby the library screening will be more efficient.  
The results show that clusters of specifically activated 58-Bbc9 cells were detected, using 
different Ii-ECPL. With further improvement of the library screening system, as well as the 
cloning procedure for CD4+ T cell antigens, new mimotopes will presumably be found soon. 
The detection of new mimotopes will validate that the Ii-ECPLs are working for the detection 
of new CD4+ T cell antigens, as it was already shown with the Ii-hMBP constructs.  
4.3 Outlook 
This study contributes to the characterisation of idioplastic encephalitis with presumably 
paraneoplastic background. It is the first study analysing the role of T cells as well as the TCR 
repertoire of a patient with GABAA receptor encephalitis. This strategy of analysing the TCR 
repertoire in inflamed tissues is transferable to several other diseases, especially auto-immune 
diseases. Thereby the role of T cells in the etiology of many diseases can be revealed.  
The analysis of the TCR repertoire in other patients with antibodies against the GABAA receptor 
is inevitable to confirm the cytotoxic role of autoaggressive CD8+ T cells in the disease. 
Furthermore, the TCR repertoire in the tumor tissue and CNS in patients with GABAA receptor 
encephalitis and thymoma have to be analysed. It would be interesting, if the same expanded 
and activated CD8+ T cells are present in the CNS as well as in the tumor, indicating the 
presence of the antigen in both tissues.  
However, the study clearly showed that CD8+ T cells play a key role in the disease. This 
knowledge can be useful for the treatment of patients with GABAA receptor encephalitis.  
After improving the library screening of CD8+ T cell antigens, like the usage of 384 well plates 
as described in Section 4.1.3, it should be possible to also identify the antigen of the expanded 
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CD8+ T cell clone IP2-8S1. This will be a big step forward for the understanding of the role of 
T cells in GABAA receptor encephalitis.  
CD4+ T cells play an important role in many auto-immune diseases, like myelin-specific CD4+ 
T cells in MS (Hohlfeld et al., 2015). To identify CD4+ T cell antigens, the detection method for 
the identification of CD8+ T cells (Siewert et al., 2012) was transferred to the screening of 
CD4+ T cell antigens. In general, the identification of CD4+ T cells antigens is even more 
challenging than the identification of CD8+ T cell antigens, due to their lower affinity (Cole et 
al., 2007). During this thesis, several technical aspects, like the transfection method, were 
improved and it was shown that the method is working for the detection of CD4+ T cell 
antigens. However, there are still some aspects which need to be adapted for the screening of 
CD4+ T cell antigens, like the calculation of how many clones have to be screened during the 
subpooling procedure as described in Section 4.2.5. Nevertheless, the new established system 
can be applied for other TCR of CD4+ T cell antigens, from any disease, like auto-immune 
diseases and tumors.  
The identification of the T cell target does not only maintain to a better understanding for the 
etiology of the disease, however it also opens the floodgates for new treatment opportunities, 
like new vaccination strategies, immune therapies and the application as biomarkers of 
diseases.  
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5 Supplement 
5.1 Primer and Oligonucleotides 
Table 5-1 Primer for TCR RT-reaction 
Label Sequence TM 
Cα-RT-imp 5‘ GCCACAGCACTGTTGC 3‘ 52 °C 
Cβ-RT-2 5‘ GWAGAAGCCTGTGGCC 3‘ 52 °C 
 
Table 5-2 Primer for TCR Touch-Down PCR 
Label Sequence 
Cα-out 5‘ GCAGACAGACTTGTCACTGG 3‘ 
Cβ-mid-4 5‘ TGGGTGTGGGAGATCTCTG 3‘ 
VP1 5‘ TSYTTTGTCTCCTGGGAGCA 3‘ 
VP2 5‘ CCTGAAGTCGCCCAGACTCC 3‘ 
VP3 5‘ GTCATSCAGAACCCAAGAYACC 3‘ 
VP4 5‘ GGWTATCTGTMAGMGTGGAACCTC 3‘ 
VP5 5‘ ATGTACTGGTATCGACAAGAYC 3‘ 
VP6 5‘ CACTGTGGAAGGAACATCAAACC 3‘ 
VP7 5‘ TCTCCACTCTSAAGATCCAGC 3‘ 
VP8 5‘ CAGRATGTARATYTCAGGTGTGATCC 3‘ 
VP9 5‘ CCAGACWCCAARAYACCTGGTCA 3‘ 
Vα-114-for-out 5‘ AGSAGCCTCACTGGAGTTG 3‘ 
Vα-1235-for-out 5‘ CTGAGGTGCAACTACTCATC 3‘ 
Vα-2-for-out 5‘ CARTGTTCCAGAGGGAGCC 3‘ 
Vα-3,25-for-out 5‘ GAARATGYCWCCATGAACTGC 3‘ 
Vα-4,20-for-out 5‘ WTGCTAAGACCACCCAGCC 3‘ 
Vα-5-for-out 5‘ AGATAGAACAGAATTCCGAGG 3‘ 
Vα-6,14-for-out 5‘ RYTGCACATATGACACCAGTG 3‘ 
Vα-7-for-out 5‘ CACGTACCAGACATCTGGG 3‘ 
Vα-8,21-for-out 5‘ CCTGAGYGTCCAGGARGG 3‘ 
Vα-9-for-out 5‘ GTGCAACTATTCCTATTCTGG 3‘ 
Vα-10,24-for-out 5‘ ASTGGAGCAGAGYCCTCAG 3‘ 
Vα-11-for-out 5‘ TCTTCAGAGGGAGCTGTGG 3‘ 
Vα-12-for-out 5‘ GGTGGAGAAGGAGGATGTG 3‘ 
Vα-13,19,26-for-out 5‘ SAASTGGAGCAGAGTCCTC 3‘ 
Vα-15-for-out 5‘ CCTGAGTGTCCGAGAGGG 3‘ 
Vα-16-for-out 5‘ ATGCACCTATTCAGTCTCTGG 3‘ 
Vα-17-for-out 5‘ TGATAGTCCAGAAAGGAGGG 3‘ 
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Vα-18-for-out 5‘ GTCACTGCATGTTCAGGAGG 3‘ 
Vα-22,31-for-out 5‘ CCCTWCCCTTTTCTGGTATG 3‘ 
Vα-23,30-for-out 5‘ GGCARGAYCCTGGGAAAGG 3‘ 
Vα-27-for-out 5‘ CTGTTCCTGAGCATGCAGG 3‘ 
Vα-28-for-out 5‘ AGACAAGGTGGTACAAAGCC 3‘ 
Vα-29-for-out 5‘ CAACCAGTGCAGAGTCCTC 3‘ 
Vα-32-for-out 5‘ GCATGTACAAGAAGGAGAGG 3‘ 
 
Table 5-3 Primer for TCR Run-off reaction 
Label Sequence 
VP1+ 5‘ ACAGCACGACTTCCAAGACTCACYTTTGTCTCCTGGGAGCA 3‘’ 
VP2+ 5‘ ACAGCACGACTTCCAAGACTCACCTGATGTCGCCCAGACTCC- 3‘’ 
VP3+ 5‘ ACAGCACGACTTCCAAGACTCAGTCATSCAGAACCCAAGAYACC 3‘ 
VP4+ 5‘ ACAGCACGACTTCCAAGACTCAGGWTATCTGTMAGMGTGGAACCTC 3‘’ 
VP5+ 5‘ ACAGCACGACTTCCAAGACTCAATGTACTGGTATCGACAAGAYC 3‘’ 
VP6+ 5‘ ACAGCACGACTTCCAAGACTCACACTGTGGAAGGAACATCAAACC 3‘ 
VP7+ 5‘ ACAGCACGACTTCCAAGACTCATCTCCACTCTSAAGATCCAGC 3‘ 
VP8+ 5‘ ACAGCACGACTTCCAAGACTCACAGRATGTARATYTCAGGTGTGATCC 3‘ 
VP9+ 5‘ ACAGCACGACTTCCAAGACTCATCAGACWCCAARAYACCTGGTCA 3‘ 
 
Table 5-4 Primer for TCR Anchor PCR 
Label Sequence 
UP-new 5‘ AGCACGACTTCCAAGACTCA 3‘ 
Cβ-in 5‘ TCTGATGGCTCAAACACAGC 3‘ 
 
Table 5-5 Primer-Sets for Alpha PCR 
Set Label Sequence 
 
Cα-rev-in 5’-AGTCTCTCAGCTGGTACACG-3’ 
#1 Vα-4/1-for-in 5’-ACAGAAGACAGAAAGTCCAGC-3’ 
 
Vα-4/2-for-in 5’-GTCCAGTACCTTGATCCTGC-3’ 
 
Vα-6-for-in 5’-GCAAAATGCAACAGAAGGTCG-3’ 
 
Vα-8/1-for-in 5’-CAGTGCCTCAAACTACTTCC-3’ 
 
Vα-8/2-for-in 5’-GCCTCAGACTACTTCATTTGG-3’ 
 
Vα-14-for-in 5’-ACAGAATGCAACGGAGAATCG-3’ 
 
Vα-24-for-in 5’-CCTTCAGCAACTTAAGGTGG-3’ 
 
Vα-28-for-in 5’-TCTCTGGTTGTCCACGAGG-3’ 
#2 Vα-2/1-for-in 5’-TGGAAGGTTTACAGCACAGC-3’ 
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Vα-2/2-for-in 5’-TGGAAGGTTTACAGCACAGG-3’ 
 
Vα-5-for-in 5’-CAGCATACTTACAGTGGTACC-3’ 
 
Vα-10-for-in 5’-TCACTGTGTACTGCAACTCC-3’ 
 
Vα-12-for-in 5’-TACAAGCAACCACCAAGTGG-3’ 
 
Vα-22-for-in 5’-AGGCTGATGACAAGGGAAGC-3’ 
 
Vα-31-for-in 5’-GTGGAATACCCCAGCAAACC-3’ 
#3 Vα-7-for-in 5’-CTCCAGATGAAAGACTCTGC-3’ 
 
Vα-13-for-in 5’-TTAAGCGCCACGACTGTCG-3’ 
 
Vα-17-for-in 5’-CTGTGCTTATGAGAACACTGC-3’ 
 
Vα-18-for-in 5’-CCTTACACTGGTACAGATGG-3’ 
 
Vα-21-for-in 5’-TGCTGAAGGTCCTACATTCC-3’ 
 
Vα-23-for-in 5’-GTGGAAGACTTAATGCCTCG-3’ 
 
Vα-32-for-in 5’-TCACCACGTACTGCAATTCC-3’ 
#4 Vα-3-for-in 5’-TTCAGGTAGAGGCCTTGTCC-3’ 
 
Vα-11-for-in 5’-AGGGACGATACAACATGACC-3’ 
 
Vα-15-for-in 5’-CCTCCACCTACTTATACTGG-3’ 
 
Vα-19-for-in 5’-CCTGCACATCACAGCCTCC-3’ 
 
Vα-25-for-in 5’-AGACTGACTGCTCAGTTTGG-3’ 
 
Vα-26-for-in 5’-CCTGCATATCACAGCCTCC-3’ 
 
Vα-29-for-in 5’-ACTGCAGTTCCTCCAAGGC-3’ 
#5 Vα-1235-for-in 5’-AAGGCATCAACGGTTTTGAGG-3’ 
 
Vα-114-for-in 5’-CTGAGGAAACCCTCTGTGC-3’ 
 
Vα-9-for-in 5’-ATCTTTCCACCTGAAGAAACC-3’ 
 
Vα-16-for-in 5’-TCCTTCCACCTGAAGAAACC-3’ 
 
Vα-20-for-in 5’-ACGTGGTACCAACAGTTTCC-3’ 
 
Vα-27-for-in 5’-ACTTCAGACAGACTGTATTGG-3’ 
 
Vα-30-for-in 5’-CTCTTCACCCTGTATTCAGC-3’ 
 
Table 5-6 Primer for Clone-specific PCR IP2-8S1 
Label Sequence TM 
N05-13_Vα8.1-spec-for 5‘ AGACATTCGTTCAAATGTGGG 3‘ 60 °C 
N05-13_Vα8.1-spec-rev 5‘ ATAGAACTGGTTACCaGTgCC 3‘ 60 °C 
N05-13_Vβ8.1-spec-for
  
5‘ AGATCCAGCCCTCAGAACC 3‘ 60 °C 
N05-13_Vβ8.1-spec-rev
  
5‘ GCCAAAATACTGCGTcTCtCC 3‘ 60 °C 
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Table 5-7 Primers fo the preparation of NGS samples 
Label Sequence 
reverse transcription 
TSO TCGUCGGCAGCGTCAGAUGTGTAUAAGAGACAGNNNNUNNNNUNNNNUCTT(rG)4 
TRA_RT AGTCTCTCAGCTGGTAC 
TRB_RT TCTGATGGCTCAAACAC 
PCR1 
TSO_PCR TCGTCGGCAGCGTCAGATG 
TRA_OUT  AGTCTCTCAGCTGGTACACG 
TRB_OUT TCTGATGGCTCAAACACAGC 
PCR2 
TSO_PCR(N) (N)2-4GCAGACAGACTTGTCACTGG 
TRA_IN (N)2–4GGGTCAGGGTTCTGGATAT 
TRBJ1.1 ACTGTGAGTCTGGTGCCTTGT 
TRBJ1.2 ACAACGGTTAACCTGGTCCCCGAA 
TRBJ1.3 GGTCCTCTACAACAGTGAGCCAAC 
TRBJ1.4 AAGACAGAGAGCTGGGTTCCACTG 
TRBJ1.5 GGAGAGTCGAGTCCCATCA 
TRBJ1.6 TGTCACAGTGAGCCTGGTCCCATT 
TRBJ2.1 CCTGGCCCGAAGAACTGCTCA 
TRBJ2.2 GTCCTCCAGTACGGTCAGCCTAGA 
TRBJ2.3 TGCCTGGGCCAAAATACTGCG 
TRBJ2.4 TCCCGGCGCCGAAGTACTGAA 
TRBJ2.5 TGACCGTGAGCCTGGTGCCCG 
TRBJ2.6 TCGAGCACCAGGAGCCGC 
TRBJ2.7 CTGCTGCCGGCCCCGAAAGTC 
 
Table 5-8 Primer for cloning MHC-I alleles and recovery PCR 
Label Sequence TM 
HLA-A0101-Lead 5‘ CTCGTCGACATGGCCGTCATGGCGCCC 3‘ 62 °C 
HLA-A0101-end 5‘ TACGGATCCTCACACTTTACAAGCTGTGAG 3‘ 60 °C 
HLA-B3501-Lead 5‘ CTCGTCGACATGCGGGTCACGGCGCC 3‘ 60 °C 
HLA-B0801-end 5‘ TACGGATCCTCAAGCTGTGAGAGACACATC ‘ 62 °C 
HLAC_for_Sal 5‘ ACACGTCGACATGCGGGTCATGGCGCC 3‘ 58 °C 
HLA-Cw1203-end 5‘ TACGGATCCTCAGGCTTTACAAGCGATGAG 3‘ 62 °C 
pcDNA 2nd for TOPO 5‘ CACCTCCGGCGCGCCACCATG 3‘ 74 °c 
rev3 5‘ TGGTGATGGTGATGATGACC 3‘ 60 °c 
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Table 5-9 Oligonucelotides Candidates IP2-8S1 for HLA-A*02:01 
Label Sequence 
CLWAWILLL-for 5’CGCGCCACCATGTGTCTTTGGGCCTGGATCCTCCTTCTGTGAGC 3’ 
CLWAWILLL-rev 5’GGCCGCTCACAGAAGGAGGATCCAGGCCCAAAGACACATGGTGG 3’ 
GLGERVTEV-for 5’CGCGCCACCATGGGATTGGGAGAGCGTGTAACCGAAGTGTGAGC 3’ 
GLGERVTEV-rev 5’GGCCGCTCACACTTCGGTTACACGCTCTCCCAATCCCATGGTGG 3’ 
ILSQVSFWL-for 5’CGCGCCACCATGATTCTCTCACAAGTCTCCTTCTGGCTCTGAGC 3’ 
ILSQVSFWL-rev 5’GGCCGCTCAGAGCCAGAAGGAGACTTGTGAGAGAATCATGGTGG 3’ 
TAMDWFIAV-for 5’CGCGCCACCATGACAGCTATGGATTGGTTTATTGCCGTGTGAGC 3’ 
TAMDWFIAV-rev 5’GGCCGCTCACACGGCAATAAACCAATCCATAGCTGTCATGGTGG 3’ 
FIAVCYAFV-for 5’CGCGCCACCATGTTTATTGCCGTGTGCTATGCCTTTGTGTGAGC 3’ 
FIAVCYAFV-rev 5’GGCCGCTCACACAAAGGCATAGCACACGGCAATAAACATGGTGG 3’ 
LLFGIFNLV-for 5’CGCGCCACCATGCTGCTATTTGGAATCTTTAACTTAGTCTGAGC 3’ 
LLFGIFNLV-rev 5’GGCCGCTCAGACTAAGTTAAAGATTCCAAATAGCAGCATGGTGG 3’ 
LLYTMRLTV-for 5’CGCGCCACCATGTTGCTGTACACCATGAGGCTGACAGTGTGAGC 3’ 
LLYTMRLTV-rev 5’GGCCGCTCACACTGTCAGCCTCATGGTGTACAGCAACATGGTGG 3’ 
YLPCIMTVI-for 5’CGCGCCACCATGTACCTGCCATGCATAATGACAGTGATTTGAGC 3’ 
YLPCIMTVI-rev 5’GGCCGCTCAAATCACTGTCATTATGCATGGCAGGTACATGGTGG 3’ 
IMTVILSQV-for 5’CGCGCCACCATGATAATGACAGTGATTCTCTCACAAGTCTGAGC 3’ 
IMTVILSQV-rev 5’GGCCGCTCAGACTTGTGAGAGAATCACTGTCATTATCATGGTGG 3’ 
YAWDGKSVV-for 5’CGCGCCACCATGTATGCATGGGATGGCAAAAGTGTGGTTTGAGC 3’ 
YAWDGKSVV-rev 5’GGCCGCTCAAACCACACTTTTGCCATCCCATGCATACATGGTGG 3’ 
RLSRIAFPL-for 5’CGCGCCACCATGCGACTGTCAAGAATAGCCTTCCCGCTGTGAGC 3’ 
RLSRIAFPL-rev 5’GGCCGCTCACAGCGGGAAGGCTATTCTTGACAGTCGCATGGTGG 3’ 
IAFPLLFGI-for 5’CGCGCCACCATGATAGCCTTCCCGCTGCTATTTGGAATCTGAGC 3’ 
IAFPLLFGI-rev 5’GGCCGCTCAGATTCCAAATAGCAGCGGGAAGGCTATCATGGTGG 3’ 
PLLFGIFNL-for 5’CGCGCCACCATGCCGCTGCTATTTGGAATCTTTAACTTATGAGC 3’ 
PLLFGIFNL-rev 5’GGCCGCTCATAAGTTAAAGATTCCAAATAGCAGCGGCATGGTGG 3’ 
GIFNLVYWA-for 5’CGCGCCACCATGGGAATCTTTAACTTAGTCTACTGGGCTTGAGC 3’ 
GIFNLVYWA-rev 5’GGCCGCTCAAGCCCAGTAGACTAAGTTAAAGATTCCCATGGTGG 3’ 
NLVYWATYL-for 5’CGCGCCACCATGAACTTAGTCTACTGGGCTACGTATTTATGAGC 3’ 
NLVYWATYL-rev 5’GGCCGCTCATAAATACGTAGCCCAGTAGACTAAGTTCATGGTGG 3’ 
TMPNKLLRI-for 5’CGCGCCACCATGACCATGCCCAACAAACTCCTGCGGATCTGAGC 3’ 
TMPNKLLRI-rev 5’GGCCGCTCAGATCCGCAGGAGTTTGTTGGGCATGGTCATGGTGG 3’ 
HLEDFPMDA-for 5’CGCGCCACCATGCATTTGGAGGACTTCCCTATGGATGCCTGAGC 3’ 
HLEDFPMDA-rev 5’GGCCGCTCAGGCATCCATAGGGAAGTCCTCCAAATGCATGGTGG 3’ 
VLTMTTLSI-for 5’CGCGCCACCATGGTGCTCACCATGACAACATTGAGCATCTGAGC 3’ 
VLTMTTLSI-rev 5’GGCCGCTCAGATGCTCAATGTTGTCATGGTGAGCACCATGGTGG 3’ 
AMDWFIAVC-for 5’CGCGCCACCATGGCTATGGATTGGTTTATTGCCGTGTGCTGAGC 3’ 
AMDWFIAVC-rev 5’GGCCGCTCAGCACACGGCAATAAACCAATCCATAGCCATGGTGG 3’ 
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Table 5-10 Oligonucelotides Candidates IP2-8S1 for HLA-A*23:01 
Lable Sequence 
EYVVMTTHF-for 5’CGCGCCACCATGGAATATGTTGTTATGACCACTCATTTCTGAGC3’ 
EYVVMTTHF-rev 5’GGCCGCTCAGAAATGAGTGGTCATAACAACATATTCCATGGTGG3’ 
TYLPCIMTV-for 5’CGCGCCACCATGACATACCTGCCATGCATAATGACAGTGTGAGC3’ 
TYLPCIMTV-rev 5’GGCCGCTCACACTGTCATTATGCATGGCAGGTATGTCATGGTGG3’ 
WFIAVCYAF-for 5’CGCGCCACCATGTGGTTTATTGCCGTGTGCTATGCCTTTTGAGC3’ 
WFIAVCYAF-rev 5’GGCCGCTCAAAAGGCATAGCACACGGCAATAAACCACATGGTGG3’ 
CYAFVFSAL-for 5’CGCGCCACCATGTGCTATGCCTTTGTGTTCTCAGCTCTGTGAGC3’ 
CYAFVFSAL-rev 5’GGCCGCTCACAGAGCTGAGAACACAAAGGCATAGCACATGGTGG3’ 
FVFSALIEF-for 5’CGCGCCACCATGTTTGTGTTCTCAGCTCTGATTGAGTTTTGAGC3’ 
FVFSALIEF-rev 5’GGCCGCTCAAAACTCAATCAGAGCTGAGAACACAAACATGGTGG3’ 
IVQSSTGEY-for 5’CGCGCCACCATGATTGTCCAGTCAAGTACAGGAGAATATTGAGC3’ 
IVQSSTGEY-rev 5’GGCCGCTCAATATTCTCCTGTACTTGACTGGACAATCATGGTGG3’ 
MDWFIAVCY-for 5’CGCGCCACCATGATGGATTGGTTTATTGCCGTGTGCTATTGAGC3’ 
MDWFIAVCY-rev 5’GGCCGCTCAATAGCACACGGCAATAAACCAATCCATCATGGTGG3’ 
KPKKVKDPL-for 5’CGCGCCACCATGAAGCCAAAGAAAGTAAAGGATCCTCTTTGAGC3’ 
KPKKVKDPL-rev 5’GGCCGCTCAAAGAGGATCCTTTACTTTCTTTGGCTTCATGGTGG3’ 
 
Table 5-11 Oligonucelotides Candidates IP2-8S1 for HLA-B*35:01 
Lable 
Sequence 
PVSDHDMEY-for 5’CGCGCCACCATGCCCGTTTCAGACCATGATATGGAATATTGAGC3’ 
PVSDHDMEY-rev 5’GGCCGCTCAATATTCCATATCATGGTCTGAAACGGGCATGGTGG3’ 
DAHACPLKF-for 5’CGCGCCACCATGGATGCCCATGCTTGCCCACTAAAATTTTGAGC3’ 
DAHACPLKF-rev 5’GGCCGCTCAAAATTTTAGTGGGCAAGCATGGGCATCCATGGTGG3’ 
LPCIMTVIL-for 5’CGCGCCACCATGCTGCCATGCATAATGACAGTGATTCTCTGAGC3’ 
LPCIMTVIL-rev 5’GGCCGCTCAGAGAATCACTGTCATTATGCATGGCAGCATGGTGG3’ 
WFIAVCYAF-for 5’CGCGCCACCATGTGGTTTATTGCCGTGTGCTATGCCTTTTGAGC3’ 
WFIAVCYAF-rev 5’GGCCGCTCAAAAGGCATAGCACACGGCAATAAACCACATGGTGG3’ 
IAVCYAFVF-for 5’CGCGCCACCATGATTGCCGTGTGCTATGCCTTTGTGTTCTGAGC3’ 
IAVCYAFVF-rev 5’GGCCGCTCAGAACACAAAGGCATAGCACACGGCAATCATGGTGG3’ 
 
Table 5-12 Oligonucelotides Candidates IP2-8S1 for HLA-B*44:03 
Lable Sequence 
MEYTIDVFF-for 5’CGCGCCACCATGATGGAATATACAATAGATGTATTTTTCTGAGC3’ 
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MEYTIDVFF-rev 5’GGCCGCTCAGAAAAATACATCTATTGTATATTCCATCATGGTGG3’ 
IEFATVNYF-for 5’CGCGCCACCATGATTGAGTTTGCCACAGTAAACTATTTCTGAGC3’ 
IEFATVNYF-rev 5’GGCCGCTCAGAAATAGTTTACTGTGGCAAACTCAATCATGGTGG3’ 
LEDFPMDAH-for 5’CGCGCCACCATGTTGGAGGACTTCCCTATGGATGCCCATTGAGC3’ 
LEDFPMDAH-rev 5’GGCCGCTCAATGGGCATCCATAGGGAAGTCCTCCAACATGGTGG3’ 
GEYVVMTTH-for 5’CGCGCCACCATGGGAGAATATGTTGTTATGACCACTCATTGAGC3’ 
GEYVVMTTH-rev 5’GGCCGCTCAATGAGTGGTCATAACAACATATTCTCCCATGGTGG3’ 
 
Table 5-13 Oligonucelotides Candidates IP2-8S1 for HLA-C*04:01 
Lable Sequence 
LLDGYDNRL-for 5’CGCGCCACCATGCTCCTAGATGGCTATGACAATCGCCTGTGAGC3’ 
LLDGYDNRL-rev 5’GGCCGCTCACAGGCGATTGTCATAGCCATCTAGGAGCATGGTGG3’ 
VFTRILDRL-for 5’CGCGCCACCATGGTCTTCACCAGGATTTTGGACAGACTCTGAGC3’ 
VFTRILDRL-rev 5’GGCCGCTCAGAGTCTGTCCAAAATCCTGGTGAAGACCATGGTGG3’ 
KTDIFVTSF-for 5’CGCGCCACCATGAAGACTGATATCTTCGTCACCAGTTTCTGAGC3’ 
KTDIFVTSF-rev 5’GGCCGCTCAGAAACTGGTGACGAAGATATCAGTCTTCATGGTGG3’ 
PMDAHACPL-for 5’CGCGCCACCATGCCTATGGATGCCCATGCTTGCCCACTATGAGC3’ 
PMDAHACPL-rev 5’GGCCGCTCATAGTGGGCAAGCATGGGCATCCATAGGCATGGTGG3’ 
QYDLLGQTV-for 5’CGCGCCACCATGCAGTATGACCTTCTTGGACAAACAGTATGAGC3’ 
QYDLLGQTV-rev 5’GGCCGCTCATACTGTTTGTCCAAGAAGGTCATACTGCATGGTGG3’ 
GYFVIQTYL-for 5’CGCGCCACCATGGGCTACTTTGTTATTCAAACATACCTGTGAGC3’ 
GYFVIQTYL-rev 5’GGCCGCTCACAGGTATGTTTGAATAACAAAGTAGCCCATGGTGG3’ 
KPPEPKKTF-for 5’CGCGCCACCATGAAACCACCAGAACCCAAGAAAACCTTTTGAGC3’ 
KPPEPKKTF-rev 5’GGCCGCTCAAAAGGTTTTCTTGGGTTCTGGTGGTTTCATGGTGG3’ 
 
Table 5-14 Oligonucelotides Candidates IP2-8S1 for HLA-C*16:01 
Lable Sequence 
TYLNREPQL-for 5’CGCGCCACCATGACGTATTTAAACAGAGAGCCTCAGCTATGAGC3’ 
TYLNREPQL-rev 5’GGCCGCTCATAGCTGAGGCTCTCTGTTTAAATACGTCATGGTGG3’ 
MTVLRLNNL-for 5’CGCGCCACCATGATGACAGTCCTCCGGTTAAATAACCTATGAGC3’ 
MTVLRLNNL-rev 5’GGCCGCTCATAGGTTATTTAACCGGAGGACTGTCATCATGGTGG3’ 
YAYTRAEVV-for 5’CGCGCCACCATGTATGCTTATACAAGAGCAGAAGTTGTTTGAGC3’ 
YAYTRAEVV-rev 5’GGCCGCTCAAACAACTTCTGCTCTTGTATAAGCATACATGGTGG3’ 
FHLKRKIGY-for 5’CGCGCCACCATGTTCCACTTGAAGAGAAAGATTGGCTACTGAGC3’ 
FHLKRKIGY-rev 5’GGCCGCTCAGTAGCCAATCTTTCTCTTCAAGTGGAACATGGTGG3’ 
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TATSYTPNL-for 5’CGCGCCACCATGACAGCAACCAGCTACACCCCTAATTTGTGAGC3’ 
TATSYTPNL-rev 5’GGCCGCTCACAAATTAGGGGTGTAGCTGGTTGCTGTCATGGTGG3’ 
 
Table 5-15 Primers for cloning MHC-II chains 
Label Sequence TM 
DRA*01-SalI-for 5‘ TATCGTCGACATGGCCATAAGTGGAGTCCC 3‘ 62°C 
DRBx-SalI-for 5‘ TATCGTCGACATGGTGTGTCTGAAGCTCCC 3‘ 62°C 
DRA*01-BamHI-rev 5‘ TATCGGATCCTTACAGAGGCCCCCTGCGT 3‘ 62°C 
DRB1-BamHI-rev 5‘ TATCGGATCCTCAGCTCAGGAATCCTGTTG 3‘ 60°C 
DRB5-BamHI-rev 5‘ TATCGGATCCTCAGCTCACGAGTCCTGTTG 3‘ 62°C 
 
Table 5-16 Primers for cloning the Invariant chain and MHC-II library screening 
Label Sequence TM 
p33-wt-AscI-for 5‘ ATAGGCGCGCCATGGATGAC 3‘ 58 °C 
p33-wt-BspEI-rev 5‘ ATCATCCGGATCACATGGGGAC 3‘ 58 °C 
delta-p33-for 5‘cgcgccatgagctctggttcgtcaaagtgtagcagaggggcc3‘ - 
delta-p33-rev-
new 
5‘ cctctgctacactttgacgaaccagagctcatgg3‘ - 
p33-lib-for 5‘ TACACCGGCTTCAGCATCC 3‘ 62 °C 
p33-lib-rev 5‘ TCCAGTCGATGGTTTCCATG 3‘ 60 °C 
 
Table 5-17 Oligonucelotides for generation of Ii-ECPL 
Label Sequence 
CLIP-AgeI-for 5‘ CCtCCCAAACCGGTGAGC 3‘  
CLIP-n27-AgeI/KasI 5‘GCAGGGCGCCCATGGGCAaCGCCTGNNNNNNNNNNNNNNNNNNNNNNNNNN
NCTTGCTCACCGGTTTGGGaGG 3‘ 
CLIP-M1,9-
AgeI/KasI-for 
5‘GCAGGGCGCCCATGGGCAaCGCCTGCATNNNNNNNNNNNNNNNNNNNNNCA
TCTTGCTCACCGGTTTGGGaGG 3‘ 
CLIP-KasI-rev 5‘ tatGGCGCCCATGGGCAG 3‘ 
CLIP-N33 AgeI/KasI 5‘agctACCGGTGAGCNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKGCGC
TGCCCATGGGCGCCata 3‘ 
CLIP-N33 Anker M 
AgeI/KasI 
5‘agctACCGGTGAGCNNKATGNNKNNKNNKNNKNNKNNKNNKATGNNKGCGC
TGCCCATGGGCGCCata 3‘ 
CLIP-N39AgeI/KasI 5‘agctACCGGTGNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKC
TGCCCATGGGCGCCata 3‘ 
CLIP-N39 Anker M 
AgeI/KasI 
5‘agctACCGGTGNNKNNKATGNNKNNKNNKNNKNNKNNKNNKATGNNKNNKC
TGCCCATGGGCGCCata 3‘ 
5 Supplement 
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CLIP-N36-C 
AgeI/KasI 
5‘agctACCGGTGAGCNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKC
TGCCCATGGGCGCCata 3‘ 
CLIP-N36-C Anker M 
AgeI/KasI 
5‘agctACCGGTGAGCNNKATGNNKNNKNNKNNKNNKNNKNNKATGNNKNNKC
TGCCCATGGGCGCCata 3‘ 
CLIP-N36-N 
AgeI/KasI 
5‘agctACCGGTGNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKGCGC
TGCCCATGGGCGCCata 3‘ 
CLIP-N36-N Anker M 
AgeI/KasI 
5‘agctACCGGTGNNKNNKATGNNKNNKNNKNNKNNKNNKNNKATGNNKGCGC
TGCCCATGGGCGCCata 3‘ 
 
Table 5-18 Primer for cloning pHSE3'-Blasticidin-large T 
Label Sequence TM 
Blasticidin-Aat-
II-for 
5‘ AGCTGACGTCATGGCCAAGCCTTTGTCTCA 3‘ 60 °C 
Blasticidn-NdeI-
rev 
5‘ GCTCATATGTTAGCCCTCCCACACATAAC 3‘ 60 °C 
SalI-large_T-for 5‘ AGCGGTCGACATGGATAAAGTTTTAAACAGAGAG 3‘  
BamHI-large_T-rev 5‘ AGCTGGATCCTTATGTTTCAGGTTCAGGGGG 3‘  
5.2 Sequences 
IP2-AV8S1  
 
   1  atg aca tcc att cga gct gta ttt ata ttc ctg tgg ctg cag ttg gac ttg 
        m   t   s   i   r   a   v   f   i   f   l   w   l   q   l   d   l 
 
  52  gtg aat gga gag aat gtg gag cag cat cct tca acc ctg agt gtc cag gag 
        v   n   g   e   n   v   e   q   h   p   s   t   l   s   v   q   e 
 
 103  gga gac agc gct gtt atc aag tgt act tat tca gac agt gcc tca aac tac 
        g   d   s   a   v   i   k   c   t   y   s   d   s   a   s   n   y 
 
 154  ttt cct tgg tat aag caa gaa ctt gga aaa aga cct cag ctt att ata gac 
        f   p   w   y   k   q   e   l   g   k   r   p   q   l   i   i   d 
 
 205  att cgt tca aat gtg ggc gaa aag aaa gac caa cga att gct gtt aca ttg 
        i   r   s   n   v   g   e   k   k   d   q   r   i   a   v   t   l 
 
 256  aac aag aca gcc aaa cat ttc tcc ctg cac atc aca gag acc caa cct gaa 
        n   k   t   a   k   h   f   s   l   h   i   t   e   t   q   p   e 
 
 307  gac tcg gct gtc tac ttc tgt gca gca agt tgg ggt acc ggt aac cag ttc 
        d   s   a   v   y   f   c   a   a   s   w   g   t   g   n   q   f 
 
 358  tat ttt ggg aca ggg aca agt ttg acg gtc att cca aat atc cag aac cct 
        y   f   g   t   g   t   s   l   t   v   i   p   n   i   q   n   p 
 
                           PvuII 
                          ----+-- 
 409  gac cct gcc gtg tac cag ctg aga gac tct aaa tcc agt gac aag tct gtc 
        d   p   a   v   y   q   l   r   d   s   k   s   s   d   k   s   v 
5 Supplement 
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 460  tgc cta ttc acc gat ttt gat tct caa aca aat gtg tca caa agt aag gat 
        c   l   f   t   d   f   d   s   q   t   n   v   s   q   s   k   d 
 
 511  tct gat gtg tat atc aca gac aaa act gtg cta gac atg agg tct atg gac 
        s   d   v   y   i   t   d   k   t   v   l   d   m   r   s   m   d 
 
 562  ttc aag agc aac agt gct gtg gcc tgg agc aac aaa tct gac ttt gca tgt 
        f   k   s   n   s   a   v   a   w   s   n   k   s   d   f   a   c 
 
 613  gca aac gcc ttc aac aac agc att att cca gaa gac acc ttc ttc ccc agc 
        a   n   a   f   n   n   s   i   i   p   e   d   t   f   f   p   s 
 
 664  cca gaa agt tcc tgt gat gtc aag ctg gtc gag aaa agc ttt gaa aca gat 
        p   e   s   s   c   d   v   k   l   v   e   k   s   f   e   t   d 
 
 715  acg aac cta aac ttt caa aac ctg tca gtg att ggg ttc cga atc ctc ctc 
        t   n   l   n   f   q   n   l   s   v   i   g   f   r   i   l   l 
 
 766  ctg aaa gtg gcc ggg ttt aat ctg ctc atg acg ctg cgg ctg tgg tcc agt 
        l   k   v   a   g   f   n   l   l   m   t   l   r   l   w   s   s 
 
 817  tga 
        - 
 
IP2-BV8S1  
   1  atg gac tcc tgg acc ttc tgc tgt gtg tcc ctt tgc atc ctg gta gcg aag 
        m   d   s   w   t   f   c   c   v   s   l   c   i   l   v   a   k 
 
  52  cat aca gat gct gga gtt atc cag tca ccc cgc cat gag gtg aca gag atg 
        h   t   d   a   g   v   i   q   s   p   r   h   e   v   t   e   m 
 
 103  gga caa gaa gtg act ctg aga tgt aaa cca att tca ggc cac aac tcc ctt 
        g   q   e   v   t   l   r   c   k   p   i   s   g   h   n   s   l 
 
 154  ttc tgg tac aga cag acc atg atg cgg gga ctg gag ttg ctc att tac ttt 
        f   w   y   r   q   t   m   m   r   g   l   e   l   l   i   y   f 
 
 205  aac aac aac gtt ccg ata gat gat tca ggg atg cct gag gat cga ttc tca 
        n   n   n   v   p   i   d   d   s   g   m   p   e   d   r   f   s 
 
 256  gct aag atg cct aat gca tca ttc tcc act ctg aag atc caa ccc tca gaa 
        a   k   m   p   n   a   s   f   s   t   l   k   i   q   p   s   e 
 
 307  ccc agg gac tca gct gtg tac ttc tgt gcc agc agc gca ggg gga gat acg 
        p   r   d   s   a   v   y   f   c   a   s   s   a   g   g   d   t 
 
 358  cag tat ttt ggc cca ggc acc cgg ctg aca gtg cta gag gac ctg aaa aac 
        q   y   f   g   p   g   t   r   l   t   v   l   e   d   l   k   n 
 
                    AvaI 
                  -+----- 
 409  gtg ttc cca ccc gag gtc gct gtg ttt gag cca tca gaa gca gag atc tcc 
        v   f   p   p   e   v   a   v   f   e   p   s   e   a   e   i   s 
 
 460  cac acc caa aag gcc aca ctg gtg tgc ctg gcc aca ggc ttc ttc cct gac 
        h   t   q   k   a   t   l   v   c   l   a   t   g   f   f   p   d 
 
 511  cac gtg gag ctg agc tgg tgg gtg aat ggg aag gag gtg cac agt ggg gtc 
        h   v   e   l   s   w   w   v   n   g   k   e   v   h   s   g   v 
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 562  agc acg gac ccg cag ccc ctc aag gag cag ccc gcc ctc aat gac tcc aga 
        s   t   d   p   q   p   l   k   e   q   p   a   l   n   d   s   r 
 
 613  tac tgc ctg agc agc cgc ctg agg gtc tcg gcc acc ttc tgg cag aac ccc 
        y   c   l   s   s   r   l   r   v   s   a   t   f   w   q   n   p 
 
 664  cgc aac cac ttc cgc tgt caa gtc cag ttc tac ggg ctc tcg gag aat gac 
        r   n   h   f   r   c   q   v   q   f   y   g   l   s   e   n   d 
 
 715  gag tgg acc cag gat agg gcc aaa ccc gtc acc cag atc gtc agc gcc gag 
        e   w   t   q   d   r   a   k   p   v   t   q   i   v   s   a   e 
 
 766  gcc tgg ggt aga gca gac tgt ggc ttt acc tcg gtg tcc tac cag caa ggg 
        a   w   g   r   a   d   c   g   f   t   s   v   s   y   q   q   g 
 
 817  gtc ctg tct gcc acc atc ctc tat gag atc ctg cta ggg aag gcc acc ctg 
        v   l   s   a   t   i   l   y   e   i   l   l   g   k   a   t   l 
 
 868  tat gct gtg ctg gtc agc gcc ctt gtg ttg atg gcc atg gtc aag aga aag 
        y   a   v   l   v   s   a   l   v   l   m   a   m   v   k   r   k 
 
 919  gat ttc tga 
        d   f   - 
 
 
 
HLA-A*02:01 
 
    1  atg gcc gtc atg gcg ccc cga acc ctc gtc ctg cta ctc tcg ggg gct ctg 
         m   a   v   m   a   p   r   t   l   v   l   l   l   s   g   a   l 
 
   52  gcc ctg acc cag acc tgg gcg ggc tct cac tcc atg agg tat ttc ttc aca 
         a   l   t   q   t   w   a   g   s   h   s   m   r   y   f   f   t 
 
  103  tcc gtg tcc cgg ccc ggc cgc ggg gag ccc cgc ttc atc gca gtg ggc tac 
         s   v   s   r   p   g   r   g   e   p   r   f   i   a   v   g   y 
 
  154  gtg gac gac acg cag ttc gtg cgg ttc gac agc gac gcc gcg agc cag agg 
         v   d   d   t   q   f   v   r   f   d   s   d   a   a   s   q   r 
 
  205  atg gag ccg cgg gcg ccg tgg ata gag cag gag ggt ccg gag tat tgg gac 
         m   e   p   r   a   p   w   i   e   q   e   g   p   e   y   w   d 
 
  256  ggg gag aca cgg aaa gtg aag gcc cac tca cag act cac cga gtg gac ctg 
         g   e   t   r   k   v   k   a   h   s   q   t   h   r   v   d   l 
 
  307  ggg acc ctg cgc ggc tac tac aac cag agc gag gcc ggt tct cac acc gtc 
         g   t   l   r   g   y   y   n   q   s   e   a   g   s   h   t   v 
 
  358  cag agg atg tat ggc tgc gac gtg ggg tcg gac tgg cgc ttc ctc cgc ggg 
         q   r   m   y   g   c   d   v   g   s   d   w   r   f   l   r   g 
 
  409  tac cac cag tac gcc tac gac ggc aag gat tac atc gcc ctg aaa gag gac 
         y   h   q   y   a   y   d   g   k   d   y   i   a   l   k   e   d 
 
  460  ctg cgc tct tgg acc gcg gcg gac atg gca gct cag acc acc aag cac aag 
         l   r   s   w   t   a   a   d   m   a   a   q   t   t   k   h   k 
 
  511  tgg gag gcg gcc cat gtg gcg gag cag ttg aga gcc tac ctg gag ggc acg 
         w   e   a   a   h   v   a   e   q   l   r   a   y   l   e   g   t 
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  562  tgc gtg gag tgg ctc cgc aga tac ctg gag aac ggg aag gag acg ctg cag 
         c   v   e   w   l   r   r   y   l   e   n   g   k   e   t   l   q 
 
  613  cgc acg gac gcc ccc aaa acg cat atg act cac cac gct gtc tct gac cat 
         r   t   d   a   p   k   t   h   m   t   h   h   a   v   s   d   h 
 
  664  gaa gcc acc ctg agg tgc tgg gcc ctg agc ttc tac cct gcg gag atc aca 
         e   a   t   l   r   c   w   a   l   s   f   y   p   a   e   i   t 
 
  715  ctg acc tgg cag cgg gat ggg gag gac cag acc cag gac acg gag ctc gtg 
         l   t   w   q   r   d   g   e   d   q   t   q   d   t   e   l   v 
 
  766  gag acc agg cct gca ggg gat gga acc ttc cag aag tgg gcg gct gtg gtg 
         e   t   r   p   a   g   d   g   t   f   q   k   w   a   a   v   v 
 
  817  gtg cct tct gga cag gag cag aga tac acc tgc cat gtg cag cat gag ggt 
         v   p   s   g   q   e   q   r   y   t   c   h   v   q   h   e   g 
 
  868  ttg ccc aag ccc ctc acc ctg aga tgg gag ccg tct tcc cag ccc acc atc 
         l   p   k   p   l   t   l   r   w   e   p   s   s   q   p   t   i 
 
  919  ccc atc gtg ggc atc att gct ggc ctg gtt ctc ttt gga gct gtg atc act 
         p   i   v   g   i   i   a   g   l   v   l   f   g   a   v   i   t 
 
  970  gga gct gtg gtc gct gct gtg atg tgg agg agg aag agc tca gat aga aaa 
         g   a   v   v   a   a   v   m   w   r   r   k   s   s   d   r   k 
 
 1021  gga ggg agc tac tct cag gct gca agc agt gac agt gcc cag ggc tct gat 
         g   g   s   y   s   q   a   a   s   s   d   s   a   q   g   s   d 
 
 1072  gtg tct ctc aca gct tgt aaa gtg tga 
         v   s   l   t   a   c   k   v   - 
 
HLA-A*23:01 
 
    1  atg gcc gtc atg gcg ccc cga acc ctc gtc ctg cta ctc tcg ggg gcc ctg 
         m   a   v   m   a   p   r   t   l   v   l   l   l   s   g   a   l 
 
   52  gcc ctg acc cag acc tgg gca ggc tcc cac tcc atg agg tat ttc tcc aca 
         a   l   t   q   t   w   a   g   s   h   s   m   r   y   f   s   t 
 
  103  tcc gtg tcc cgg ccc ggc cgc ggg gag ccc cgc ttc atc gcc gtg ggc tac 
         s   v   s   r   p   g   r   g   e   p   r   f   i   a   v   g   y 
 
  154  gtg gac gac acg cag ttc gtg cgg ttc gac agc gac gcc gcg agc cag agg 
         v   d   d   t   q   f   v   r   f   d   s   d   a   a   s   q   r 
 
  205  atg gag ccg cgg gcg ccg tgg ata gag cag gag ggg ccg gag tat tgg gac 
         m   e   p   r   a   p   w   i   e   q   e   g   p   e   y   w   d 
 
  256  gag gag aca ggg aaa gtg aag gcc cac tca cag act gac cga gag aac ctg 
         e   e   t   g   k   v   k   a   h   s   q   t   d   r   e   n   l 
 
  307  cgg atc gcg ctc cgc tac tac aac cag agc gag gcc ggt tct cac acc ctc 
         r   i   a   l   r   y   y   n   q   s   e   a   g   s   h   t   l 
 
  358  cag atg atg ttt ggc tgc gac gtg ggg tcg gac ggg cgc ttc ctc cgc ggg 
         q   m   m   f   g   c   d   v   g   s   d   g   r   f   l   r   g 
 
  409  tac cac cag tac gcc tac gac ggc aag gat tac atc gcc ctg aaa gag gac 
         y   h   q   y   a   y   d   g   k   d   y   i   a   l   k   e   d 
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  460  ctg cgc tct tgg acc gcg gcg gac atg gcg gct cag atc acc cag cgc aag 
         l   r   s   w   t   a   a   d   m   a   a   q   i   t   q   r   k 
 
  511  tgg gag gcg gcc cgt gtg gcg gag cag ttg aga gcc tac ctg gag ggc acg 
         w   e   a   a   r   v   a   e   q   l   r   a   y   l   e   g   t 
 
  562  tgc gtg gac ggg ctc cgc aga tac ctg gag aac ggg aag gag acg ctg cag 
         c   v   d   g   l   r   r   y   l   e   n   g   k   e   t   l   q 
 
  613  cgc acg gac ccc ccc aag aca cat atg acc cac cac ccc atc tct gac cat 
         r   t   d   p   p   k   t   h   m   t   h   h   p   i   s   d   h 
 
  664  gag gcc act ctg aga tgc tgg gcc ctg ggc ttc tac cct gcg gag atc aca 
         e   a   t   l   r   c   w   a   l   g   f   y   p   a   e   i   t 
 
  715  ctg acc tgg cag cgg gat ggg gag gac cag acc cag gac acg gag ctt gtg 
         l   t   w   q   r   d   g   e   d   q   t   q   d   t   e   l   v 
 
  766  gag acc agg cct gca ggg gat gga acc ttc cag aag tgg gca gct gtg gtg 
         e   t   r   p   a   g   d   g   t   f   q   k   w   a   a   v   v 
 
  817  gta cct tct gga gag gag cag aga tac acc tgc cat gtg cag cat gag ggt 
         v   p   s   g   e   e   q   r   y   t   c   h   v   q   h   e   g 
 
  868  ctg ccc aag ccc ctc acc ctg aga tgg gag cca tct tcc cag ccc acc gtc 
         l   p   k   p   l   t   l   r   w   e   p   s   s   q   p   t   v 
 
  919  cac atc gtg ggc atc att gct ggc ctg gtt ctc ctt gga gct gtg atc act 
         h   i   v   g   i   i   a   g   l   v   l   l   g   a   v   i   t 
 
  970  gga gct gtg gtc gct gct gtg atg tgg agg agg aac agc tca gat aga aaa 
         g   a   v   v   a   a   v   m   w   r   r   n   s   s   d   r   k 
 
 1021  gga ggg agc tac tct cag gct gca agc agt gac agt gcc cag ggc tct gat 
         g   g   s   y   s   q   a   a   s   s   d   s   a   q   g   s   d 
 
 1072  gtg tct ctc aca gct tgt aaa gtg tga 
         v   s   l   t   a   c   k   v   - 
 
HLA-A35:01 
 
    1  atg cgg gtc acg gcg ccc cga acc gtc ctc ctg ctg ctc tgg ggg gca gtg 
         m   r   v   t   a   p   r   t   v   l   l   l   l   w   g   a   v 
 
   52  gcc ctg acc gag acc tgg gcc ggc tcc cac tcc atg agg tat ttc tac acc 
         a   l   t   e   t   w   a   g   s   h   s   m   r   y   f   y   t 
 
  103  gcc atg tcc cgg ccc ggc cgc ggg gag ccc cgc ttc atc gca gtg ggc tac 
         a   m   s   r   p   g   r   g   e   p   r   f   i   a   v   g   y 
 
  154  gtg gac gac acc cag ttc gtg agg ttc gac agc gac gcc gcg agt ccg agg 
         v   d   d   t   q   f   v   r   f   d   s   d   a   a   s   p   r 
 
  205  acg gag ccc cgg gcg cca tgg ata gag cag gag ggg ccg gag tat tgg gac 
         t   e   p   r   a   p   w   i   e   q   e   g   p   e   y   w   d 
 
  256  cgg aac aca cag atc ttc aag acc aac aca cag act tac cga gag agc ctg 
         r   n   t   q   i   f   k   t   n   t   q   t   y   r   e   s   l 
 
  307  cgg aac ctg cgc ggc tac tac aac cag agc gag gcc ggg tct cac atc atc 
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         r   n   l   r   g   y   y   n   q   s   e   a   g   s   h   i   i 
 
  358  cag agg atg tat ggc tgc gac ctg ggg ccc gac ggg cgc ctc ctc cgc ggg 
         q   r   m   y   g   c   d   l   g   p   d   g   r   l   l   r   g 
 
  409  cat gac cag tcc gcc tac gac ggc aag gat tac atc gcc ctg aac gag gac 
         h   d   q   s   a   y   d   g   k   d   y   i   a   l   n   e   d 
 
  460  ctg agc tcc tgg acc gcg gcg gac acc gcg gct cag atc acc cag cgc aag 
         l   s   s   w   t   a   a   d   t   a   a   q   i   t   q   r   k 
 
  511  tgg gag gcg gcc cgt gtg gcg gag cag ctg aga gcc tac ctg gag ggc ctg 
         w   e   a   a   r   v   a   e   q   l   r   a   y   l   e   g   l 
 
  562  tgc gtg gag tgg ctc cgc aga tac ctg gag aac ggg aag gag acg ctg cag 
         c   v   e   w   l   r   r   y   l   e   n   g   k   e   t   l   q 
 
  613  cgc gcg gac ccc cca aag aca cac gtg acc cac cac ccc gtc tct gac cat 
         r   a   d   p   p   k   t   h   v   t   h   h   p   v   s   d   h 
 
  664  gag gcc acc ctg agg tgc tgg gcc ctg ggc ttc tac cct gcg gag atc aca 
         e   a   t   l   r   c   w   a   l   g   f   y   p   a   e   i   t 
 
  715  ctg acc tgg cag cgg gat ggc gag gac caa act cag gac act gag ctt gtg 
         l   t   w   q   r   d   g   e   d   q   t   q   d   t   e   l   v 
 
  766  gag acc aga cca gca gga gat aga acc ttc cag aag tgg gca gct gtg gtg 
         e   t   r   p   a   g   d   r   t   f   q   k   w   a   a   v   v 
 
  817  gtg cct tct gga gaa gag cag aga tac aca tgc cat gta cag cat gag ggg 
         v   p   s   g   e   e   q   r   y   t   c   h   v   q   h   e   g 
 
  868  ctg ccg aag ccc ctc acc ctg aga tgg gag cca tct tcc cag tcc acc atc 
         l   p   k   p   l   t   l   r   w   e   p   s   s   q   s   t   i 
 
  919  ccc atc gtg ggc att gtt gct ggc ctg gct gtc cta gca gtt gtg gtc atc 
         p   i   v   g   i   v   a   g   l   a   v   l   a   v   v   v   i 
 
  970  gga gct gtg gtc gct act gtg atg tgt agg agg aag agc tca ggt gga aaa 
         g   a   v   v   a   t   v   m   c   r   r   k   s   s   g   g   k 
 
 1021  gga ggg agc tac tct cag gct gcg tcc agc gac agt gcc cag ggc tct gat 
         g   g   s   y   s   q   a   a   s   s   d   s   a   q   g   s   d 
 
 1072  gtg tct ctc aca gct tga 
         v   s   l   t   a   - 
 
HLA-B44:03 
 
    1  atg cgg gtc acg gcg ccc cga acc ctc ctc ctg ctg ctc tgg ggg gca gtg 
         m   r   v   t   a   p   r   t   l   l   l   l   l   w   g   a   v 
 
   52  gcc ctg acc gag acc tgg gcc ggc tcc cac tcc atg agg tat ttc tac acc 
         a   l   t   e   t   w   a   g   s   h   s   m   r   y   f   y   t 
 
  103  gcc atg tcc cgg ccc ggc cgc ggg gag ccc cgc ttc atc acc gtg ggc tac 
         a   m   s   r   p   g   r   g   e   p   r   f   i   t   v   g   y 
 
  154  gtg gac gac acg ctg ttc gtg agg ttc gac agc gac gcc acg agt ccg agg 
         v   d   d   t   l   f   v   r   f   d   s   d   a   t   s   p   r 
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  205  aag gag ccg cgg gcg cca tgg ata gag cag gag ggg ccg gag tat tgg gac 
         k   e   p   r   a   p   w   i   e   q   e   g   p   e   y   w   d 
 
  256  cgg gag aca cag atc tcc aag acc aac aca cag act tac cga gag aac ctg 
         r   e   t   q   i   s   k   t   n   t   q   t   y   r   e   n   l 
 
  307  cgc acc gcg ctc cgc tac tac aac cag agc gag gcc ggg tct cac atc atc 
         r   t   a   l   r   y   y   n   q   s   e   a   g   s   h   i   i 
 
  358  cag agg atg tac ggc tgc gac gtg ggg ccg gac ggg cgc ctc ctc cgc ggg 
         q   r   m   y   g   c   d   v   g   p   d   g   r   l   l   r   g 
 
  409  tat gac cag gac gcc tac gac ggc aag gat tac atc gcc ctg aac gag gac 
         y   d   q   d   a   y   d   g   k   d   y   i   a   l   n   e   d 
 
  460  ctg agc tcc tgg acc gcg gcg gac acc gcg gct cag atc acc cag cgc aag 
         l   s   s   w   t   a   a   d   t   a   a   q   i   t   q   r   k 
 
  511  tgg gag gcg gcc cgt gtg gcg gag cag ctg aga gcc tac ctg gag ggc ctg 
         w   e   a   a   r   v   a   e   q   l   r   a   y   l   e   g   l 
 
  562  tgc gtg gag tcg ctc cgc aga tac ctg gag aac ggg aag gag acg ctg cag 
         c   v   e   s   l   r   r   y   l   e   n   g   k   e   t   l   q 
 
  613  cgc gcg gac ccc cca aag aca cat gtg acc cac cac ccc atc tct gac cat 
         r   a   d   p   p   k   t   h   v   t   h   h   p   i   s   d   h 
 
  664  gag gtc acc ctg agg tgc tgg gcc ctg ggc ttc tac cct gcg gag atc aca 
         e   v   t   l   r   c   w   a   l   g   f   y   p   a   e   i   t 
 
  715  ctg acc tgg cag cgg gat ggc gag gac caa act cag gac acc gag ctt gtg 
         l   t   w   q   r   d   g   e   d   q   t   q   d   t   e   l   v 
 
  766  gag acc aga cca gca gga gat aga acc ttc cag aag tgg gca gct gtg gtg 
         e   t   r   p   a   g   d   r   t   f   q   k   w   a   a   v   v 
 
  817  gtg cct tct gga gaa gag cag aga tac aca tgc cat gta cag cat gag ggg 
         v   p   s   g   e   e   q   r   y   t   c   h   v   q   h   e   g 
 
  868  ctg ccg aag ccc ctc acc ctg aga tgg gag ccg tct tcc cag tcc acc gtc 
         l   p   k   p   l   t   l   r   w   e   p   s   s   q   s   t   v 
 
  919  ccc atc gtg ggc att gtt gct ggc ctg gct gtc cta gca gtt gtg gtc atc 
         p   i   v   g   i   v   a   g   l   a   v   l   a   v   v   v   i 
 
  970  gga gct gtg gtc gct gct gtg atg tgt agg agg aag agc tca ggt gga aaa 
         g   a   v   v   a   a   v   m   c   r   r   k   s   s   g   g   k 
 
 1021  gga ggg agc tac tct cag gct gcg tgc agc gac agt gcc cag ggc tct gat 
         g   g   s   y   s   q   a   a   c   s   d   s   a   q   g   s   d 
 
 1072  gtg tct ctc aca gct tga 
         v   s   l   t   a   - 
 
HLA-C*04:01 
 
    1  atg cgg gtc atg gcg ccc cga acc ctc atc ctg ctg ctc tcg gga gcc ctg 
         m   r   v   m   a   p   r   t   l   i   l   l   l   s   g   a   l 
 
   52  gcc ctg acc gag acc tgg gcc ggc tcc cac tcc atg agg tat ttc tcc aca 
         a   l   t   e   t   w   a   g   s   h   s   m   r   y   f   s   t 
5 Supplement 
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  103  tcc gtg tcc tgg ccc ggc cgc ggg gag ccc cgc ttc atc gca gtg ggc tac 
         s   v   s   w   p   g   r   g   e   p   r   f   i   a   v   g   y 
 
  154  gtg gac gac acg cag ttc gtg cgg ttc gac agc gac gcc gcg agt cca aga 
         v   d   d   t   q   f   v   r   f   d   s   d   a   a   s   p   r 
 
  205  ggg gag ccg cgg gag ccg tgg gtg gag cag gag ggg ccg gag tat tgg gac 
         g   e   p   r   e   p   w   v   e   q   e   g   p   e   y   w   d 
 
  256  cgg gag aca cag aag tac aag cgc cag gca cag gct gac cga gtg aac ctg 
         r   e   t   q   k   y   k   r   q   a   q   a   d   r   v   n   l 
 
  307  cgg aaa ctg cgc ggc tac tac aac cag agc gag gac ggg tct cac acc ctc 
         r   k   l   r   g   y   y   n   q   s   e   d   g   s   h   t   l 
 
  358  cag agg atg ttt ggc tgc gac ctg ggg ccg gac ggg cgc ctc ctc cgc ggg 
         q   r   m   f   g   c   d   l   g   p   d   g   r   l   l   r   g 
 
  409  tat aac cag ttc gcc tac gac ggc aag gat tac atc gcc ctg aac gag gat 
         y   n   q   f   a   y   d   g   k   d   y   i   a   l   n   e   d 
 
  460  ctg cgc tcc tgg acc gcc gcg gac acg gcg gct cag atc acc cag cgc aag 
         l   r   s   w   t   a   a   d   t   a   a   q   i   t   q   r   k 
 
  511  tgg gag gcg gcc cgt gag gcg gag cag cgg aga gcc tac ctg gag ggc acg 
         w   e   a   a   r   e   a   e   q   r   r   a   y   l   e   g   t 
 
  562  tgc gtg gag tgg ctc cgc aga tac ctg gag aac ggg aag gag acg ctg cag 
         c   v   e   w   l   r   r   y   l   e   n   g   k   e   t   l   q 
 
  613  cgc gcg gaa cac cca aag aca cac gtg acc cac cat ccc gtc tct gac cat 
         r   a   e   h   p   k   t   h   v   t   h   h   p   v   s   d   h 
 
  664  gag gcc acc ctg agg tgc tgg gcc ctg ggc ttc tac cct gcg gag atc aca 
         e   a   t   l   r   c   w   a   l   g   f   y   p   a   e   i   t 
 
  715  ctg acc tgg cag tgg gat ggg gag gac caa act cag gac acc gag ctt gtg 
         l   t   w   q   w   d   g   e   d   q   t   q   d   t   e   l   v 
 
  766  gag acc agg cca gca gga gat gga acc ttc cag aag tgg gca gct gtg gtg 
         e   t   r   p   a   g   d   g   t   f   q   k   w   a   a   v   v 
 
  817  gtg cct tct gga gaa gag cag aga tac acg tgc cat gtt cag cac gag ggg 
         v   p   s   g   e   e   q   r   y   t   c   h   v   q   h   e   g 
 
  868  ctg ccg gag ccc ctc acc ctg aga tgg aag ccg tct tcc cag ccc acc atc 
         l   p   e   p   l   t   l   r   w   k   p   s   s   q   p   t   i 
 
  919  ccc atc gtg ggc atc gtt gct ggc ctg gct gtc ctg gct gtc cta gct gtc 
         p   i   v   g   i   v   a   g   l   a   v   l   a   v   l   a   v 
 
  970  cta gga gct atg gtg gct gtt gtg atg tgt agg agg aag agc tca ggt gga 
         l   g   a   m   v   a   v   v   m   c   r   r   k   s   s   g   g 
 
 1021  aaa gga ggg agc tgc tct cag gct gcg tcc agc aac agt gcc cag ggc tct 
         k   g   g   s   c   s   q   a   a   s   s   n   s   a   q   g   s 
 
 1072  gat gag tct ctc atc gct tgt aaa gcc tga 
         d   e   s   l   i   a   c   k   a   - 
 
 
5 Supplement 
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HLA-C*16:01 
 
    1  atg cgg gtc atg gcg ccc cga acc ctc atc ctg ctg ctc tcg gga gcc ctg 
         m   r   v   m   a   p   r   t   l   i   l   l   l   s   g   a   l 
 
   52  gcc ctg acc gag acc tgg gcc tgc tcc cac tcc atg agg tat ttc tac acc 
         a   l   t   e   t   w   a   c   s   h   s   m   r   y   f   y   t 
 
  103  gcc gtg tcc cgg ccc ggc cgc gga gag ccc cgc ttc atc gca gtg ggc tac 
         a   v   s   r   p   g   r   g   e   p   r   f   i   a   v   g   y 
 
  154  gtg gac gac acg cag ttc gtg cgg ttc gac agc gac gcc gcg agt cca aga 
         v   d   d   t   q   f   v   r   f   d   s   d   a   a   s   p   r 
 
  205  ggg gag ccg cgg gcg ccg tgg gtg gag cag gag ggg ccg gag tat tgg gac 
         g   e   p   r   a   p   w   v   e   q   e   g   p   e   y   w   d 
 
  256  cgg gag aca cag aag tac aag cgc cag gca cag act gac cga gtg agc ctg 
         r   e   t   q   k   y   k   r   q   a   q   t   d   r   v   s   l 
 
  307  cgg aac ctg cgc ggc tac tac aac cag agc gag gcc ggg tct cac acc ctc 
         r   n   l   r   g   y   y   n   q   s   e   a   g   s   h   t   l 
 
  358  cag tgg atg tat ggc tgc gac ctg ggg ccc gac ggg cgc ctc ctc cgc ggg 
         q   w   m   y   g   c   d   l   g   p   d   g   r   l   l   r   g 
 
  409  tat gac cag tcc gcc tac gac ggc aag gat tac atc gcc ctg aac gag gac 
         y   d   q   s   a   y   d   g   k   d   y   i   a   l   n   e   d 
 
  460  ctg cgc tcc tgg acc gcc gcg gac acg gcg gct cag atc acc cag cgc aag 
         l   r   s   w   t   a   a   d   t   a   a   q   i   t   q   r   k 
 
  511  tgg gag gcg gcc cgt gcg gcg gag cag cag aga gcc tac ctg gag ggc acg 
         w   e   a   a   r   a   a   e   q   q   r   a   y   l   e   g   t 
 
  562  tgc gtg gag tgg ctc cgc aga tac ctg gag aac ggg aag gag acg ctg cag 
         c   v   e   w   l   r   r   y   l   e   n   g   k   e   t   l   q 
 
  613  cgc gcg gaa cac cca aag aca cac gtg acc cac cat ctc gtc tct gac cat 
         r   a   e   h   p   k   t   h   v   t   h   h   l   v   s   d   h 
 
  664  gag gcc acc ctg agg tgc tgg gcc ctg ggc ttc tac cct gcg gag atc aca 
         e   a   t   l   r   c   w   a   l   g   f   y   p   a   e   i   t 
 
  715  ctg acc tgg cag cgg gat ggc gag gac caa act cag gac acc gag ctt gtg 
         l   t   w   q   r   d   g   e   d   q   t   q   d   t   e   l   v 
 
  766  gag acc agg cca gca gga gat gga acc ttc cag aag tgg gca gct gtg gtg 
         e   t   r   p   a   g   d   g   t   f   q   k   w   a   a   v   v 
 
  817  gtg cct tct gga gaa gag cag aga tac acg tgc cat gtg cag cac gag ggg 
         v   p   s   g   e   e   q   r   y   t   c   h   v   q   h   e   g 
 
  868  ctg ccg gag ccc ctc acc ctg aga tgg gag cca tct tcc cag ccc acc atc 
         l   p   e   p   l   t   l   r   w   e   p   s   s   q   p   t   i 
 
  919  ccc atc gtg ggc atc gtt gct ggc ctg gct gtc ctg gct gtc cta gct gtc 
         p   i   v   g   i   v   a   g   l   a   v   l   a   v   l   a   v 
 
  970  cta gga gct gtg gtg gct gtt gtt atg tgt agg agg aag agc tca ggt gga 
         l   g   a   v   v   a   v   v   m   c   r   r   k   s   s   g   g 
 
5 Supplement 
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 1021  aaa gga ggg agc tgc tct cag gct gcg tcc agc aac agt gcc cag ggc tct 
         k   g   g   s   c   s   q   a   a   s   s   n   s   a   q   g   s 
 
 1072  gat gag tct ctc atc gct tgt aaa gcc tga 
         d   e   s   l   i   a   c   k   a   - 
 
HLA-DRA 
 
   1  atg gcc ata agt gga gtc cct gtg cta gga ttt ttc atc ata gct gtg ctg 
        m   a   i   s   g   v   p   v   l   g   f   f   i   i   a   v   l 
 
  52  atg agc gct cag gaa tca tgg gct atc aaa gaa gaa cat gtg atc atc cag 
        m   s   a   q   e   s   w   a   i   k   e   e   h   v   i   i   q 
 
 103  gcc gag ttc tat ctg aat cct gac caa tca ggc gag ttt atg ttt gac ttt 
        a   e   f   y   l   n   p   d   q   s   g   e   f   m   f   d   f 
 
 154  gat ggt gat gag att ttc cat gtg gat atg gca aag aag gag acg gtc tgg 
        d   g   d   e   i   f   h   v   d   m   a   k   k   e   t   v   w 
 
 205  cgg ctt gaa gaa ttt gga cga ttt gcc agc ttt gag gct caa ggt gca ttg 
        r   l   e   e   f   g   r   f   a   s   f   e   a   q   g   a   l 
 
 256  gcc aac ata gct gtg gac aaa gcc aac ctg gaa atc atg aca aag cgc tcc 
        a   n   i   a   v   d   k   a   n   l   e   i   m   t   k   r   s 
 
 307  aac tat act ccg atc acc aat gta cct cca gag gta act gtg ctc acg aac 
        n   y   t   p   i   t   n   v   p   p   e   v   t   v   l   t   n 
 
 358  agc cct gtg gaa ctg aga gag ccc aac gtc ctc atc tgt ttc atc gac aag 
        s   p   v   e   l   r   e   p   n   v   l   i   c   f   i   d   k 
 
 409  ttc acc cca cca gtg gtc aat gtc acg tgg ctt cga aat gga aaa cct gtc 
        f   t   p   p   v   v   n   v   t   w   l   r   n   g   k   p   v 
 
 460  acc aca gga gtg tca gag aca gtc ttc ctg ccc agg gaa gac cac ctt ttc 
        t   t   g   v   s   e   t   v   f   l   p   r   e   d   h   l   f 
 
 511  cgc aag ttc cac tat ctc ccc ttc ctg ccc tca act gag gac gtt tac gac 
        r   k   f   h   y   l   p   f   l   p   s   t   e   d   v   y   d 
 
 562  tgc agg gtg gag cac tgg ggc ttg gat gag cct ctt ctc aag cac tgg gag 
        c   r   v   e   h   w   g   l   d   e   p   l   l   k   h   w   e 
 
 613  ttt gat gct cca agc cct ctc cca gag act aca gag aac gtg gtg tgt gcc 
        f   d   a   p   s   p   l   p   e   t   t   e   n   v   v   c   a 
 
 664  ctg ggc ctg act gtg ggt ctg gtg ggc atc att att ggg acc atc ttc atc 
        l   g   l   t   v   g   l   v   g   i   i   i   g   t   i   f   i 
 
 715  atc aag gga gtg cgc aaa agc aat gca gca gaa cgc agg ggg cct ctg taa 
        i   k   g   v   r   k   s   n   a   a   e   r   r   g   p   l   - 
 
HLA-DR1 
 
   1  atg gtg tgt ctg aag ctc cct gga ggc tcc tgc atg aca gcg ctg aca gtg 
        m   v   c   l   k   l   p   g   g   s   c   m   t   a   l   t   v 
 
  52  aca ctg atg gtg ctg agc tcc cca ctg gct ttg gct ggg gac acc cga cca 
        t   l   m   v   l   s   s   p   l   a   l   a   g   d   t   r   p 
5 Supplement 
124 
 
 103  cgt ttc ttg tgg cag ctt aag ttt gaa tgt cat ttc ttc aat ggg acg gag 
        r   f   l   w   q   l   k   f   e   c   h   f   f   n   g   t   e 
 
 154  cgg gtg cgg ttg ctg gaa aga tgc atc tat aac caa gag gag tcc gtg cgc 
        r   v   r   l   l   e   r   c   i   y   n   q   e   e   s   v   r 
 
 205  ttc gac agc gac gtg ggg gag tac cgg gcg gtg acg gag ctg ggg cgg cct 
        f   d   s   d   v   g   e   y   r   a   v   t   e   l   g   r   p 
 
 256  gat gcc gag tac tgg aac agc cag aag gac ctc ctg gag cag agg cgg gcc 
        d   a   e   y   w   n   s   q   k   d   l   l   e   q   r   r   a 
 
 307  gcg gtg gac acc tac tgc aga cac aac tac ggg gtt ggt gag agc ttc aca 
        a   v   d   t   y   c   r   h   n   y   g   v   g   e   s   f   t 
 
 358  gtg cag cgg cga gtt gag cct aag gtg act gtg tat cct tca aag acc cag 
        v   q   r   r   v   e   p   k   v   t   v   y   p   s   k   t   q 
 
 409  ccc ctg cag cac cac aac ctc ctg gtc tgc tct gtg agt ggt ttc tat cca 
        p   l   q   h   h   n   l   l   v   c   s   v   s   g   f   y   p 
 
 460  ggc agc att gaa gtc agg tgg ttc cgg aac ggc cag gaa gag aag gct ggg 
        g   s   i   e   v   r   w   f   r   n   g   q   e   e   k   a   g 
 
 511  gtg gtg tcc aca ggc ctg atc cag aat gga gat tgg acc ttc cag acc ctg 
        v   v   s   t   g   l   i   q   n   g   d   w   t   f   q   t   l 
 
 562  gtg atg ctg gaa aca gtt cct cgg agt gga gag gtt tac acc tgc caa gtg 
        v   m   l   e   t   v   p   r   s   g   e   v   y   t   c   q   v 
 
 613  gag cac cca agt gtg acg agc cct ctc aca gtg gaa tgg aga gca cgg tct 
        e   h   p   s   v   t   s   p   l   t   v   e   w   r   a   r   s 
 
 664  gaa tct gca cag agc aag atg ctg agt gga gtc ggg ggc ttc gtg ctg ggc 
        e   s   a   q   s   k   m   l   s   g   v   g   g   f   v   l   g 
 
 715  ctg ctc ttc ctt ggg gcc ggg ctg ttc atc tac ttc agg aat cag aaa gga 
        l   l   f   l   g   a   g   l   f   i   y   f   r   n   q   k   g 
 
 766  cac tct gga ctt cag cca aca gga ttc ctg agc tga 
        h   s   g   l   q   p   t   g   f   l   s   - 
 
 
HLA-DR2a 
 
   1  atg gtg tgt ctg aag ctc cct gga ggt tcc tac atg gca aag ctg aca gtg 
        m   v   c   l   k   l   p   g   g   s   y   m   a   k   l   t   v 
 
  52  aca ctg atg gtg ctg agc tcc cca ctg gct ttg gct ggg gac acc cga cca 
        t   l   m   v   l   s   s   p   l   a   l   a   g   d   t   r   p 
 
 103  cgt ttc ttg cag cag gat aag tat gag tgt cat ttc ttc aac ggg acg gag 
        r   f   l   q   q   d   k   y   e   c   h   f   f   n   g   t   e 
 
 154  cgg gtg cgg ttc ctg cac aga gac atc tat aac caa gag gag gac ttg cgc 
        r   v   r   f   l   h   r   d   i   y   n   q   e   e   d   l   r 
 
 205  ttc gac agc gac gtg ggg gag tac cgg gcg gtg acg gag ctg ggg cgg cct 
        f   d   s   d   v   g   e   y   r   a   v   t   e   l   g   r   p 
 
5 Supplement 
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 256  gac gct gag tac tgg aac agc cag aag gac ttc ctg gaa gac agg cgc gcc 
        d   a   e   y   w   n   s   q   k   d   f   l   e   d   r   r   a 
 
 307  gcg gtg gac acc tac tgc aga cac aac tac ggg gtt ggt gag agc ttc aca 
        a   v   d   t   y   c   r   h   n   y   g   v   g   e   s   f   t 
 
 358  gtg cag cgg cga gtt gag cct aag gtg act gtg tat cct gca agg acc cag 
        v   q   r   r   v   e   p   k   v   t   v   y   p   a   r   t   q 
 
 409  acc ctg cag cac cac aac ctc ctg gtc tgc tct gtg aat ggt ttc tat cca 
        t   l   q   h   h   n   l   l   v   c   s   v   n   g   f   y   p 
 
 460  ggc agc att gaa gtc agg tgg ttc cgg aac agc cag gaa gag aag gct ggg 
        g   s   i   e   v   r   w   f   r   n   s   q   e   e   k   a   g 
 
 511  gtg gtg tcc aca ggc ctg att cag aat gga gac tgg acc ttc cag acc ctg 
        v   v   s   t   g   l   i   q   n   g   d   w   t   f   q   t   l 
 
 562  gtg atg ctg gaa aca gtt cct cga agt gga gag gtt tac acc tgc caa gtg 
        v   m   l   e   t   v   p   r   s   g   e   v   y   t   c   q   v 
 
 613  gag cac cca agc gtg acg agc cct ctc aca gtg gaa tgg aga gca cag tct 
        e   h   p   s   v   t   s   p   l   t   v   e   w   r   a   q   s 
 
 664  gaa tct gca cag agc aag atg ctg agt gga gtc ggg ggc ttt gtg ctg ggc 
        e   s   a   q   s   k   m   l   s   g   v   g   g   f   v   l   g 
 
 715  ctg ctc ttc ctt ggg gcc ggg cta ttc atc tac ttc aag aat cag aaa ggg 
        l   l   f   l   g   a   g   l   f   i   y   f   k   n   q   k   g 
 
 766  cac tct gga ctt cac cca aca gga ctc gtg agc tga 
        h   s   g   l   h   p   t   g   l   v   s   - 
 
 
HLA-DR2b 
 
   1  atg gtg tgt ctg aag ctc cct gga ggc tcc tgc atg aca gcg ctg aca gtg 
        m   v   c   l   k   l   p   g   g   s   c   m   t   a   l   t   v 
 
  52  aca ctg atg gtg ctg agc tcc cca ctg gct ttg tct ggg gac acc cga cca 
        t   l   m   v   l   s   s   p   l   a   l   s   g   d   t   r   p 
 
 103  cgt ttc ctg tgg cag cct aag agg gag tgt cat ttc ttc aat ggg acg gag 
        r   f   l   w   q   p   k   r   e   c   h   f   f   n   g   t   e 
 
 154  cgg gtg cgg ttc ctg gac aga tac ttc tat aac cag gag gag tcc gtg cgc 
        r   v   r   f   l   d   r   y   f   y   n   q   e   e   s   v   r 
 
 205  ttc gac agc gac gtg ggg gag ttc cgg gcg gtg acg gag ctg ggg cgg cct 
        f   d   s   d   v   g   e   f   r   a   v   t   e   l   g   r   p 
 
 256  gac gct gag tac tgg aac agc cag aag gac atc ctg gag cag gcg cgg gcc 
        d   a   e   y   w   n   s   q   k   d   i   l   e   q   a   r   a 
 
 307  gcg gtg gac acc tac tgc aga cac aac tac ggg gtt gtg gag agc ttc aca 
        a   v   d   t   y   c   r   h   n   y   g   v   v   e   s   f   t 
 
 358  gtg cag cgg cga gtc caa cct aag gtg act gta tat cct tca aag acc cag 
        v   q   r   r   v   q   p   k   v   t   v   y   p   s   k   t   q 
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 409  ccc ctg cag cac cac aac ctc ctg gtc tgc tct gtg agt ggt ttc tat cca 
        p   l   q   h   h   n   l   l   v   c   s   v   s   g   f   y   p 
 
 460  ggc agc att gaa gtc agg tgg ttc ctg aac ggc cag gaa gag aag gct ggg 
        g   s   i   e   v   r   w   f   l   n   g   q   e   e   k   a   g 
 
 511  atg gtg tcc aca ggc ctg atc cag aat gga gac tgg acc ttc cag acc ctg 
        m   v   s   t   g   l   i   q   n   g   d   w   t   f   q   t   l 
 
 562  gtg atg ctg gaa aca gtt cct cga agt gga gag gtt tac acc tgc caa gtg 
        v   m   l   e   t   v   p   r   s   g   e   v   y   t   c   q   v 
 
 613  gag cac cca agc gtg aca agc cct ctc aca gtg gaa tgg aga gca cgg tct 
        e   h   p   s   v   t   s   p   l   t   v   e   w   r   a   r   s 
 
 664  gaa tct gca cag agc aag atg ctg agt gga gtc ggg ggc ttt gtg ctg ggc 
        e   s   a   q   s   k   m   l   s   g   v   g   g   f   v   l   g 
 
 715  ctg ctc ttc ctt ggg gcc ggg ctg ttc atc tac ttc agg aat cag aaa gga 
        l   l   f   l   g   a   g   l   f   i   y   f   r   n   q   k   g 
 
 766  cac tct gga ctt cag cca aca gga ttc ctg agc tga 
        h   s   g   l   q   p   t   g   f   l   s   - 
 
 
Bbc9 TRAV22S1 
 
   1  atg aac tat tct cca ggc tta gta tct ctg ata ctc tta ctg ctt gga aga 
        m   n   y   s   p   g   l   v   s   l   i   l   l   l   l   g   r 
 
  52  acc cgt gga gat tca gtg acc cag atg gaa ggg cca gtg act ctc tca gaa 
        t   r   g   d   s   v   t   q   m   e   g   p   v   t   l   s   e 
 
 103  gag gcc ttc ctg act ata aac tgc acg tac aca gcc aca gga tac cct tcc 
        e   a   f   l   t   i   n   c   t   y   t   a   t   g   y   p   s 
 
 154  ctt ttc tgg tat gtc caa tat cct gga gaa ggt cta cag ctc ctc ctg aaa 
        l   f   w   y   v   q   y   p   g   e   g   l   q   l   l   l   k 
 
 205  gcc acg aag gct gat gac aag gga agc aac aaa ggt ttt gaa gcc aca tac 
        a   t   k   a   d   d   k   g   s   n   k   g   f   e   a   t   y 
 
 256  cgt aaa gaa acc act tct ttc cac ttg gag aaa ggc tca gtt caa gtg tca 
        r   k   e   t   t   s   f   h   l   e   k   g   s   v   q   v   s 
 
 307  gac tca gcg gtg tac ttc tgt gct ttg ata ggc ttt ggg aat gtg ctg cat 
        d   s   a   v   y   f   c   a   l   i   g   f   g   n   v   l   h 
 
 358  tgc ggg tcc ggc act caa gtg att gtt tta cca cat atc cag aac cct gac 
        c   g   s   g   t   q   v   i   v   l   p   h   i   q   n   p   d 
 
 409  cct gcc gtg tac cag ctg aga gac tct aaa tcc agt gac aag tct gtc tgc 
        p   a   v   y   q   l   r   d   s   k   s   s   d   k   s   v   c 
 
 460  cta ttc acc gat ttt gat tct caa aca aat gtg tca caa agt aag gat tct 
        l   f   t   d   f   d   s   q   t   n   v   s   q   s   k   d   s 
 
 511  gat gtg tat atc aca gac aaa act gtg cta gac atg agg tct atg gac ttc 
        d   v   y   i   t   d   k   t   v   l   d   m   r   s   m   d   f 
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 562  aag agc aac agt gct gtg gcc tgg agc aac aaa tct gac ttt gca tgt gca 
        k   s   n   s   a   v   a   w   s   n   k   s   d   f   a   c   a 
 
 613  aac gcc ttc aac aac agc att att cca gaa gac acc ttc ttc ccc agc cca 
        n   a   f   n   n   s   i   i   p   e   d   t   f   f   p   s   p 
 
 664  gaa agt tcc tgt gat gtc aag ctg gtc gag aaa agc ttt gaa aca gat acg 
        e   s   s   c   d   v   k   l   v   e   k   s   f   e   t   d   t 
 
 715  aac cta aac ttt caa aac ctg tca gtg att ggg ttc cga atc ctc ctc ctg 
        n   l   n   f   q   n   l   s   v   i   g   f   r   i   l   l   l 
 
 766  aaa gtg gcc ggg ttt aat ctg ctc atg acg ctg cgg ctg tgg tcc agt tga 
        k   v   a   g   f   n   l   l   m   t   l   r   l   w   s   s   - 
 
Bbc9 TRBV9S1 
 
   1  atg tgc agg ctc ctc tgc tgt gtg gtc ttc tgc ctc ctc caa gca ggt ccc 
        m   c   r   l   l   c   c   v   v   f   c   l   l   q   a   g   p 
 
  52  ttg gac aca gct gtt tcc cag act cca aaa tac ctg gtc aca cag atg gga 
        l   d   t   a   v   s   q   t   p   k   y   l   v   t   q   m   g 
 
 103  aac gac aag tcc att aaa tgt gaa caa aat ctg ggc cat gat act atg tat 
        n   d   k   s   i   k   c   e   q   n   l   g   h   d   t   m   y 
 
 154  tgg tat aaa cag gac tct aag aaa ttt ctg aag ata atg ttt agc tac aat 
        w   y   k   q   d   s   k   k   f   l   k   i   m   f   s   y   n 
 
 205  aat aag gag ctc att ata aat gaa aca gtt cca aat cgc ttc tca cct aaa 
        n   k   e   l   i   i   n   e   t   v   p   n   r   f   s   p   k 
 
 256  tct cca gac aaa gct cac tta aat ctt cac atc aat tcc ctg gag ctt ggt 
        s   p   d   k   a   h   l   n   l   h   i   n   s   l   e   l   g 
 
 307  gac tct gct gtg tat ttc tgt gcc agc agc cag ggc aga tct agc aat cag 
        d   s   a   v   y   f   c   a   s   s   q   g   r   s   s   n   q 
 
 358  ccc cag cat ttt ggt gat ggg act cga ctc tcc ata cta gag atc tcc cac 
        p   q   h   f   g   d   g   t   r   l   s   i   l   e   i   s   h 
 
 409  acc caa aag gcc aca ctg gtg tgc ctg gcc aca ggc ttc ttc ccc gac cac 
        t   q   k   a   t   l   v   c   l   a   t   g   f   f   p   d   h 
 
 460  gtg gag ctg agc tgg tgg gtg aat ggg aag gag gtg cac agt ggg gtc agc 
        v   e   l   s   w   w   v   n   g   k   e   v   h   s   g   v   s 
 
 511  acg gac ccg cag ccc ctc aag gag cag ccc gcc ctc aat gac tcc aga tac 
        t   d   p   q   p   l   k   e   q   p   a   l   n   d   s   r   y 
 
 562  tgc ctg agc agc cgc ctg agg gtc tcg gcc acc ttc tgg cag aac ccc cgc 
        c   l   s   s   r   l   r   v   s   a   t   f   w   q   n   p   r 
 
 613  aac cac ttc cgc tgt caa gtc cag ttc tac ggg ctc tcg gag aat gac gag 
        n   h   f   r   c   q   v   q   f   y   g   l   s   e   n   d   e 
 
 664  tgg acc cag gat agg gcc aaa ccc gtc acc cag atc gtc agc gcc gag gcc 
        w   t   q   d   r   a   k   p   v   t   q   i   v   s   a   e   a 
 
 715  tgg ggt aga gca 
        w   g   r   a 
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Ii-wt 
 
          AscI 
       ---+------ 
   1  cgg cgc gcc atg gat gac cag cgc gac ctt atc tcc aac aat gag caa ctg 
                    m   d   d   q   r   d   l   i   s   n   n   e   q   l 
 
  52  ccc atg ctg ggc cgt aga ccc ggc gct cct gag agc aag tgt agc aga ggg 
        p   m   l   g   r   r   p   g   a   p   e   s   k   c   s   r   g 
 
 103  gcc ctg tac acc ggc ttc agc atc ctc gtg aca ctg ctg ctg gcc gga cag 
        a   l   y   t   g   f   s   i   l   v   t   l   l   l   a   g   q 
 
 154  gct acc acc gcc tac ttt ctg tat cag cag cag ggc cgg ctg gac aag ctg 
        a   t   t   a   y   f   l   y   q   q   q   g   r   l   d   k   l 
 
 205  acc gtg acc agc cag aac ctg cag ctg gaa aac ctg cgg atg aag ctg ccc 
        t   v   t   s   q   n   l   q   l   e   n   l   r   m   k   l   p 
 
                      AgeI 
                    --+----- 
 256  aag ccc ccc aaa ccg gtg agc aag atg cgc atg gcc acc ccg ctg ctg atg 
        k   p   p   k   p   v   s   k   m   r   m   a   t   p   l   l   m 
                              >>.................CLIP...................> 
 
                            KasI 
                          -+----- 
 307  cag gcg ctg ccc atg ggc gcc ctg cca cag gga cct atg cag aac gcc acc 
        q   a   l   p   m   g   a   l   p   q   g   p   m   q   n   a   t 
      >....CLIP....>> 
 
 358  aaa tac ggc aac atg acc gag gac cac gtg atg cat ctg ctg cag aat gcc 
        k   y   g   n   m   t   e   d   h   v   m   h   l   l   q   n   a 
 
 409  gac ccc ctg aag gtg tac ccc cca ctg aag ggc agc ttt ccc gag aac ctg 
        d   p   l   k   v   y   p   p   l   k   g   s   f   p   e   n   l 
 
 460  cgg cac ctg aag aac acc atg gaa acc atc gac tgg aag gtg ttc gag agc 
        r   h   l   k   n   t   m   e   t   i   d   w   k   v   f   e   s 
 
 511  tgg atg cac cac tgg ctg ctg ttc gag atg agc cgg cac agc ctg gaa cag 
        w   m   h   h   w   l   l   f   e   m   s   r   h   s   l   e   q 
 
 562  aag cct acc gac gcc cct ccc aaa gag tcc ctg gaa ctg gaa gat ccc agc 
        k   p   t   d   a   p   p   k   e   s   l   e   l   e   d   p   s 
 
 613  agc ggc ctg ggc gtg acc aag cag gat ctg gga ccc gtg ccc atg tga 
        s   g   l   g   v   t   k   q   d   l   g   p   v   p   m   - 
 
 
delta-Ii 
 
          AscI 
       ---+------ 
   1  cgg cgc gcc atg agc tct ggt tcg tca aag tgt agc aga ggg gcc ctg tac 
        r   r   a   m   s   s   g   s   s   k   c   s   r   g   a   l   y 
 
  52  acc ggc ttc agc atc ctc gtg aca ctg ctg ctg gcc gga cag gct acc acc 
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        t   g   f   s   i   l   v   t   l   l   l   a   g   q   a   t   t 
 
 103  gcc tac ttt ctg tat cag cag cag ggc cgg ctg gac aag ctg acc gtg acc 
        a   y   f   l   y   q   q   q   g   r   l   d   k   l   t   v   t 
 
 154  agc cag aac ctg cag ctg gaa aac ctg cgg atg aag ctg ccc aag ccc ccc 
        s   q   n   l   q   l   e   n   l   r   m   k   l   p   k   p   p 
 
          AgeI 
        --+----- 
 205  aaa ccg gtg agc aag atg cgc atg gcc acc ccg ctg ctg atg cag gcg ctg 
        k   p   v   s   k   m   r   m   a   t   p   l   l   m   q   a   l 
                  >>.......................CLIP.........................> 
 
 256  ccc atg ggc gcc ctg cca cag gga cct atg cag aac gcc acc aaa tac ggc 
        p   m   g   a   l   p   q   g   p   m   q   n   a   t   k   y   g 
      >>>  
 
 307  aac atg acc gag gac cac gtg atg cat ctg ctg cag aat gcc gac ccc ctg 
        n   m   t   e   d   h   v   m   h   l   l   q   n   a   d   p   l 
 
 358  aag gtg tac ccc cca ctg aag ggc agc ttt ccc gag aac ctg cgg cac ctg 
        k   v   y   p   p   l   k   g   s   f   p   e   n   l   r   h   l 
 
 409  aag aac acc atg gaa acc atc gac tgg aag gtg ttc gag agc tgg atg cac 
        k   n   t   m   e   t   i   d   w   k   v   f   e   s   w   m   h 
 
 460  cac tgg ctg ctg ttc gag atg agc cgg cac agc ctg gaa cag aag cct acc 
        h   w   l   l   f   e   m   s   r   h   s   l   e   q   k   p   t 
 
 511  gac gcc cct ccc aaa gag tcc ctg gaa ctg gaa gat ccc agc agc ggc ctg 
        d   a   p   p   k   e   s   l   e   l   e   d   p   s   s   g   l 
 
 562  ggc gtg acc aag cag gat ctg gga ccc gtg ccc atg tga 
        g   v   t   k   q   d   l   g   p   v   p   m   - 
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5.3 Vector maps 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1 Vector map of pRSV-neo and pRSV-hygro for the expression of TCR β and TCRα. (A) 
TCR β chains are cloned into pRSV-neo. The Plasmid carries the gene of β-lactamase (bla), for 
ampicillin resistence, the origin of replication of Simian virus 40 (SV40_ori), SV40 polyadenylation site 
(SV40-PolyA), gene for neomycine resistance (NeoR) and SV40 promotor. The constant region of the 
β-chain was cloned into pRSV-neo, and can be complemented with BV-BN(D)N-BJ via SalI and AvaI. 
(B) TCR α chains are cloned into pRSV-hygro. It was constructed by replacing the neomycin resistance 
of pRSV-neo by the gene for hygromycine resistance. The constant region of the α-chain was cloned 
into the vector and can be complemented with the AV-AN-AJ via SalI and PvuII. The vector maps were 
constructed with Savvy Version 0.1.  
Figure 5-2 Vector maps of pHSE3'-neo and pHSE3'-hygro for the expression of MHC. MHC-I 
alleles as well as the β-chain of MHC-II alleles were cloned into pHSE3’-neo via the restriction sites 
SalI and BamHI. The vector carries gene for neomycine resistance, gene for β-lactamase (bla), for 
ampicillin resistance and an origin of replication (ori). (B) The α-chain of MHC-II was cloned into 
pHSE3’-hygro via the restriction sites SalI and BamHI. It is a derivate of pHSE3’-neo, however the 
neomycine resistance was substituted by hygromycine resistance. The vector maps were constructed 
with Savvy Version 0.1 
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Figure 5-4 Vector map pcDNA6/V5-His ABC. Source: Invitrogen 
Figure 5-3 pCR®2.1-TOPO vector for TOPO-TA cloning. Source: Invitrogen.  
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Figure 5-5 pcDNA3.1D/V5-His-TOPO for directional TOPO cloning. Source: Invitrogen 
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